Ataxia-telangiectasia and other Primary Immunodeficiency Diseases by Stray-Pedersen, Asbjørg
Ataxia-telangiectasia and other 
Primary Immunodeficiency Diseases 
Asbjørg Stray-Pedersen 
Thesis for the degree of dr.med. 
Pediatric Department and Department of Medical Genetics 
Rikshospitalet Medical Centre 
Oslo 2008
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Asbjørg Stray-Pedersen, 2008 
 
 
Series of dissertations submitted to the  
Faculty of Medicine, University of Oslo 
No. 626 
 
ISBN 978-82-8072-755-8 
 
 
All rights reserved. No part of this publication may be  
reproduced or transmitted, in any form or by any means, without permission.   
 
 
 
 
 
 
 
 
Cover: Inger Sandved Anfinsen. 
Printed in Norway: AiT e-dit AS, Oslo, 2008.   
 
Produced in co-operation with Unipub AS.  
The thesis is produced by Unipub AS merely in connection with the  
thesis defence. Kindly direct all inquiries regarding the thesis to the copyright  
holder or the unit which grants the doctorate.   
 
Unipub AS is owned by  
The University Foundation for Student Life (SiO) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Opptrykk av avhandlingen er finansiert  
av Norsk Immunsviktforening 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
www.immunsvikt.no 
 

Table of Contents 
Acknowledgements .................................................................................................................... 7 
List of Papers.............................................................................................................................. 8 
General Introduction................................................................................................................... 9 
Primary immunodeficiency diseases ...................................................................................... 9 
Primary immunodeficiencies and infections ...................................................................... 9 
Types of PID - characteristic signs and symptoms .......................................................... 10 
Syndromes in which PID may be a part of the phenotype ............................................... 10
Age of onset...................................................................................................................... 10 
Family history................................................................................................................... 11 
Incidence and prevalence of PID...................................................................................... 11 
Treatment of PID.............................................................................................................. 11 
Quality of life studies in PID patients .............................................................................. 16 
Curative treatment does not always exist ......................................................................... 16 
DNA repair and immunodeficiency ..................................................................................... 17 
DNA breaks and repair in development of T cells and B cells: ....................................... 17 
The four major DNA repair pathways.............................................................................. 22 
Examples of diseases caused by defects in various DNA repair mechanisms................. 22 
DNA repair defects cause immunodeficiency, cancer and/or neurodegeneration ........... 23 
Ataxia-telangiectasia ............................................................................................................ 25 
Diagnosis .......................................................................................................................... 25 
History .............................................................................................................................. 25 
Clinical manifestations of A-T ......................................................................................... 26 
Immunodeficiency in A-T ................................................................................................ 31 
Increased risk of cancer in A-T ........................................................................................ 32 
Radiation sensitivity ......................................................................................................... 32 
Treatment of A-T.............................................................................................................. 33 
A-T carriers ...................................................................................................................... 35 
Incidence of A-T .............................................................................................................. 36 
The ATM gene and mutation spectrum............................................................................. 36 
Alpha fetoprotein in A-T.................................................................................................. 38 
AFP in other neurodegenerative diseases......................................................................... 38 
Differential diagnoses to A-T........................................................................................... 38 
Other DNA repair disorders with immunodeficiency ...................................................... 41 
Fungal infections in PIDs, .................................................................................................... 44 
Candida ............................................................................................................................ 44 
Chronic mucocutaneous candidiasis (CMC).................................................................... 45 
APECED .......................................................................................................................... 45 
Treatment of Candida in CMC ........................................................................................ 45 
The susceptibility to Candida is still a mystery. .............................................................. 45 
Studies of CMC and autoimmunity in knockout mice ..................................................... 46 
Human leukocyte antigen (HLA) = major histocompatibility complex (MHC).............. 48 
HLA and connection to APCs .......................................................................................... 49 
HLA and autoimmune diseases ........................................................................................ 49 
Autoimmune thyroiditis versus congenital thyroid disease. ............................................ 49 
Mannose binding lectin – part of innate immunity .............................................................. 50 
MBL and complement activation, MBL deficiency and pneumococcal disease ............. 50 
MBL and Candida albicans ............................................................................................. 50 
Streptococcoccus pneumonia and immune defence ............................................................. 52 
Aims of the study ..................................................................................................................... 53 
3
Material and Methods............................................................................................................... 54 
Patients: ................................................................................................................................ 54 
Patients with PIDs – epidemiology (Paper I) ................................................................... 54 
Patients with antibody deficiencies .................................................................................. 54 
- selected for the coping, quality of life, and hope study (Paper II) ................................. 54 
Patients with Ataxia-Telangiectasia (Paper III-V) ........................................................... 54 
- and their parents (Paper III-V) ....................................................................................... 55 
Control persons in the vaccine study (Paper IV).............................................................. 55 
Patients with Chronic mucocutaneous candidiasis (Paper VI)......................................... 56 
14 q deletion and MBL deficiency (Paper VII)................................................................ 56 
Methods ................................................................................................................................ 57 
The epidemiological PID study........................................................................................ 57 
Coping, quality of life, and hope study in adults with PID .............................................. 58 
A-T studies - Longitudinal follow-up of a selected cohort .............................................. 59 
Immunological tests ......................................................................................................... 60 
Genetic tests ..................................................................................................................... 64 
Statistics............................................................................................................................ 65 
Results 1 ................................................................................................................................... 66 
Paper I................................................................................................................................... 66 
PID in Norway – epidemiology........................................................................................ 66 
Paper II ................................................................................................................................. 66 
Coping, quality of life, and hope in adults with primary antibody deficiencies .............. 66 
Paper III ................................................................................................................................ 67 
A-T and Immunology....................................................................................................... 67 
Paper IV................................................................................................................................ 67 
A-T and pneumococcal vaccine ....................................................................................... 67 
Paper V ................................................................................................................................. 68 
A-T and alpha fetoprotein ................................................................................................ 68 
Paper VI................................................................................................................................ 68 
Chronic mucocutaneous candidiasis and hypothyroidism ............................................... 68 
Paper VII .............................................................................................................................. 69 
Proximal 14q Deletion and MBL deficiency ................................................................... 69 
Results 2 ................................................................................................................................... 70 
Update report – PID epidemiology and treatment................................................................ 70 
PID epidemiology............................................................................................................. 70 
PID update report - Treatment.......................................................................................... 70 
Ataxia-Telangiectasia in Norway, epidemiology and genetics ............................................ 75 
Norwegian founder mutation from Rendalen in Hedmark County.................................. 75 
Other mutations in ATM ................................................................................................... 75 
Predicted consequences of mutations............................................................................... 76
 
 
 
 
 
 
  
4
General Discussion................................................................................................................... 81 
Epidemiological studies in rare disorders and medical quality registries in Scandinavia 81 
PID epidemiology - Not all PID registered ...................................................................... 81 
Classifications and definitions of PID are dynamic ......................................................... 82 
Medical records - from paper to electronic charts............................................................ 82 
Change in organisation of health care system in Norway – implications for management 
of PID patients and disease awareness ............................................................................. 83 
Other national PID registries and the ESID registry ........................................................ 83 
Focus on particular groups within the PID registry ......................................................... 85 
Coping, quality of life, and hope study in adults with PID .............................................. 85 
Triangulation  – combining quantitative and qualitative studies ..................................... 86
Choice of Instruments ...................................................................................................... 87 
SF-36 versus measuring global QLI................................................................................. 88 
Further discussion of results of the coping, quality of life, and hope study    – 
implications for follow-up................................................................................................ 89 
Studies of coping, quality of life, and hope in other PID patients ................................... 90 
Clinical studies based on the PID registry............................................................................ 90 
A characteristic immunological pattern in A-T patients .................................................. 90 
Laboratory immunological evaluation ............................................................................. 91 
Clinical immunodeficiency .............................................................................................. 91 
Immunoglobulin supplementation in A-T........................................................................ 92 
Frequency and severity of infections – interpretation difficulties.................................... 92 
Vaccination in A-T........................................................................................................... 92 
Vaccination in other PIDs ................................................................................................ 94 
Revising the ESID diagnostic criteria for A-T................................................................. 94 
A-T and phenotype - genotype correlations ..................................................................... 94 
Alpha fetoprotein in A-T.................................................................................................. 96 
Large cohort of A-T patients for population size ............................................................. 97 
A-T Clinical Care Centers................................................................................................ 97 
Longitudinal follow-up is needed for rare disorders. ....................................................... 97 
Study humans in human disease, in addition performing animal studies ........................ 98 
Caring for A-T carriers and other relatives of PID patients ............................................. 99 
Immunological study of patients with familial CMC with hypothyroidism .................... 99 
Inherited thyroid diseases: Autoimmune thyroiditis versus congenital thyroid disease 101 
Recurrent pulmonary problems, related to MBL deficiency.......................................... 102 
Contiguous gene syndromes and the contribution of single genes ................................ 102 
Conclusions ............................................................................................................................ 103 
Future Perspectives................................................................................................................. 105    
       
References .............................................................................................................................. 111 
Other publications .................................................................................................................. 135 
Supplement............................................................................................................................. 136 
Appendices: Abbreviations (i-iv) and Errata (v)…………………..…………………………… 149 
Original articles PAPER I-VII……………………………………………………………... 155  
5
Have faith in the future
Hope for a cure
Love the patients
6
Acknowledgements  
The research projects in Papers III, IV, V, VII were financed with the aid of EXTRA funds 
from the Norwegian Foundation for Health and Rehabilitation. The epidemiology project 
(Paper I) was initiated by the Centre for Rare Disorders, Rikshospitalet. Project grants for 
Paper I came from the Norwegian Ministry of Health and Social Affairs. The CMC study 
(Paper VI) was conducted in collaboration with Anne Grethe Myhre, was part of her doctoral 
thesis in 2004, and is included here with her approval. The coping, quality of life, and hope 
study (Paper II) was carried out in collaboration with dr. polit. H.M.H.Sigstad and constitutes 
the bulk of her thesis. This study is also included here with her consent because I participated 
in designing the study, selecting patients, distributing the questionnaires, evaluating results 
pertaining to medical issues and writing up the results for publication in an international 
journal. The outcome of hematopoietic stem cell transplantation in patients with primary 
immunodeficiency diseases (Table 6 in Results 2) is presented here with permission from 
Senior Consultant Anders Glomstein, Section of Pediatric Hematology, Department of 
Pediatrics, Rikshospitalet. I thank the Letten Foundation for supporting the work in Paper V.  
I am grateful to The Norwegian Immunodeficiency Association, represented by Eva Brox, 
Arnstein Rugland and Marianne Skreden among others for their enthusiasm and financial 
support. 
To base research on clinical work is to be dependent on others. The studies in paper III, IV, V 
and VI have been accomplished in collaboration with a variety of professionals from different 
hospital departments who represent an orchestra of players who allowed themselves to be 
conducted by the first author. These studies could not have been carried out without help from 
many others. Thanks to the following people for excellent technical support: Laila Jansen, 
Anne-Cathrine (Tine) Kristoffersen, Marianne Svendsen, Louise Tunge, Bitte Eriksen, Nina 
Ørvim and Kari Leone. Thanks to the nurses and secretaries at the pediatric outpatient clinic, 
Pediatric Department, Rikshospitalet, represented by Heidi Sandersen, Kathleen Halvorsen, 
Alfhild Bustnes, Kari Gjersum, Ellen Johanne Tung, and Anne Mette Aamodt. Thanks to 
collaborators at Children Habilitation Unit Hedmark, Center for Rare Disorders Rikshospitalet 
and Frambu. Thanks to colleagues and collaborators at the Departments of Medical Genetics 
Rikshospitalet and Ullevål University Hospital for patience and support during the final phase 
of this thesis. Thanks to Trine Prescott, both a clinical geneticist and a pediatrician, for her 
valuable comments on the summary.  
Thanks to prof. Tore Abrahamsen for 3x3 years of education, collaboration and support, and 
most of all for introducing me and letting me into the most interesting field of medicine, the 
Primary Immunodeficiencies. 
A special thanks to the patients and their families for participating in and supporting the 
research projects. 
7
List of Papers  
Paper I  
Stray-Pedersen A, Abrahamsen TG, Froland SS. Primary immunodeficiency diseases in 
Norway. J Clin Immunol. 2000 Nov;20(6):477-85 
Paper II 
Sigstad HM, Stray-Pedersen A, Froland SS. Coping, quality of life, and hope in adults with 
primary antibody deficiencies. Health Qual Life Outcomes. 2005 May 4;3(1):31. 
Paper III 
Stray-Pedersen A, Jonsson T, Heiberg A, Lindman CR, Widing E, Aaberge IS, Borresen-Dale 
AL, Abrahamsen TG. The impact of an early truncating founder ATM mutation on 
immunoglobulins, specific antibodies and lymphocyte populations in ataxia-
telangiectasia patients and their parents. Clin Exp Immunol. 2004 Jul;137(1):179-86.  
Paper IV 
Stray-Pedersen A, Aaberge IS, Fruh A, Abrahamsen TG. Pneumococcal conjugate vaccine 
followed by pneumococcal polysaccharide vaccine; immunogenicity in patients with 
ataxia-telangiectasia. Clin Exp Immunol. 2005 Jun;140(3):507-16. 
Paper V 
Stray-Pedersen A, Borresen-Dale AL, Paus E, Lindman CR, Burgers T, Abrahamsen TG. 
Alpha fetoprotein is increasing with age in Ataxia-Telangiectasia Eur J Paediatr Neurol. 
2007 May 29 
Paper VI 
Myhre AG, Stray-Pedersen A, Spangen S, Eide E, Veimo D, Knappskog PM, Abrahamsen 
TG, Husebye ES. Chronic mucocutaneous candidiasis and primary hypothyroidism in 
two families. Eur J Pediatr. 2004 Oct;163(10):604-11.
Paper VII 
Stray-Pedersen A, Rodningen O, Garred P, Heggelund L, Heiberg A, Holmskov U, Lindman 
CR, Lybæk H, Stoltenberg L, Tvedt B, Van der Hagen CB, Vermeesch J, Aaberge IS, 
Abrahamsen TG. Choreoathetosis, developmental delay and severe pulmonary infections 
due to TITF1 haploinsufficiency and homozygosity for MBL2 variant alleles Submitted 
Eur J Pediatr December 2007 (attached)
8
General Introduction 
Primary immunodeficiency diseases  
Primary immunodeficiency diseases (PIDs) are a heterogeneous group of disorders which 
give rise to increased susceptibility to infections and/or autoimmunity. Some disorders carry 
an increased risk of malignancy. As of 2007, more than 150 different PIDs have been 
characterized, and more will be described during the coming years thanks to the ongoing 
development of molecular genetic techniques. PIDs are often termed “experiments of nature”, 
because they provide unique and valuable insights into the function of the human immune 
system. The immunological cells including T- and B lymphocytes, NK cells, neutrophils and 
monocytes, are white blood cells derived from the bone marrow (Figure 2). PIDs can affect 
components of the adaptive immune system, i.e. T cells and B cells including antibodies 
(immunoglobulins). Components of the innate immune system may also be compromised, i.e. 
phagocytes (neutrophils, monocytes), NK cells, antimicrobial peptides, complement and other 
pattern recognition receptors such as toll-like receptors and collectins. 
PIDs can be classified into eight categories based on immunologic phenotype. A modified 
version of information presented in the IUIS PID ESID-PAGID reports (1;2) is attached here 
(Supplement Table 1- 9). For an algorithm for the diagnostic workup of severe combined 
immunodeficiency (SCID), see Supplement Table 2. 
Primary immunodeficiencies and infections 
Infections are the hallmark of PIDs: recurrent bacterial infections, prolonged infections that 
are difficult to treat, severe infections or infections with unusual pathogens.  
Other signs include: recurrent abscesses in the skin or internal organs, chronic and recurrent 
diarrhoea, extensive candidiasis, disseminated infection caused by live vaccines such as BCG. 
Types of PID - specific pathogens 
The type of infections and microbiological findings are often very characteristic for the 
different categories of immunodeficiencies. Some pathogens are linked exclusively to specific 
PIDs. For instance, B cell deficiencies (antibody deficiencies) predispose to Streptococcus 
pneumoniae and Haemophilus influenzae ear, nose, throat (ENT) infections and pneumonia. 
Complement deficiencies are characterised by infections with neisseria including gonococci 
and with capsular microbes. Phagocyte deficiencies predispose to infections with 
Staphylococcus aureus, Aspergillus and Pseudomonas aerginosa. T cell deficiencies result in 
vulnerability to opportunistic infections with Pneumocystis jerovici and Candida albicans as 
well as to fulminant viral infections with CMV and varicella. Signs of subtle T cell deficiency 
are disseminated and persistent warts and molluscs, chronic candidiasis and fungal nail 
infections (onchomycosis). EBV infections in X-linked lymphoproliferative disease can result 
in fatal disease, and trigger development of immunodeficiency and lymphoproliferation. 
Atypical mycobacteria can cause disease in inherited interferon gamma receptor deficiency 
(IFNGR1), but are rarely if ever otherwise pathogenic. The Sword of Damocles in patients 
with X-linked Hyper IgM syndrome (CD40 ligand defect) is Cryptosporidium infection which 
causes treatment resistant sclerosing cholangitis and severe liver disease(3). Recognition of 
genetic defects associated with selective susceptibility to specific pathogens has led to the 
proposal of a new classification scheme for PIDs on the basis of clinical criteria, and to 
development of diagnostic protocols for PIDs based on presenting clinical signs (4;5). 
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Types of PID - typical loci for infection 
Site of infection is often very characteristic for specific PIDs. Skin infections and recurrent 
otitis media are frequent in the phagocytic disorders. Sinopulmonary infections and 
bronchiectasis are typical of the antibody deficiencies. Osteomyelitis is seen in IFNGR1. 
Lung abscesses with pneumatocele may complicate Hyper IgE syndrome. Abscesses in 
internal organs including the liver are a feature of chronic granulomatous disease (CGD).  
Recurrent infection at the same site, however, warrants the search for a localized structural or 
functional predisposing factor. 
Types of PID - characteristic signs and symptoms 
PIDs characteristically present in childhood with persistent, recurrent, antibiotic resistant 
infections. Failure to thrive and developmental delay are nonspecific, but significant clues to
serious infections in young children.  Older children and adults may experience involuntary 
weight loss. Many immunodeficient children develop additional signs such as rashes. Many 
have associated developmental anomalies of the face, skeletal system, heart, or skin. These 
manifestations may initially be more prominent than their susceptibility to infection. For some 
PIDs, non-infection related features are good diagnostic “handles” e.g. delayed separation of 
the umbilical cord in phagocytic disorders, lack of tonsils in Bruton's agammaglobulinemia, 
telangiectasias in A-T, microcephaly in certain DNA repair defects, changes in the 
skin/hair/nails/teeth (ectodermal dysplasia) in NEMO, massive generalized scaling 
erythrodermia in Omenn syndrome, eczema and bruising in Wiskott Aldrich syndrome 
(WAS), specific skeletal findings in Schimke immunoosseous dysplasia and Chediak-Higashi 
syndrome, characteristic endocrinopathy such as hypoparathyroidism plus Addison disease in 
APECED. In some PIDs the clinical pictures is dominated by autoimmunity or 
immunodysregulation rather than by infections. 
Syndromes in which PID may be a part of the phenotype 
PID may be a feature of syndromes in which other characteristic findings dominate the 
clinical picture, i.e. chronic mucocutaneous candidiasis in APECED, the immunodeficiency in 
Hoyeraal-Hreidarsson syndrome or the immunodeficiency which accompanies various 
congenital platelet disorders (6;7). Immunodeficiency, as a component of recognizable 
syndromes, may be a good diagnostic handle. For example, DNA repair disorders may result 
in a characteristic pattern of immunodeficiency, and point to the specific defect. Reduced 
immunity is a feature of some monogenetic syndromes e.g. Smith Lemli Opitz syndrome and 
some dysmorphic syndromes of unknown etiology e.g., Kabuki syndrome (8;9). 
Immunodeficiency is frequently reported in patients with chromosomal abnormalities (such as 
22q11 deletion (10)and 10p14-p13 deletion in DiGeorge (MIM%601362), 4p deletion 
(11;12), trisomy 10p (13), Jacobsen syndrome (11q deletion syndrome), 15q duplication and 
18q deletion syndrome (14). In some of conditions where immunodeficiency may be a 
feature, the specifics of the immunodeficiency have not been well characterized, e.g. trisomy 
21 (Down syndrome). Even if the immunodeficiency has been characterized, the underlying 
immunological defect has often not been defined, e.g. males with microduplications which 
encompass the MECP2 gene (15).  
Age of onset 
The age of onset of symptoms may aid in elucidating underlying aetiology. Maternal 
immunoglobulin is present in infants in the first months of life, and may mask antibody 
deficiency. If ubiquitous opportunistic pathogens cannot be combated, as in SCID and severe 
congenital neutropenia (SCN), infections start in the first two months of life. When 
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immunodeficiency develops later in life, infections start later, as in common variable 
immunodeficiency (CVID), in which infections may start in adolescence or early adulthood. 
Family history 
In addition to the patient’s medical history and physical examination, the family history may 
be of great diagnostic importance. The presence of other individuals in the family with 
possible immunodeficiency, or the occurrence in relatives of similar symptoms and/or death 
in early childhood due to infection, should raise the suspicion of PID. Consanguinity and/or 
ethnicity may deserve consideration in the diagnostic work-up in some cases. A considerable 
proportion of the PIDs demonstrate X-linked inheritance e.g., Bruton’s agammaglobulinemia, 
Wiskott Aldrich syndrome, Hyper IgM syndrome caused by CD40 ligand deficiency, X-
linked SCID caused by γc deficiency (IL2RG deficiency), X-linked CGD (gp91phox 
deficiency), Hoyeraal-Hreidarsson syndrome, NEMO, IPEX. 
Incidence and prevalence of PID 
Previously, we have had rough estimates of PID patients in Norway. We wanted to describe 
the true incidence and prevalence of the various PIDs and their regional distribution, in order 
to improve care and treatment and facilitate better healthcare planning.   
Treatment of PID 
Lack of awareness of PID delays diagnosis and can lead to chronic organ damage and other 
complications of recurrent infections. Treatment may prevent infections or lessen their 
sequelae. Bone marrow transplantation may be curative for some severe PIDs.  
The history of Bruton's agammaglobulinemia. Antibiotics, antiviral and antifungal agents 
PID as a clinical entity was not discovered until after antibiotics were in widespread use for infections. Patients 
with an unusual tendency to recurrent infection led physicians to suspect the existence of PID. Antibody 
deficiency was firstly reported by the physician Colonel Ogden C. Bruton in 1952. Bruton's patient, a four-year-
old boy, was first admitted to hospital because of an infected knee. The child recovered well after a course of 
penicillin, but over the next four years had multiple infections including ten episodes of pneumococccal 
septicemia. Serum from Bruton’s patient was tested with a new laboratory method: electophoresis. Surprisingly, 
for Bruton the patient had no gammaglobulin fraction. He gave the boy gammaglobulin injections 
intramuscularly, thereby introduced immunoglobulin replacement therapy.  
Over the years, the development of new immunological methods has driven the discovery of new forms of PID. 
Targeting therapy, replacing the deficient immunological factor, is the ideal therapy when feasible. However, 
antibiotics are still required to clear intercurrent and recurrent infection in immunocompromised patients. PID 
patients often need higher doses of anti-infectious agents, intravenous administration and longer treatment time 
than others. Some PID patients profit from prophylactic antibiotics. Because of the risk of generating resistant 
microbes, prophylactic therapy is confined to a few selected drugs (such as trimetoprim/sulpha or tobramycin) 
and to situations without other adequate treatment options. Introduction of antifungal agents such as the lipid 
formulations of amphotericin B, the second-generation triazoles, and the echinocandins, have increased the 
options for medical management of severe fungal infections. Antiviral therapy is effective for some severe 
systemic viral infections in PID patients. However, antibiotics, antifungals and antiviral agents alone are not 
always able to eradicate the pathogen, because full clearance is often dependent on competence of specific 
immunological function(s). 
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Immunoglobulin replacement therapy  
Immunoglobulin replacement therapy is the mainstay of treatment in antibody deficiencies. 
Replacement therapy with immunoglobulin in primary antibody deficiencies increases life 
expectancy, and reduces infection frequency and severity (16). Immunoglobulins can be 
administered intravenously (usually once a month) in hospital, or as home based subcutaneous 
self treatment (usually once a week). Subcutaneous infusion is given by a battery driven 
electric pump. Subcutaneous infusion, causes fewer systemic reactions than intravenous 
therapy, and may be the treatment of choice, particularly in individuals requiring small doses 
of immunoglobulins.(17;18).  
  
Self administered, subcutaneous  
immunoglobulin therapy; ScIg,  
administered (weekly) at home  
Intravenous immunoglobulin therapy; IVIg,  
administered (monthly) in hospital. 
from “Our immune system” www.octapharma.com 
Figure 1 Immunoglobulin replacement therapy  
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Cytokine and various other adjunctive treatment 
Cytokine treatment is used in patients with phagocytic disorders. Interferon gamma injections 
are given for CGD and autosomal dominant IFNGR1. Granulocyte colony stimulating factor 
(G-CSF) is used in the treatment of severe congenital neutropenia. Various immune 
modifying treatments (FK506, cyclosporin, corticosteroids) are helpful in some 
immunodefiencies with autoimmune manifestations such as IPEX, ALPS and CVID.   
Bone marrow transplantation  
Hematopoietic stem cells are produced in the bone marrow (Figure 2). Bone marrow 
transplantation, i.e. allogenic hematopoietic stem cell transplantation, (Figure 3) has the 
potential to cure SCID. Recent data support bone marrow transplantation in Wiskott Aldrich 
syndrome (19), CD40 ligand deficiency and severe CGD (20;21). Non-identical HLA 
hematopoietic stem cell transplantation may cause severe acute or chronic graft versus host 
disease (GVHD) where donor T cells (= graft) attack the recipient’s (= host’s) organs. In PID 
an HLA identical sibling is the optimal donor, followed by HLA identical registry donor. 
Haploidentical family donors and mismatched unrelated donors are used less frequently 
because of poor overall survival.  
Preconditioning regimens prior to transplantation may vary from none in T-B-NK+ SCID 
with HLA identical sibling donor, to reduced or modified regimens in adult PID patients with 
pre-existing organ damage, to nonmyeloablative conditioning regimens in DNA repair 
disorders (22), to standard irradiation-based myeloablation. Bone marrow transplantation is 
associated with potentially life threatening complications, and is reserved for severe PIDs. 
Survival depends on the specific diagnosis, tolerance of the preconditioning regimen, the 
patient’s age and health, and most importantly, the degree of HLA match between donor and 
recipient. Generally speaking, treatment by bone marrow transplantation is increasingly 
successful (23). The EBMT guidelines for hematopoietic stem cell transplantation in primary 
immunodeficiencies presented in Paris, June 2004 are available at: 
http://www.esid.org/downloads/BMT_Guidelines_old.doc  
Gene therapy
In the absence of a HLA identical donor, gene therapy has been performed in a few cases 
internationally (24-29). Retroviral vectors have been successfully used ex vivo to transduce 
hematopoietic precursors from patients with X-linked SCID and ADA deficiency. Trials with 
gene therapy for other types of SCID and other PIDs such as X-linked CGD are ongoing. 
PIDs are good targets for hematopoietic stem cell-targeted gene therapy. Treatment of SCID 
patients was the first example of successful gene therapy based on ex vivo retroviral vectors. 
Advances in gene transfer technology can potentially lead to safe and effective gene therapy 
for immunodeficiency diseases, primarily for the severe forms.    
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http://stemcells.nih.gov
Figure 2 Hematopoietic stem cells are produced in the bone marrow 
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http://www.centerspan.org/pubs/news/art/fig1.gif 
Figure 3 Schematic overview of bone marrow transplantation 
Bone marrow is harvested 
from iliac crest of donor 
Marrow is filtered 
in operating room 
Filtered marrow is given to 
recipient as a blood transfusion. 
The cells find their way to the 
recipent’s bone marrow 
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Quality of life studies in PID patients  
- previous studies focused on comparing treatment methods 
Despite intensive treatment, patients with PIDs may have problems with infections or other 
disease manifestations. For example, patients with antibody deficiencies have increased 
incidence of autoimmune diseases and experience long-term complications of infections 
and/or treatment. Chronic disease will often have consequences for quality of life. Previous 
quality-of-life studies in patients with PID have been mainly been limited to the study of 
different treatment methods in patients with antibody deficiency. As part of the re-
introduction of subcutaneous immunoglobulin (ScIg) treatment there have been many studies 
of quality-of-life status before and after changing from one treatment modality to another e.g. 
from IVIg to ScIg. After initiation of subcutaneous replacement therapy, increased health-
related function and improved self-rated health have been documented in some studies(30-
33). It may be that one of the main motives has been to ensure the market of the safety and 
advantage of the ScIg product rather than to focus on how patients are coping with life in 
general. We were curious about broader aspects of quality of life among our patients with 
PIDs. We wanted to know how they are managing their lives which are complicated by persist 
or recurrent infections and the need for life-long medical treatment. We were interested in 
how frequently they are on sick-leave because of their disease, if they have missed 
educational opportunities and so on.  
During the late eighties and early nineties (1987-1993) there was a scandal with hepatitis C 
virus contaminated immunoglobulin preparation for intravenous administration (IVIg)(34;35). 
Several patients with antibody deficiency who had been treated with IVIg during the interval 
became infected with HCV and experienced significant morbidity. We wanted to study the 
possible effect of HCV disease on these patients’ quality of life. We also wanted to look 
closer at other factors that are known to be important for coping, good quality of life, and 
hope, in general, and see if we could find certain areas of significance for this particular 
group.  
Curative treatment does not always exist 
Some immunodeficiencies are accompanied by other genetically determined manifestations, 
for which there are no cures. This is the case for some of the DNA repair defects which affect 
multiple organs including the central nervous system (CNS) e.g. ataxia-telangiectasia, 
radiosensitive SCIDs (Artemis, DNA ligase IV and NHEJ1deficiency), Hoyeraal-Hreidarsson 
syndrome, and to a lesser degree Nijmegen breakage syndrome and Bloom syndrome. In 
radiosensitive SCID, the immunodeficiency is fatal unless treated with bone marrow 
transplantation, but there is no curative treatment for CNS manifestations. Supportive 
treatment can, however, sometimes prolong life expectancy and quality of life in such 
disorders. Precautionary measures may slow disease progression e.g. in DNA-repair disorders 
with radiosensitivity. 
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DNA repair and immunodeficiency 
Various genetic defects in the DNA repair machinery identified in humans provide insight 
into consequences of genomic instability for the immune system. Increasingly, 
immunodeficiency is recognized as a feature of these syndromes. In many conditions with 
defective DNA repair, the immunodeficiency is clinically variable. Immune function may 
range from normal to severely impaired. Antibody deficiency is the most common 
manifestation, and often involves defective antipolysaccharide antigen responses(36). 
DNA breaks and repair in development of T cells and B cells:  
VDJ recombination  
Cellular DNA is constantly exposed to insults that threaten cellular control and replication. 
The most devastating form of damage is a DNA double-strand break (DSB) which can be 
caused by exogenous agents such as ionizing radiation. Double-strand breaks also occur in 
intermediate stages of normal metabolic processes including DNA replication, immune 
system development and meiotic recombination. Damage response mechanisms maintain 
genomic stability, and include recognition and repair of damage, assessment at checkpoints 
that prevent cell cycle progression in the presence of damage, and mechanisms, such as 
apoptosis, that remove damaged cells (Figure 4).  
In contrast, effective immune responses require the generation of >1000 genetically diverse 
cells bearing a unique receptor capable of recognizing a unique antigen/MHC combination. In 
higher organisms, these genetically diverse cells are created by breaking, randomly re-
sorting/selecting and then joining the DNA sequences coding for antigen receptors by 
adapting the DNA repair mechanisms normally utilized to maintain genomic stability. This 
V(D)J recombination of immunoglobulin in B cell precursors and T cell receptor loci in T cell 
precursors (Figure 5) is a stepwise process during which site-specific DSBs are generated by 
the endonucleases RAG1/RAG2, followed by DSB repair by nonhomologous end joining 
(Figure 6). V in V(D)J stands for variable, D for diversity; and J for joining. During V(D)J 
recombination, one V of the multiple Vs within the TCR and BCR genes is selected and 
joined with one selected D and one J to form the variable regions of immunoglobulins and T 
cell receptor, respectively (Figure 7). 
The T cell TCR genes with their corresponding chromosomal loci are: TCR beta: 7q35, TCR 
alpha and TCR delta: 14q11.2, TCR gamma 7p15-p14. B cell immunoglobulin genes and their 
loci are: Immunoglobulin heavy chain constant region genes (encoding IgM, IgD, IgG1-4, 
IgA, IgE) and genes for the variable V, D, J regions: 14q32.33, Kappa light chain genes: 
2p12, Lambda light chain genes: 22q11.2 (Figure 7). Notice that, in contrast to T and B 
lymphocytes, no rearranging/recombination take place in NK cells. 
Inherited V(D)J recombination defects 
Complete defects in V(D)J recombination result in severe combined immunodeficiency 
(SCID) which is characterized by absence of mature B cells and T cells with preservation of 
NK cells. As in ataxia-telangiectasia, a subset of T-B-NK+ SCID patients is extremely 
sensitive to ionizing radiation. In some of these patients mutations in the DNA repair genes 
Artemis, DNA Ligase IV or NHEJ1(cernunnos-XLF) have been reported. DNA ligase IV and 
NHEJ1 activity are responsible for the ligation step in nonhomologous DNA end joining and 
in V(D)J recombination.  
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Figure 4  Induction of DNA damage and the intracellular responses 
to DNA damage 
DNA repair 
• Direct reversal 
• Base excision repair 
• Nucleotide exision repair 
• Minimal mismatch repair 
• Double strand break repair  
      • Non-homologous end joining 
      • Homologous recombination 
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Figure 5  VDJ recombination, class switch recombination and 
somatic hyper mutation                  
Genes are rearranged to produce B cell immunglobulins. The VDJ step also takes place in T 
cell receptor formation. Somatic hypermutation (SHM) and class switch recombination (CSR) 
are confined to B cells. V in V(D)J stands for variable, D for diversity; and J for joining. 
During V(D)J recombination, one V of the multiple Vs within the TCR and BCR genes is 
selected and joined with one selected D and one J to form the variable regions of 
immunoglobulins and T cell receptor, respectively. VDJ recombination involves DNA double 
strand breaks and DNA ends are repaired by non-homologous end joining. CSR and SHR are 
examples of DNA single strand breaks involving base-excision repair processes. 
Only in B cells Only in B cells 
BONE MARROW V(D)J recombination 
In B cells and T cells, not in NK cells
   
     IgG2:
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                                             DNA double strand breaks caused by 
Figure 6  DNA double strand breaks repair: Homologous or non-
homologous end joining. 
Homologous recombination occurs in cell cycle S phase, while non-homologous end joining 
takes place in G1 (and G2). ATM (ataxia telangiectasia mutated) kinase arrests cell cycle 
progression, allowing DNA repair processes to occur. 
V(D)J recombination Singel strand breaks 
in replication
Homologous 
recombination 
Error-free
Non-homologous end-joining
Resultant loss or gain 
of a few nucleotides 
Ionizing radiation 
chemical agents
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Figure 7 Genes important for a diversified T- and B-cell immune 
response 
T cell TCR genes and B cell immunoglobulin genes and their chromosomal loci on 
chromosome 2, 7, 14 and 22. 
Abbreviations: IGL, Immuoglobulin lambda light chain; IGK, immunoglobulin kappa light 
chain; IGH immunoglobulin heavy chain, TRA, T cell receptor alpha; TRC, T cell receptor 
beta; TRD, T cell receptor delta, TRG, T cell receptor gamma genes; V, variable; D, diversity; 
J, joining; ter, terminal; cer, centromere; p, short arm of the chromosome; q, long arm of the 
chromosome 
V(D)J rearranging/recombination in B-cells: 
    chromosomal loci 14q32, 2p11 and 22q11
V(D)J rearranging/recombination in T-cells:  
   chromosomal loci 7p14, 7q34 and 14q11       
Somatic recombination of V region
B cells only 
Subclass-switch 
Only in IgH region 14q32 B cells 
21
Further DNA damage and repair processes in B-lymphocyte development:                       
Somatic hypermutation and class switch recombination 
B cell response undergoes a secondary repertoire diversification, which is antigen-triggered 
and occurs in germinal centres within lymphoid organs. Somatic hypermutations (SHM) of 
the V region take place (Figure 5) and increase antibody specificity against microbial agents 
(antigens) Refinement of the antibody response involves changing from IgM isotype to Ig 
isotypes (IgA, IgE, IgG) during class switch recombination (CSR). CSR is a region-specific 
DNA recombination reaction that replaces one immunoglobulin (Ig) heavy-chain constant 
region gene with another. A single variable region gene in conjunction with different 
downstream heavy-chain constant region genes, can give rise to several gene products, each 
of which has unique biologic activity. The ability of B cells to express immunoglobulins with 
identical antigen specificity, but different effector functions is a result of CSR. The constant 
(C) heavy chain genes are located in reading frame, 5’ to 3’, as follows: Cμ, Cδ, Cγ3, Cγ1, 
Cα1, Cγ2, Cγ4, Cε, Cα2 (Figure 5). Both SHM and CSR are dependent upon activation-
induced cytidine deaminase (AID), coded for by the AICDA gene. Defects in AID or uracil-
DNA glycosylase (UNG) result in Hyper IgM syndrome types 2 and 4, respectively, with 
inability to switch from IgM to other Ig isotypes and reduced antigen specificity (37;38). AID 
and UNG deficiency are examples of defective base excision repair of DNA single strand 
breaks 
The four major DNA repair pathways  
The four major DNA repair pathways in humans are:  
1. base excision repair (BER),  
2. nucleotide excision repair (NER),  
3. mismatch repair (MMR) and  
4. recombinational repair/repair of DNA double strand breaks (DSBs) including  
a) nonhomologous end joining (NHEJ) (Figure 6) 
b) homologous recombination (HR) (Figure 6)  
In addition, mechanisms for direct repair of damage exist. For example, methylation of 
guanine bases may be directly reversed by the protein methyl guanine methyl transferase. 
Examples of diseases caused by defects in various DNA repair mechanisms 
Diseases caused by defects in BER include Hyper IgM syndrome type 2 (AID deficiency), 
type 5 (UNG deficiency), and familial adenomatous polyposis (FAP). FAP is caused by 
mutations in the APC gene. Patients have numerous colorectal polyps and increased risk of 
developing colon cancer. Examples of defects in NER are Cockayne syndrome, Xeroderma 
pigmentosum and trichothiodystrophy. These diseases have in common extreme UV-
sensitivity. Examples of defects in MMR are hereditary nonpolyposis colon cancer (HNPCC), 
recently renamed Lynch syndrome. Inherited mutations in MLH1 and MSH2 account for 60% 
and 35%, respectively, of genetically characterized Lynch syndrome cases.  Examples of 
defects in DNA double strand breaks repair are ataxia-telangiectasia, Nijmegen breakage 
syndrome, ATR Seckel, and Omenn syndrome or SCID caused by deficiency in RAG1/RAG2, 
Artemis, NHEJ or DNA ligase IV.  Some of these disorders are characterized by radiation 
sensitivity, neurological symptoms and/or immunodeficiency. 
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DNA repair defects cause immunodeficiency, cancer and/or 
neurodegeneration 
Different DNA repair mechanisms are associated with immunodeficiencies, cancer and 
neurodegenerative disorders 
DSBs occurring at random upon genotoxic stress are preferentially repaired by 
nonhomologous end-joining (NHEJ) in higher eukaryotes (Figure 6). Homologous 
recombination (HR) functions only in cell cycle S phase. In mammalian cells, the checkpoint 
response to DNA damage, or replication stress, regulates processes such as cell-cycle 
progression, apoptosis, and DNA replication. Damaged DNA is detected by sensor proteins 
and is relayed to downstream effectors leading to cell cycle arrest, activation of DNA repair 
processes or apoptotic cell death depending on context. DSBs, induced by ionizing radiation, 
for example, are detected by a complex of sensor proteins including γ-H2AX, 53BP1, MDC1, 
BRCA1, and the MRN complex which is composed of MRE11, RAD50, and NBS1 (Figure 
8). Damage signals are then relayed to the central checkpoint mediator, ATM (ataxia-
telangiectasia mutated), which in turn activates CHK2 via phosphorylation resulting in G2 
cell cycle arrest, (Figure 6) allowing the DNA damage to be repaired. UV-induced DNA 
damage and replication stress are detected by an alternative set of sensor proteins including 
the 911 complex (composed of HUS1, RAD1, RAD9), RAD17 and RAD26 (Figure 8). 
Signals are subsequently relayed to the central checkpoint mediator, ATR, which in turn 
activates CHK1 and either inter S phase (leading to HR) or G2 cell cycle arrest (leading to 
NHEJ)(Figure 6). Cancer cells often adapt to DNA damaging chemotherapeutic agents and 
escape apoptosis. This adaptive mechanism may include cell cycle arrest and repair of 
damaged DNA. The checkpoint proteins are important in oncogenesis and, thus, a potential 
target for cancer therapy. Failure to properly repair DSBs results in genomic instability, 
aberrant CNS development, and various forms of immunodeficiency. Reduced repair capacity 
caused by mutations in one of the DNA repair genes is linked to several human syndromes 
which feature cancer predisposition, developmental abnormalities, neurological abnormalities, 
and/or premature aging.
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Figure 8 Current view of the ATM-dependent DSB response network. 
When the MRN complex (MRE11, RAD50, NBS1) sense DNA double strand breaks (DSB), ATM is 
phosphorylated from the inactive dimer to the active monomer which activates multiple processes through 
phosphorylation, and coordinates further events leading to DSB repair. The MRN complex acts both upstream 
and downstream of ATM. ATR are able to phosphorylate some of ATM’s substrates in response to these DNA 
lesions at later time points and slower kinetics  
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Ataxia-telangiectasia 
Ataxia-telangiectasia (A-T) is an autosomal recessively inherited disorder caused by 
mutations in the ATM gene. The condition is pleiotropic with manifestations from many 
different body systems including: progressive cerebellar ataxia, oculomotor apraxia, 
dysarthria, immunodeficiency, progressive oculocutaneous telangiectasias, progeric hair and 
skin changes, endocrine abnormalities, growth retardation, chromosomal instability, radiation 
sensitivity and cancer susceptibility particularly for lymphomas and leukemia (MIM#208900).  
Life expectancy  
Malignancies or chronic lung failure with pulmonary infections cause death in early 
adulthood. The role of the immunodeficiency has not been clearly defined. Median survival in 
two large cohorts of patients with this disease, one prospective and one retrospective was 25 
and 19 years, with a wide range. Life expectancy did not correlate well with severity of 
neurological impairment in one study (39). 
Diagnosis 
Elevated serum alpha fetoprotein (AFP) and reduced serum IgA are characteristic and support 
the diagnosis (40-42) (Table 1), given a clinical suspicion of A-T. Identification of mutations 
in both the patient’s ATM genes is diagnostic. A characteristic finding in lymphoblastoid cell 
lines derived from A-T patients is the absence of ATM protein or, when residual protein is 
present, reduced kinase activity (43). ATM protein kinase is involved in DSB response and 
repair (44), and in maintenance of cell homeostasis after oxidative damage (45-48).  
Classic A-T is the result of two truncating mutations leading to total loss of function of the 
ATM protein. Milder disease is associated with leaky splice site or missense mutations (49-
52). 
Table 1  Diagnostic criteria for A-T, from the guidelines developed by ESID http://www.esid.org/
Definitive: 
Male or female patient with either increased radiation induced chromosomal breakage in cultured cells, or 
progressive cerebellar ataxia, who has disabling mutations on both alleles of ATM. 
Probable:
Male or female patient with progressive cerebellar ataxia and three out of the following four findings: 
1) Ocular or facial telangiectasia 
2) Serum IgA at least 2 SD below normal for age 
3) Alpha fetoprotein at least 2 SD above normal for age 
4) Increased chromosomal breakage after exposure to irradiation 
Possible: 
Male or female patient with progressive cerebellar ataxia and at least one of the above mentioned four findings. 
History 
Syllaba and Henner published the first descriptions of patients with A-T in 1926 (53) after 
observing progressive choreoathetosis and ocular telangiectasia in three members of a single 
family. The next report describing patients with A-T came in 1941 when Louis-Bar described 
progressive cerebellar ataxia and cutaneous telangiectasia in a Belgian child (54). This 
condition was subsequently named Louis-Bar syndrome. A-T was not described as a distinct 
clinical entity for another two decades when Boder and Sedgwick as well as Biemond and 
another Belgian pediatrician, Pelc, reviewed autopsy findings and reported abnormal organ 
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development, cerebellar atrophy, neurologic manifestations and two additional major features, 
immunodeficiency and increased risk of lymphoreticular malignancies (55-60). In Norway, 
five cases were described by Smeby in 1966 (61). The Norwegian immunologists Natvig, 
Harboe et al reported IgA deficiency in 5 out of 8 A-T patients (62). Assays of the other 
isotypes IgM, IgE, IgD, IgG including IgG subclasses were not available clinically until 80s. 
Clinical manifestations of A-T 
Progressive cerebellar ataxia 
The earliest manifestation of A-T is truncal ataxia, usually noticed when the child begins to 
walk between 1-1 ½ years of age. The child’s head and trunk sway on standing and even on 
sitting. In contrast to other cerebellar ataxias the gait is narrow, not broad-based. The child is 
often a better runner than walker, and finds walking in uneven terrain easier than on level 
surfaces. Standing upright without support is the biggest challenge. Cerebellar ataxia 
progresses with age and is accompanied by drooling and dysarthria. Later loss of deep tendon 
reflexes and dystonia can be present. After age 5 years, ataxia is increasingly apparent and the 
child needs support for walking. The child usually prefers a wheel chair instead to walking by 
age 10 or 11 years. Electric wheel chairs are introduced early so that the child can rest as 
needed, not use all his or her strength on ambulating, and have energy to play with the other 
children. The all terrain electric wheelchairs allow individuals with A-T independent mobility. 
Joystick and remote controls are easy to manage for most children with A-T. 
Conjunctival telangiectasis 
Oculocutaneous telangiectasia, the second diagnostic hallmark of A-T, usually manifests later 
than ataxia and oculomotor apraxia. The name ataxia-telangiectasia can be misinterpreted to 
mean that telangiectasis is a mandatory feature and delay diagnosis. The mean age of onset for 
telangiectasias is 5 years with a range from 4 to 10 years (63). Conjunctival telangiectasias are 
first visible in the palpebral fissure, later they can also be seen in the conjunctival fornix 
(Figure 9). Dilatation and tortuosity of blood vessels increases gradually with age (Figure 10). 
With time cutaneous telangiectasias can also typically be observed on the backs of the hands, 
neck and ear lobes (Figure 11).  
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Figure 9  Conjunctival telangiectasias 
Conjunctival telangiectasias in a 19-year old individual with A-T  
6 years of age                    10 years of age 
Patient 1      
6 years of age                    10 years of age 
Patient 2    
(Photos: Dr.Ruth Riise) 
Figure 10  Conjunctival telangiectasias increasing with age in A-T 
                   
A                                    B    (Photos: Dr. Ruth Riise) 
Figure 11  Cutaneous telangiectasias 
Ear lobe of a child with A-T (A). Hands of an adult with A-T (B).  
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Oculomotor apraxia/ataxia 
The onset of ocular movement abnormalities, especially saccades, precedes the advent of 
telangiectasias. The four components of ocular stability and motility: ocular fixation, smooth 
pursuit movements, saccades and optokinetic nystagmus, are affected from early childhood in 
A-T, and the changes are progressive and irreversible. The oculomotor disturbance in A-T has 
been described as oculomotor apraxia, but oculomotor ataxia is a more appropriate term. 
Ocular fixation becomes unstable with small saccades and a tendency to ocular flutter. 
Normal fixation is universally lost after the age of six years. Smooth pursuit movements are 
affected from the age of four years, when small catch-up saccades can be seen. The eyes 
follow a moving object in a step-wise/staccato manner, sometimes with over-shooting.  
The ocular movement abnormalities are characteristic for cerebellar abnormalities, but also 
point to brainstem abnormalities (64).  
In A-T there is increased delay time for the initiation of visually and verbally induced 
saccades. There are many small saccades with low gain (under-shooting), both horizontally 
and vertically (oculomotor apraxia). Compensating head thrusts as in Cogans’ congenital 
ocular motor apraxia have been reported previously, but were not seen in the Norwegian A-T 
patients (63). Optokinetic nystagmus is lost before three years of age in classical A-T patients. 
To read along lines becomes increasingly difficult. Instead of learning to read by spelling the 
letters to form words, children are better off learning to recognize whole words. Children with 
A-T should have the opportunity to learn to read as early as possible, before the oculomotoric 
problems progress. Visual acuity and retinal appearance are usually normal in patients with A-
T.  
Cerebral and cerebellar MRI findings 
Typical MRI findings in A-T are diffuse cerebellar atrophy, particularly affecting the vermis 
and the superior cerebellar cortex (65;66) (Figure 12). Head circumference is usually within 
normal range. A small proportion of A-T patients are microcephalic. Head circumference is 
not related to severity of neurological impairment in a linear manner (Personal 
communication dr.Tom Crawford, A-T Clinical Center John Hopkins Hospital). Proton MRI 
spectroscopic features in A-T correlate closely with the structural neuroimaging finding of 
posterior fossa atrophy. Older A-T patients exhibit profound loss of all metabolites in the 
cerebellar vermis and a trend towards decreased metabolite content within the cerebellar 
hemispheres. Although symptoms suggesting extrapyramidal dysfunction are part of the A-T 
phenotype, these are not associated with altered metabolite levels in the basal ganglia. A few 
older A-T patients tested had multiple small foci of hypointensity on T2*-weighted images 
suggestive of capillary telangiectasia throughout the brain (67;68) 
Degeneration of cerebellar Purkinje cells 
Cortical cerebellar degeneration in A-T involves primarily Purkinje and granular cells, while 
adjacent basket cells remain unaffected. Although degenerative changes in the central nervous 
system are seen predominantly in the cerebellum, changes in other parts of the CNS have also 
been described, and are clinically demonstrated by the characteristic oculomotor 
abnormalities and by additional neurological signs in older patients.  
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 MRI picture of a 20 year 
old patient with A-T 
These cerebral MRI pictures of a 10 year old child with A-T show cerebellar atrophy, especially of the vermis.  
The fourth ventricle is secondarily enlarged. The brain stem and cerebrum appear structurally normal. 
Figure 12  MRI images showing cerebellar degeneration in A-T 
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Other clinical neurological findings 
• Dysarthria, slow and slurred speech becomes a prominent feature with age and is 
caused by cerebellar degeneration.  
• Drooling and hypersalivation are usually present at the age of diagnosis but often 
become less of a problem with age. Most patients are not treated for drooling.  
• Individuals with A-T are not mentally retarded. A modest decline in short-term 
memory and cognitive functioning has been observed as has a reduction in age specific 
skills,  when the tests of cognitive functions are adjusted so that time expenditure or 
ataxia do not affect results (Reported by Oril Johnsen, Children Habilitation Unit, 
Hamar). 
• In contrast to other diseases with cerebellar damage, individuals with A-T generally 
have normal or increased muscle tone. Increasing rigidity is present in older patients. 
Exercise and physiotherapy are recommended, do not cause harm and will eventually 
improve muscle strength, and may help to compensate for loss of balance. 
• Extrapyramidal signs such as rigidity, bradykinesia, mask-like facies, adventitious 
movements, chorea, athetosis and tremor have been reported in older A-T patients and 
reflect more global neurodegeneration of the brain involving areas such as the basal 
ganglia.  
• Proprioception is good in individuals with A-T until late in the disease. A peripheral 
neuropathy, large fiber sensory neuropathy, can be observed in older A-T patients. 
Plantar responses become inverted or disappear. Deep tendon reflexes are lost with 
age. In very late disease, muscle weakness and distal spinal muscular atrophy can be 
seen (69;70). 
• Clinical data including autopsy reports of patients older than 25 with classical A-T 
point to vascular abnormalities/microangiopathy in the brain parenchyma with an 
increased risk of intracerebral haemorrhage. The vascular changes are similar to those 
seen in the long term in post-radiation brain injury (71-73).  
Other non-neurological clinical manifestations 
High incidence of lung problems in A-T, risk of chronic lung failure  
Chronic neuromuscular diseases affect the respiratory muscles in varying patterns and to 
different degrees. As a result, patients with such disorders develop restrictive pulmonary 
disease, ineffective coughing, atelectases and pneumonia, and chronic respiratory 
insufficiency leading to respiratory failure. Therapeutic strategies are under development to 
augment coughing and airway clearance, improve lung volume, and generally support the 
patient with progressive ventilatory failure. These techniques have improved longevity and 
quality of life for many patients with neuromuscular disease. 
Pulmonary infections are reported in older A-T patients. Recurrent respiratory infections have 
previously been linked to the immunodeficiency. Pulmonary status is a prognostic factor for 
A-T patients. Older patients tend to have a bell-shaped chest, chronic lung failure and 
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insufficient oxygenation. There is also a risk of severe rare interstitial lung disease in A-T 
(74). 
Endocrine and autoimmune abnormalities. Progeria 
Growth retardation  
Patients with A-T tend to be short as adults.  Short stature and a slender habitus (cachectic) 
are also observed in other DNA repair disorders such as Bloom’s syndrome, Fanconi’s anemia 
and Nijmegen breakage syndrome. There are reports of growth hormone deficiency in A-T 
(75;76). Progressive difficulties with chewing and swallowing as well as malnutrition may 
influence growth in A-T.  
  
Endocrine abnormalities 
Laboratory and clinical findings in A-T patients indicate that primary gonadal failure is an 
integral part of the disease (77). A link between the gonadal dysfunction in males and 
chromosomal instability may also exist. In addition to hypogonadism, other endocrine 
abnormalities are frequent (78).  Diabetes mellitus is often observed in older A-T patients.   
Autoimmunity 
Various autoimmune phenomena are frequently observed in A-T. Coombs positive transient 
erythroblastopenia has been reported. Autoimmune signs of the skin and hair may include 
alopecia, café au lait spots and vitilligo. The patients have signs of premature aging (progeria) 
of the skin and hair.  
Immunodeficiency in A-T
Immunodeficiency has been highlighted as one of the major health issues in A-T. Several 
reports list recurrent sinopulmunary infections as a prominent feature and the cause of age-
related respiratory failure (79). In early reports 80-90 % of A-T patients were noted to be 
immunologically impaired:  IgA deficiency (60-80%)(62), IgE deficiency (23-80%), IgG2 
deficiency (50%), IgG4 deficiency and hypogammaglobulinemia (10-20%). At least 10% 
were on intravenous Ig treatment. Both humoral and cellular immunodeficiency has been 
reported previously  (80-83). Underdevelopment of the thymus was emphasized as an 
important diagnostic sign as well as a sign of the severe immunodeficiency. There have been 
reports describing a reduced number of T cells, increased proportions of HLA-DR+ activated 
T cells, double negative gamma delta T cells, and memory T cells compared to alpha beta T 
cells and naïve T cells (81). However, there have been no reports of Pneumocystis jerovicii
infection, invasive fungal infection or other clinical signs of severe T cell deficiency in A-T. 
High IgM levels have been reported frequently, but in contrast to patients with hyper IgM 
syndrome, most patients with A-T have had IgG1 levels within the reference range. There are 
some reports which describe inter-personal variation in type and degree of immunodeficiency, 
including variation between siblings (84). No ATM genotype- immunological phenotype 
studies had been performed previously.  
A-T patients were previously advised to avoid exposure to chickenpox and live vaccines such 
as MMR, BCG and oral polio. It was thought that because of the immunodeficiency other 
vaccines would be less effective or only have negligible effect.  In some countries vaccines 
were not recommended in A-T. Low levels of pneumococcal antibodies were documented in 
A-T patients. Other researchers found A-T patients did not mount an antibody response after 
vaccination with pneumococcal polysaccharide vaccine (85). The conjugate pneumococcal 
vaccine had previously not been tested on A-T patients. We wanted to test our patients’ 
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response to this vaccine, in an attempt to potentially severe invasive pneumococcal disease. 
See the end of this introductory chapter for a more detailed description of Streptococcoccus 
pneumonia and immune defence. 
Spontaneous and irradiation induced chromosomal changes in A-T lymphocytes 
A-T patients may have spontaneous chromosomal breakage in peripheral lymphocytes on 
standard karyotyping after PHA stimulation. Chromosome 14 is frequently involved and 
chromosome 7;14 translocation, is seen in 5-15% of cells (Aurias 1980). The spontaneous 
chromosomal rearrangements in lymphocytes from A-T patients harbour breakpoints which 
consistently involve the TCR and BCR loci, including the immunoglobulin heavy chain 
genes, on chromosomes 7 and 14, respectively (86) (Figure 7). These clones may undergo 
expansion as part of the evolving malignancy process and precede overt lymphocytic 
malignancies (87-89) 
Increased risk of cancer in A-T 
Patients with A-T are predisposed to cancer. The lifelong cancer risk is estimated to lie 
between 20-30%, but estimates vary in different reports (90). This incidence is approximately 
100-fold greater than expected for an age-matched population. Lymphomas and acute 
promyelocytic leukemias constitute the majority of childhood cancers in A-T and half of 
cancers after age 20 years. Older patients have been reported to have an increased risk of 
other malignancies, such as epithelial tumors including breast cancer (91-93). Although A-T 
patients develop both B cell and T cell malignancies, the relative proportions are quite 
different than in the non A-T population, malignancies of pro-T cell origin dominate in A-T 
(90){Taylor, 1996 194 /id}. A-T disease is caused by germline (constitutional) ATM 
mutations. Somatic (acquired) mutations in ATM have been found in lymphoid cells from 
non-A-T patients with leukemia and lymphoma of T cell or B cell origin, and in T cell 
preleukemic clonal proliferations. The mutational spectrum includes missense mutations, in-
frame deletions, and null mutations, scattered across the ATM gene. Thus, ATM is directly 
linked to the development of leukemias/lymphomas, but no single location within the ATM
coding sequence predisposes to a specific type of lymphoid malignancy. Recently, Matei et al.
have shown that ATM deficiency increases the frequency of T cell receptor alpha deletion 
events, compromising T cell maturation, and may be responsible for oncogenic T cell receptor 
translocations (94). The risk of leukemia and lymphoma need to be kept in mind.  
Radiation sensitivity 
A-T patients are extremely sensitive to ionizing radiation. Radiotherapy is contraindicated 
because it can cause acute as well as chronic damage to various organs. Cytostatic drugs 
containing radiomimetic and DNA damaging agents may have similar effects. X-rays and CT 
scans should be reduced to a minimum and replaced by MRI or ultrasound scans whenever 
possible. 
In vitro sensitivity to radiation  
The abnormal response manifests in vitro as hypersensitivity of cultured fibroblasts to 
ionizing radiation and radiomimetic chemicals (95). Radiosensitivity assays of 
lymphoblastoid cell lines show abnormal cell survival in patients and carriers, and has been 
used diagnostically in some countries (Table 1). By and large, mutation analyses have 
replaced radiosensitivity assays diagnostically.  
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Treatment of A-T 
At present there is no cure for the progressive neurodegeneration in A-T. Little progress has 
been made in treating the progressive ataxia. The only therapeutic options are medical 
management of the patient’s problems such as immunodeficiency, sinopulmonary infections, 
reduced lung function, malignancy, various neurologic dysfunctions, and rehabilitation for 
physical and social disabilities.  
Treatment of the immunodeficiency:
Immunoglobulin treatment is indicated whenever hypogammaglobulinemia causes symptoms 
that likely will be ameliorated by replacement therapy. Antibiotics should be given promptly 
when pneumonia is suspected. Respiratory infections respond well to antibiotics. Fungal 
infections of the skin and/or nails are treated with standard doses of antifungal therapy. Local 
antiviral therapy can be used in herpes simplex virus (HSV) relapses. Usage of vaccines in A-
T has long been debated. Avoidance of live vaccines has been advised previously. Bone 
marrow transplantation suggested by Matei (89) and Bagley (96) should not be done in A-T 
patients because the typical A-T immunodeficiency is far from classical SCID, and because 
preconditioning cytostatics may worsen neurological defects, as well as confer an increased 
risk of secondary cancer.  
Treatment of cancer – avoid radiomimetic agents and radiation therapy
If a child with A-T develops cancer, special protocols for treatment should be followed, and 
the child must be cared for by a pediatric oncologist experienced in cancer therapy in DNA 
repair disorders. In addition to the extreme sensitivity to cytostatic agents with radiomimetic 
properties, patients with A-T are also particularly sensitive to agents with neurotoxic effects 
such as bleomycine and vincristine.   
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Treatment of neurological symptoms 
Modest improvement in associated neurological symptoms can sometimes be achieved with 
treatment:  
Basal ganglia dysfunction may respond to L-DOPA derivatives, dopamine agonists and, occasionally, to 
anticholinergics. Anticholinergics may also reduce drooling. None of our patients have been treated with 
dopaminergics. 
Treatments for drooling include 1) oro-facial training or massage 2) prochlorperazine (stemetil®), an 
antipsychotic drug with mild sedative effect. The drug is widely used for its antiemetic effect. It produces 
hyposalivation and has been used widely in the treatment of drooling. 3) Trimonthly botox injections in the 
submandibular and parotid glands. 
Loss of balance may respond to amantadine, fluoxetine or buspiron. These may also improve speech and 
coordination. None of our patients have been treated with these compounds. Tremor may be controlled with 
gabapentin, clonazepan or propanalol. None of our patients are treated with these compounds, since it is not a big 
problem and because of the potential side effects. 
The most debilitating feature of this disorder is progressive neurodegeneration due to the loss of Purkinje cells in 
the cerebellum and the malfunctioning of other neuronal cells. Correcting the loss of Purkinje cells is technically 
very difficult and would require transplantation of embryonic stem cells. Embryonic stem cell transplantations 
have great promise but delivery to the most affected regions of the brain, is a formidable challenge. 
A recent observation shows that treatment with the steroid bethametasone produces a short-term improvement in 
ataxia (97). However, the long-term complications of steroid use are likely to outweigh the short-term benefit.  
Some promise exists in the development of methodology designed to target specific prototypes of mutations in 
the ATM gene. Aminoglycoside antibiotics cause expression of functional ATM protein by reading through the 
termination codon of the ATM mutation. This is promising.  However aminoglycosides are toxic in effective 
doses and transport across the blood-brain barrier to the Purkinje cells within the cerebellum is difficult to 
achieve. 
Another treatment strategy is to replace ATM functions or circumvent the ATM kinase deficiency in the DSB 
response network within the Purkinje cells. ATR and ATM are close siblings within the PIKK family (Figure 9), 
having similar structure and functions. Increased ATR activity may be able to act as an ATM backup system.  
Topoisomerase increases ATR expression. ATR phosphorylates some ATM substrates and restores partial ATM 
function. 
Although deficiencies of thiamine, vitamin B12 and vitamin E can cause ataxia, ordinary multivitamin 
supplements do not correct ataxia in A-T patients.
New treatment strategies should focus on slowing the progress of neurodegeneration. Since it seems likely that 
oxidative stress contributes to neurodegeneration, potential therapies based on the use of antioxidants (98) offer 
some hope(97;99-102). Antioxidants may reduce reactive oxygen species (ROS) which cause DNA damage. 
Antioxidants may concomitantly slow progression of the neurological phenotype and reduce the risk of cancer. 
Antioxidant treatment and effects on immunological functions in A-T patients is more uncertain (Lederman, 
Crawford et al) (103). 
While the number of treatment options for A-T patients is limited at present, the great 
advances achieved over the past decade in identifying mutations and understanding how ATM 
functions in response to DNA damage, provide additional hope for the future therapies.  
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A-T carriers 
Immunological findings in A-T carriers 
Low serum IgE levels (104) and IgA deficiency (105)have been reported in relatives of A-T 
patients (105). The clinical implications of the findings were not reported. 
A-T carriers and cancer risk 
Several studies cite a three-to five-fold risk compared to normal for developing breast cancer 
in A-T carriers (93;106-109). The Nordic follow-up study (83) of 1445 blood relatives of 75 
A-T patients, comprising 66 families of Danish, Finnish, Swedish or Norwegian origin, 
showed an increased risk of breast cancer among female carriers, especially among mothers < 
55 years. The standardised incidence rate (SIR) was 2,9 (95% confidence interval, range 1.8-
4.5) for all female carriers, and a SIR of 8.1 (95% CI, 3.3-17) was found for mothers < 55 
years (110) (Olsen 2005). Cancer incidence and mortality information for 1160 relatives of 
169 UK A-T patients showed that the overall relative risk (RR) of breast cancer in carriers 
was 2.23 (95% CI, 1.16- 4.28) compared with the general population, but was 4.94 (95% 
CI,1.90-12.9) in those younger than age 50 years (111).  
Mutations in genes identified to date explain approximately 20% of the familial aggregation 
of breast cancer. In the context of multiple-case families, mutations in BRCA1 and BRCA2
confer high lifetime risks of breast cancer and ovarian cancer, and more moderate risks of 
prostate cancer and some other cancer types. Mutations in the CHEK2 and ATM genes, but 
not in the ATR gene, cause more modest, but important, risks of breast cancer. Female carriers 
of NBS1 mutations are also susceptible to breast cancer (112;113). Interactions between ATM, 
ATR, NBS, CHEK2, BRCA1 and BRCA2 are illustrated in Figure 8. 
Further studies to explain the differences in cancer occurrence between the A-T carriers are 
needed. It appears that specific mutant ATM protein can mitigate the neurological aspects of 
the clinical phenotype, as well as cellular features measured in vitro, but, at the same time, may
promote a tumor phenotype. Other expressed in-frame deletions and missense mutations 
appear to contribute to the development of tumors, without the same mitigation of other 
aspects of the phenotype. In some A-T families with truncating mutations in which there is no 
ATM expression, however, the relationship of ATM mutations to tumor development appears 
to be more complex, and additional factors may be involved. Variation in breast cancer risk 
has been suggested to be due to exogenous/environmental factors (114) and to endogenous 
factors such as modifier gene variants. ATM gene variants/polymorphisms that are not linked 
to A-T disease are currently under study as are other factors which modulate ATM protein 
responses, such as MDM2 (Figure 8). 
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Incidence of A-T 
Disease incidence and carrier frequency - international data:  
A-T has been reported in all regions of the world. The incidence of A-T is about 1 per 
100.000 livebirths (115). The frequency of A-T mutant heterozygous alleles has been 
estimated to be 1.4-2% in  the general population (115;116). 
The ATM gene and mutation spectrum 
The ATM (A-T mutated) gene, maps to chromosome 11q22.23 (117), spans~150 kb of 
genomic DNA, contains 66 exons and was identified in 1995 (118). GDB:593364 
[http://gdbwww.gdb.org/]; (119). ATM protein kinase is involved in DSB response and repair 
(44), and in maintenance of cell homeostasis in response to oxidative damage (45-48). 
Mutations in ATM are spread widely across the gene’s 66 exons (Figure 13). As of year 2007, 
more than 400 different A-T disease causing sequence alterations in ATM have been reported 
(http://chromium.liacs.nl/lovd/).  
ATM databases: 
• The former A-T mutation database was last updated May 27, 2004:  
http://benaroyaresearch.org/investigators/concannon_patrick/atmut-t.htm.  
• The new international A-T mutation database is electronically available at 
http://chromium.liacs.nl/lovd/  
• ATM protein kinase database:  “Showcase for ATM Related Pathways” (SHARP) is designed to assist 
researchers in integrating, visualizing and interpreting pre-existing and new information on the ever-
growing ATM-mediated network. SHARP is available on internet address: http://www.cs.tau.ac.il/
sharp. 
Figure 13 Mutations in the ATM gene detected in A-T patients by exons 
Picture from the ATM mutation database year 2004 at Virginia Mason Research Center, USA: 
http://benaroyaresearch.org/investigators/concannon_patrick/images/atgraph.gif
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Figure 14  Schematic figure of the human PIKK proteins.                                       
The number of residues is indicated for each protein. All of these proteins with the exception of TRRAP possess 
protein kinase activity. Three motifs are common to all: the FAT and FATC domains are of unknown functional 
significance, but the FAT domain of ATM contains serine 1981—the site that is autophosphorylated during 
ATM activation. The PI3K domain, which contains the phosphatidylinositol 3-kinase motifs, harbors the 
catalytic site in the active kinases of the family.
The gene product – the ATM protein kinase and its functions 
The deduced amino acid sequence of the ATM gene contains 3056 residues and, at its 
carboxyl-terminal end, shows similarity to the catalytic domain of phosphatidylinositol-3 
kinases (Figure 14). The PI-3 kinase motif is common to a group of proteins that are involved 
in cell-cycle regulation, response to DNA damage, interlocus recombination, and control of 
telomere length. The gene product, the ATM protein kinase, is confined to the nucleus and has 
multiple functions. ATM has a central role in DSBs (DNA double strand breaks) response and 
DSBs repair processes and in intracellular signalling pathways (44) (Figure 8) and also in 
maintenance of the cell homeostasis in response to oxidative damage(45-47;47;48). The MRN 
complex sense DSB, ATM is phosphorylated from the inactive dimer to the active monomer 
which activates multiple processes through phosphorylation, and coordinates further events 
leading to DSB repair. MRN complex acts both upstream and downstream of ATM. ATM has 
a central and coordinating function both in HR and NHEJ. ATM is involved in VDJ 
recombination (in T and B cells) and isotype class switch (in B cells), but not in somatic 
hypermutation (120). ATM plays an important regulatory role in phosphorylation of TP53 
(p53), a tumor suppressor, thereby abolishing TP53–MDM2 interaction and allowing TP53 to 
accumulate. ATM also phosphorylates MDM2 which interferes with the nucleo-cytoplasmic 
shuttling of the MDM2–TP53 complex and contributes to TP53 stabilization. In addition, 
ATM functions as a regulator of a wide variety of downstream proteins, including tumor 
suppressor BRCA1, checkpoint kinase CHK2, checkpoint protein RAD50 and DNA repair 
protein NBS1. 
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Alpha fetoprotein in A-T 
The finding of elevated serum alpha fetoprotein (AFP) is characteristic of A-T and supportive 
of the diagnosis (40-42). The AFP elevation in A-T was initially recognized because it was 
evident on the serum protein electrophoresis when serum albumin and immunoglobulin levels 
were measured. It was postulated to be related to the immunodeficiency and immunoglobulin 
levels or caused by a common defect in tissue differentiation. Although the elevation of serum 
AFP in A-T has been known for decades, the underlying mechanism including the link to 
ATM protein kinase deficiency has not been defined.
Elevated serum levels of AFP have proven to be a reliable marker of A-T after the age of two 
years. An age-dependent elevation was commented upon in some of the first reports and 
reviews of A-T (121). But in a large cross-sectional study from the UK, the AFP levels of 48 
A-T patients were measured on one occasion and no correlation between age and serum AFP 
level was found (42). This finding has influenced practice over the last 15 years, and serum 
AFP levels have not been followed longitudinally as a routine in A-T patients.  
AFP in other neurodegenerative diseases 
Other similar and rare neurodegenerative diseases with increased levels of AFP are ataxia 
oculomotor apraxia syndrome 2 (AOA2 = SCAR1) and ataxia with vitamin E deficiency 
(AVED caused by mutations in the alpha-tocopherol transfer protein, TTPA)(122-124). But 
remarkably, given the clinical similarity of these diseases, AFP is not increased in the A-T 
like disorder (ATLD=MRE11 deficiency) or in Nijmegen Breakage Syndrome, AOA1 and 
autosomal recessive spinocerebellar ataxia with axonal neuropathy (SCAN1)(125). Table 2 
summarizes serum AFP levels in A-T and A-T related disorders.  
Differential diagnoses to A-T 
The differential diagnosis of AT includes a variety of conditions: infectious encephalitis, 
Friedreich's ataxia which has a later onset, ataxia associated with a number of metabolic
diseases of infancy and childhood, ATLD and the autosomal recessive syndromes with ataxia 
ATLD, AOA1 and AOA2. Figure 12 is a diagnostic algorithm of progressive ataxia in 
childhood. 
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Figure 15 Algorithm for the work-up of progressive childhood ataxia  
Abbreviations: AFP, alpha fetoprotein; AOA, Ataxia oculomotoric apraxia; A-T, Ataxia telangeictasia; AVED, Fredreich-like 
ataxia with selective vitamin E deficiency; ALD, Adrenoleukodystrophy; CTX, Cerebrotendinous xanthomatosis; CDG, 
Congenital disorder of glycosylation; CDT, Carbohydrate deficient transferring; TIEF, Transferrin isoelectric focusing; GM1, 
Gangliosidosis with defect beta-galactosidase; GM2, Gangliosidosis with defect beta-hexosaminidase; MLD, Metachromatic 
leucodystrophy; NPC, Niemann Pick type C disease; SCAN1, Spinocerebellar ataxia with axonal neuropathy type 1. 
Progressive childhood ataxia  
    Check for Friedreichs ataxia
      if GAA repeats in frataxin FXN gene are normal, 
      perform brain MRI scan: 
           Cerebellar atrophy                       
               Yes
Check 
Oculomotor 
apraxia  : A-T, AOA1, AOA2, SCAN1 
AFP ↑   :  A-T or AOA2 
Albumin ↓ and 
Cholesterol ↑   :  AOA1 or SCAN1       
Cholestanol ↑  
and diarrhoea  :  CTX     
CDT, TIEF    :       CDG    
           No
Check 
Vitamin E ↓  :         AVED or Abetalipoproteinemia 
Phytanic acid ↑ :   Refsum’s disease 
Ceruloplasmin ↓ :  Wilson’s disease 
Blood smear      :   Sideroblastic x-linked anemia  
Leucodystrophy  
on cerebral MRI : Krabbe, MLD, GM1, GM2, NPC, ALD 
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Other DNA repair disorders with immunodeficiency 
DNA repair disorders similar to A-T with defect DNA double strand breaks repair   
Mutations in NBS1 and MRE11 give rise to Nijmegen breakage syndrome (NBS) and ataxia-telangiectasia-like 
disorder (ATLD), respectively, the clinical and cellular phenotypes of which overlap considerably with ataxia-
telangiectasia 
Nijmegen breakage syndrome (NBS)   
The Nijmegen breakage syndrome (NBS1; OMIM 251260), is an autosomal recessive disease characterized by 
microcephaly, characteristic facial features, growth retardation, immunodeficiency and cancer predisposition 
(high risk of lymphoma/leukaemia). NBS cells show spontaneous chromosomal instability and hypersensitivity 
to ionizing radiation in combination with radioresistant DNA synthesis. At the cellular level, NBS has some 
features in common with A-T. NBS is caused by a hypomorphic mutation of the NBS1 gene 8q21, encoding 
nibrin, which forms a protein complex with Mre11 and Rad50, both involved in DNA repair. Nibrin participate 
in the repair of gamma-irradiation damage and maintenance of chromosomal stability. Unlike A-T there is a 
limited spectrum of different mutations. Over 90% of NBS patients are homozygous for the hypomorphic 
657del5 mutation and are of Slavic origin. A couple of other truncating mutations have been identified in 
patients of other ethnic origin. Partially functional proteins produced by alternative initiation of translation, 
reducing the severity of the NBS phenotype, have been described for some of these NBS1 mutations (126). And 
homozygozity for 1089C>A has been linked to a Fanconi anemia phenotype. Incidence of NBS is 1: 100.000 
live births, with an estimated carrier frequency 1/150 in the Eastern Europe.  
NBS and cancer 
In 40% of the NBS patients cancer are noted before the age of 21 years, mainly lymphomas. Thus, they seem to 
be more at risk for cancer than in A-T (127). Compared to A-T, they have earlier sign of growth deficiency, with 
lower than normal birth weight and small for gestational age. The microcephaly is progressive but usually not 
accompanied by severe mental retardation or ataxia. Important additional features are the skin abnormalities, 
particularly cafe au lait spots and vitiligo. 
NBS carriers and increased risk of breast cancer 
Heterozygous carriers are healthy, but may have an increased risk of breast cancer (112;113). 
NBS and immunodeficiency 
As part of the Mre11/Rad50/NBS complex Nibrin plays a role in the recombination of Ig constant region genes 
and in B lymphocytes and in Ig class-switch recombination. Nibrin localizes to chromosomal sites of class 
switching, and B cells from NBS patients show an enhanced presence of microhomologies at the sites of switch 
recombination.  nibrin acts downstream of switch transcript-induced targeting of switch regions and activation-
induced cytidine deaminase (AID)-induced DNA breaks in the targeted switch regions (128). Similar to A-T a 
characteristic, variable deficiency of serum IgG and IgA with normal IgM levels is observed. Individual Sµ–
Sα switch-recombination junctions of Ig class-switched B lymphocytes from NBS and ATLD patients show a 
preponderance of microhomologies at the site of recombination which is also seen in A-T. In addition to the 
important role that nibrin plays in CSR, nibrin is also crucial for the survival of B lymphocytes. 
Agammaglobulinemia has been found in 35% and IgA deficiency in 20% of affected individuals. Deficiencies in 
IgG2 and IgG4 are frequent even when the IgG serum concentration is normal. The most commonly reported 
defects in cellular immunity are reduced percentages of total CD3+ T cells and CD4+ cells. An increased 
frequency of memory T cells and a concomitant decrease in naive T cells has been reported. (129).  
NBS interacts with ATM 
NBS has an important role within the Mre11-Rad50-Nbs1 complex. This Mre11-complex acts both upstream and 
downstream of ATM as a sensor of DSBs, in the cell cycle control and DSBs repair machinery. 
MRE11 A-T like disease    
MRE11 mutations are the underlying cause of the Ataxia-telangiectasia-like disorder (ATLD), also a rare 
autosomal recessive disorder (locus 11q21, OMIM 604391). The clinical features of patients with ATLD are 
very similar to those with A-T, with ATLD patients showing progressive cerebellar ataxia plus ocular apraxia. 
However, the neurological features have a later onset and slower progression. As of 2006, less than 20 ATLD 
patients have been reported internationally. No elevation of serum alpha fetoprotein has been observed, and most 
of the patients reported do not have telangiectasia. Chromosomal instability, increased sensitivity to ionizing 
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radiation, defective induction of stress-activated signal transduction pathways, and radioresistant DNA synthesis 
are observed at the cellular level. Clinical immunodeficiency and cancer risk may be part of the syndrome.  
The mutations identified in ATLD are hypomorphic. The severity of the disease may be dependent on the 
residual activity of the mutated MRE11 alleles 
MRE11 interacts with ATM 
Mre11 has an important role within the Mre11-Rad50-Nbs1 complex (130). This Mre11-complex acts both 
upstream and downstream of ATM as a sensor of DSBs, in the cell cycle control and DSBs repair machinery. 
DNA repair disorders causing either T-B-NK+ SCID or Omenn syndrome T(+)B-NK+:  
defective DNA double strand breaks repair including defect NHEJ
RAG1/RAG2 
Mutations in the recombinase activating genes RAG1 (MIM*179615) or RAG2 (MIM*179616), both located to 
11p13 and containing only one exon, cause T-B-NK+ SCID without radiosensitivity. The inheritance is 
autosomal recessive. Omenn syndrome (MIM#603554), a milder SCID variant with massive eosinophilia and 
generalized erytrodermia/ eczema is also due to mutations in the RAG1 and RAG2 genes. The patients have no 
increased sensitivity to irradiation while this is a feature of the other DNA repair disorders causing SCID or 
Omenn, such as Artemis or DNA Ligase IV 
Artemis 
Null mutations of the Artemis gene (10p, OMIM 605988) result in a complete absence of T and B lymphocytes 
and increased cellular sensitivity to ionizing radiations, causing radiosensitive-SCID. Hypomorphic mutations 
in Artemis resulting in partial SCID/Omenn syndrome with radiosensitivity have been observed. Both T-B-
NK+SCID and Omenn syndrome have been observed within the same family (131). 
Hypomorphic mutations provide residual protein function often causing a heterogeneous phenotype, like 
hypomorphic Artemis mutations, which have been found to cause partial T and B lymphocyte immunodeficiency 
associated with lymphoma predisposition or Omenn syndrome. In contrast, null mutations lead to a complete loss 
of protein function inducing a homogenous phenotype like Artemis RS-SCID.  
Artemis interacts with ATM 
Atremis is a DNA cross-link repair protein involved in V(D)J recombination by cleavage of the hairpin 
intermediate generated by RAG1/RAG2, this process seems ATM independent. Artemis is phosphorylated in an 
ATM dependent manner after irradiation. ATM is specifically required for the repair of a subset of lesions (10%) 
induced by X or gamma rays that are normally rejoined by slow kinetics in control cells, whilst ATM is 
dispensable for the more rapidly repaired DSBs after irradiation. The slow kinetics process requires Artemis. 
ATM regulates the artemis-dependent end-processing prior to rejoining by NHEJ (132) 
DNA ligase IV 
Ligase IV syndrome is an extremely rare autosomal recessive condition caused by hypomorphic mutations in the 
LIG4 gene (13q22-q24, OMIM 601837)  the condition closely resembles that of Nijmegen breakage syndrome 
(NBS), and is characterized by microcephaly, characteristic facial features, growth retardation, developmental 
delay, pancytopenia and immunodeficiency, extreme radiosensitivity. The patients have normal levels of LIG4 
protein with impaired function. Dependent on the type of LIG4 mutation the phenotype can vary and also be 
radiosensitive T-B-NK+ severe combined immunodeficiency with or without microcephaly and 
developmental delay. These patients have undetectable levels of LIG4 protein. Hence, different LIG4 mutations 
can result in either a developmental defect with minor immunological abnormalities or a SCID picture with 
normal development.(133;134). Hypomorphic mutations provide residual protein function often causing a 
heterogeneous phenotype, like hypomorphic Artemis mutations, which have been found to cause partial T and B 
lymphocyte immunodeficiency associated with lymphoma predisposition or Omenn syndrome. In contrast, null 
mutations lead to a complete loss of protein function inducing a homogenous phenotype like Artemis RS-SCID. 
Lig4 is critically required for murine development, as Lig4-/- mice die during embryogenesis. The neuronal 
defect of LIG4- or XRCC4-deficient mice can be rescued by a homozygous mutation in TP53 or ATM (25-27). 
However, the V(D)J recombination process cannot be rescued. Cell lines from patients with LIG4 syndrome 
show pronounced radiosensitivity, however, unlike NBS cell lines, they show normal cell cycle checkpoint 
responses but impaired DNA double-strand break rejoining in NHEJ  
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Cernunnos-XLF/ NHEJ1 
Radiosensitive T-B-NK+ SCID, +/- microcephaly and developmental delay. 
Patients homozygous for mutations in the Cernunnos gene have growth retardation, microcephaly, and T-B-
NK+ SCID(134;135). The patients’ features overlap with those described in DNA ligase IV deficiency (36). 
Cernunnos; XRCC4-like factor (XLF) and NHEJ1 are all names for the same gene. Cernunnos-XLF represents a 
novel DNA repair factor essential for the NHEJ pathway and is involved in the last step, the DNA religation, of 
the NHEJ pathway. Cernunnos physically interacts with the XRCC4 & DNA-ligase IV complex.  
Bloom syndrome 
Bloom syndrome (also called Congenital Telangiectatic Erythema) is caused by mutations in the gene BLM 
encoding DNA helicase RecQ protein-like-3 (15q26.1, OMIM 210900), and is an autosomal recessive disorder 
characterized by proportionate pre- and postnatal growth deficiency, UV-sensitivity, and predisposition to 
malignancy. The classical skin changes are erythematous telangiectasias of the face and areas with hypo- and 
hyperpigmentation. The patients have risk of developing diabetes type II starting already in their second/third 
decade. Low IgM and IgA have been reported in a few Bloom patients (136-138).  
Several different mutations in the BLM gene have been identified as causing Bloom Syndrome. Bloom disease is 
most common among the Ashkenazi Jewish population, where 1/100 is a carrier. 
Cells from patients with Bloom syndrome show various types of chromosomal instability, including 
chromosomal breaks, gaps, deletions, and elevated levels of sister chromatid exchanges which can be used for 
diagnostic reasons. This disorder is the only one that features an increased risk of sister chromatid exchange. In 
individuals with Bloom syndrome, the chromosomes will show an approximately 10-fold increased rate of sister 
chromatid exchange.  
BLM is a member of the RecQ family of helicases which are enzymes that unwind DNA so that replication, 
transcription, and DNA repair can occur. Helicases are vital to the life of a cell and aid in the maintenance of 
genomic stability. Werner Syndrome and Rothmund-Thomson Syndrome are also caused by mutations RecQ 
helicase genes, RECQL2 and RECQ4 respectively. Both of these diseases, along with Bloom Syndrome, exhibit 
a cancer predisposition. 
BLM interacts with ATM: 
BLM is linked to the ATM induced pathways; ATM interacts with and directly phosphorylates BLM. LIG4 
interacts with BLM and ATR phosphorylates BLM.  
Høyeraal Hreidarsson syndrome 
Hoyeraal-Hreidarsson (HH) syndrome (Xq28, MIM#300240) is a multisystem disorder affecting boys 
characterized by aplastic anaemia (AA), immunodeficiency, progressive pancytopenia including 
thrombocytopenia, microcephaly, cerebellar-hypoplasia and growth failure of prenatal onset. The disorder has 
been found to be caused by mutation in the DKC1 (dyskerin) gene. Mutation in the same gene causes X-linked 
dyskeratosis congenital. Dyskerin is closely associated with the telomerase, and aid the function and the location 
of the resulting telomerase complex. Activated telomerase is responsible for the de novo synthesis and the 
maintenance of telomere ends to extend the lifespan of activated lymphocytes, germline cells and tissue stem 
cells.  
The patients have severe truncal ataxia, without telangiectasia and their cells exhibit chromosomal instability. 
Cerebellum demonstrates reduced cellularity of the molecular and granular layers with relative preservation of 
Purkinje cells and minimal gliosis(139). 
X-linked Hoyeraal-Hreidarsson syndrome (XL-HHS) is the severe infantile variant of X-linked dyskeratosis 
congenita (XL-DC) and both are due to mutations in the DKC1 gene within Xq28. Progressive combined 
immunodeficiency has become a recognized feature of the syndrome since immunoglobulin deficiency and 
lymphocyte abnormalities have been documented in half of the published cases (140;141) (142;143) 
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More DNA repair genes and DNA repair disorders will be detected in the future  
In the near future additional disease causing genes are expected to be found in the pathways of 
DNA maintenance and repair. The diseases caused by defects within these pathways have a 
wide spectrum of features including: hair and skin changes, premature aging, 
immunodeficiency, cancer and neurological disease. These manifestations can facilitate 
diagnosis. 
ATM knock-out mice: Knock-out, Knock-in 
Mice knockout studies provide valuable knowledge in the field of DNA repair and 
immunodeficiency. The Atm -/- mice are immunodeficient and develop leukemias and 
lymphomas, but do not have all of the other features of A-T. Disrupting the ATM protein in 
mice gives rise to some of the same findings as in A-T-patients, but not neurodegeneration. 
However, an increased amount of ROS are generated in the cerebellum, particularly in the 
Purkinje cells from Atm -/-mice.
Difference in symptoms and disease manifestations between species is a phenomenon in other 
inherited disorders as well. Aire-/- mice unlike humans with APECED, do not get candidiasis. 
Fungal infections in PIDs,  
- focusing on candida infections and chronic mucocutaneous candidiasis 
Patients with phagocytic (144), cellular, combined and other primary immunodeficiencies 
exhibit immune deficits that confer increased susceptibility to fungal infections. A number of 
yeasts and moulds, most commonly Candida and Aspergillus but also Cryptococcus, 
Histoplasma, Paecilomyces, Scedosporium, Trichosporon, Penicillium and other, rarely 
isolated, fungal organisms, have been variably implicated in causing disease in patients with 
CGD, SCID, hyper-IgE syndrome, myeloperoxidase deficiency, leukocyte adhesion 
deficiency, defects in the interferon-γ/interleukin-12 axis, DiGeorge syndrome, X-linked 
hyper-IgM syndrome, Wiskott Aldrich syndrome, CVID and chronic mucocutaneous 
candidiasis including APECED. Differences in the spectrum of fungal pathogens as well as in 
the incidence and clinical presentation of infections may be observed among patients with 
different PIDs, as a function of their various underlying immune disorders.  
Candida 
Candida is the most common fungal pathogen in humans. It is also a frequent colonizer of 
human skin and mucous membranes and part of the normal flora of skin, mouth, vagina, and 
gut. It is present in the environment, particularly on leaves, flowers, water, and soil. The 
genus Candida includes more than 150 species. Among these, six are most frequently isolated 
in human infections. While Candida albicans is the most abundant and significant species, 
Candida tropicalis, Candida glabrata and Candida parapsilosis often cause invasive 
candidiasis.  Candida krusei and Candida lusitaniae can also cause infection. With the 
introduction of antifungal therapy, azole resistant C. glabrata and C. krusei have become 
more prevalent. The diversity of Candida spp. that is encountered in infections is expanding 
and the emergence of other species as infectious agents is likely used. 
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Chronic mucocutaneous candidiasis (CMC) 
Patients with chronic mucocutaneous candidiasis (CMC) are selectively unable to clear 
Candida, and are prone to persistent debilitating infections of the skin, nails, and mucous 
membranes. C. albicans is implicated in most of cases(145). Other C. species have also been 
reported to cause disease in CMC patients(146-148).  The exact molecular defect is not 
known for most forms of primary CMC, with the exception of the autoimmune 
polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) syndrome. Patients with 
primary CMC rarely develop invasive disease or disseminated Candida infection. 
APECED 
Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED; 
MIM#240300, locus 21q22.3), also known as autoimmune polyendocrine syndrome type I 
(APS I), is an autosomal recessive disorder caused by mutations in the AIRE gene. There is 
progressive loss of tolerance against self which leads to multiple organ failure via 
immunological destruction of endocrine glands. Functional studies of AIRE suggest a role as a 
transcription factor in antigen presenting cells. APECED may also be inherited as an 
autosomal dominant disorder (149) due to AIRE mutations resulting in a dominant negative 
effect. The mutant protein binds to the wild-type AIRE protein, preventing formation of 
complexes needed for transactivation. APECED patients usually present with CMC in 
childhood. The most common endocrine manifestations are hypoparathyroidism, Addison
disease, and ovarian failure, followed by diabetes mellitus type 1, testicular failure, 
hypophysitis, and autoimmune thyroiditis. Patients may have autoimmune gastritis, 
autoimmune hepatitis, and malabsorption. Hyposplenia/asplenia has been reported. 
Keratoconjunctivitis, vitiligo, alopecia, nail pitting are common.  
Autosomal dominant and recessive inheritance of CMC  
APECED usually follows autosomal recessive inheritance. Sporadic occurrence or autosomal 
dominant inheritance has been described in most CMC families where APECED has been 
excluded. 
Treatment of Candida in CMC
The persistent immunological defect of chronic mucocutaneous candidiasis requires a long-
term approach that is analogous to that used in AIDS patients with rapidly relapsing 
oropharyngeal candidiasis. Systemic therapy is needed, and all azole antifungal agents
(ketoconazole, fluconazole, and itraconazole) have been used successfully. Dosage is as in 
other forms of mucocutaneous candidiasis. Development of resistance to these fungal agents 
has been described.  
The susceptibility to Candida is still a mystery. 
Even if the gene responsible for APECED has been found, the immunological defect causing 
susceptibility to candida is still a mystery. Studies in Aire-/- knockout mice highlight the 
importance of type 1 cytokines in protection against Candida, and previous work suggests that 
CMC patients may have aberrant cytokine production in response to Candida.  
Protection against C. albicans has been considered to be T-cell-mediated 
When the antigen presenting cells (APCs) interacts with CD4+ T helper cells, the T cell 
responses induced are classified as Th1 or Th2. In general, Th2 responses are linked to 
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induction of humoral responses, and Th1 to cellular responses. Protection against C. albicans
is generally considered to be T cell mediated. Clearance of Candida is dependent on an 
appropriate Th1 response. Th1 type response, characterized by antigen stimulated lymphocyte 
production of cytokine IL-12 and interferon gamma, is associated with protection against 
Candida in animal studies(150), although the situation in humans is less well understood.   
Studies of CMC and autoimmunity in knockout mice 
Pathogenesis of the endocrinopathy in APECED has been studied, but remains somewhat 
unclear. Most patients have autoantibodies against autoantigens that are expressed in affected 
tissues. Studies in knockout mouse models have highlighted a role for AIRE in regulating
expression in the thymus of a subset of autoantigens from peripheral tissues. Normally, 
potentially autoaggressive T cells that recognize these antigens are deleted, but they are 
presumed to escape to the periphery in patients with AIRE mutations or in Aire–/– mice, 
leading to autoimmune inflammation in selected organs. Aire is expressed in APCs in the 
thymus, spleen and in peripheral dendritic cells.
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(Photos: TAKO centre & A.Stray-Pedersen) 
Figure 16 Photos of patients with chronic mucocutaneous 
candidiasis 
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Dendritic cells (DCs) are antigen presenting cells (APCs) 
Dendritic cells (DCs) form an enormously heterogeneous group of APC with different lineage 
backgrounds, precursors and various stages of differentiation and maturation (Figure 2 and 
Figure 17). The lymphoid DCs originate from pre T cells in the thymus and predominantly 
populate the thymic cortico-medullary junction where they are instrumental in the deletion of 
deleterious autoreactive T cells. The myeloid DCs originate from a specific CD34+ precursor 
in peripheral blood or from CD14+ circulating monocytes. The monocyte-derived DCs are 
closely linked to other classes of APC, such as the veiled macrophages and often to other 
types of accessory macrophages. 
Figure 17 A scheme of origin and maturation of dendritic cells  
Human leukocyte antigen (HLA) = major histocompatibility complex (MHC)
Selection of both related and unrelated donors for hematopoietic stem cell transplantation 
includes matching for alleles of each human leukocyte antigen (HLA) locus within the major 
histocompatibility complex (MHC) on chromosome 6p21.3. In human populations, multiple 
blocks of genetic variation in the MHC are strongly associated with each other as extended 
haplotypes.  
HLA haplotypes Class I and Class II 
Haplotypes are a set of closely linked alleles on a single chromosome that tend to be inherited 
en bloc, i.e. the alleles do not become separated by recombination at meiosis. The class I gene 
complex contains three major loci, B, C and A, each coding for an alpha-chain which contains 
antigenic determinants and is polymorphic (i.e., has many alleles). In the cell membrane, the 
alpha-chain associates with beta-2 microglobulin (beta-chain), encoded by B2M at locus 
15q21-q22. The class II gene complex also contains at least three loci, DP, DQ and DR; each 
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of these loci codes for one alpha- and one beta-chain polypeptide which associate to form the 
class II antigens. Like the class I antigens, the class II antigens are polymorphic. HLA 
specificities are identified by a letter for locus and a number (A1, B5, etc.) and the haplotypes 
are identified by individual specificities (e.g., A1, B7, Cw4, DP5, DQ10, DR8). Specificities 
defined by PCR analyses are named with a letter for the locus and a four digit number (e.g. 
A0101, B0701, C0401 etc). MHC antigens are expressed on the cell surface in a co-dominant 
manner:  i.e., products of both parental genes are found on the same cells.  
HLA and connection to APCs 
Class I antigens are expressed on all nucleated cells and platelets, but not on erythrocytes. 
Class II antigens are only expressed on B lymphocytes and a proportion of APCs: monocytes, 
macrophages and DCs. Small molecules (processed proteins) function as antigens and are 
presented in the cell membrane by MHC Class I and MHC Class II and both complexes are 
recognized by T cells which exhibit direct cytotoxic activity.  CD4+ T cells further activate B 
cells causing humoral antigenic responses. When the MHCs are recognized by T cells as 
“foreign”, cytolytic and humoral responses are induced. This is the mechanism underlying 
GVHD in stem cell transplantation, HVG in organ transplantation, and some autoimmune 
diseases.  
HLA and autoimmune diseases 
A number of autoimmune diseases have been found to occur at a higher frequency in 
individuals with certain HLA haplotypes. Most prominent among these are ankylosing 
spondylitis (B27), celiac disease (DR3) and Reiter's syndrome (B27). Unlike many other 
autoimmune diseases, APECED does not show an association to a specific HLA haplotype 
(151). We wanted to investigate if familial CMC with hypothyroidism, APECED excluded, 
was associated with certain HLA haplotypes. 
Inherited thyroid diseases:   
Autoimmune thyroiditis versus congenital thyroid disease. 
Autoimmune thyroiditis is the main cause of acquired hypothyroidism in childhood in non-
endemic goitre regions. In APSII, autoimmune thyroid disease accompanies Addison disease, 
and type I diabetes mellitus may also occur. CMC is not a feature of APSII. Autoimmune 
thyroiditis is a well known feature of APECED (=APSI), however in this context, it is far less 
frequent than hypoparathyroidism and Addison disease. There is increasing evidence that 
when APECED disease is excluded in the group of CMC patients, autoimmune thyroiditis is a 
frequent associated feature. In these CMC families, the disease is occurs sporadically or in an 
autosomal dominant inheritance pattern. Inherited resistance to TSH is the cause of the rare 
genetic congenital thyroid diseases.  These patients may represent with neonatal 
hypothyroidism, but not all are detected on neonatal TSH screening. If hypothyroidism is 
detected, patients do not have a favorable outcome despite early and adequate treatment. 
Resistance to TSH is an inherited disorder of variable hyposensitivity to TSH. The metabolic 
consequences can range from euthyroid hyperthyrotropinemia to severe congenital
hypothyroidism with thyroid hypoplasia. Causative gene mutations have been reported in the 
genes: TSHR, PAX8 and also in the TITF1, GNAS, FOXE1 genes associated with syndromic 
forms of congenital thyroid disease.
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Mannose binding lectin – part of innate immunity  
Mannose binding lectin (MBL) and other collectins 
The collectins (C-type lectins containing collagen-like domains) are a small subfamily of 
large glycoproteins which includes the surfactant proteins A and D, and MBL among others 
{Lu, 2002 1594 /id;Holmskov, 2000 240 /id;Hansen, 1998 1595 /id}.  Humans have serum 
and liver isoforms of MBL. Differentiation arises from alternative splicing and post-
translational modification, as both are products of a single functional gene (MBL-2) on 
chromosome 10 {Kurata, 1994 1596 /id;Kilpatrick, 2002 280 /id;Cedzynski, 2004 1597 /id}.  
Surfactant A(SP-A) and D (SP -D) are important not only for enhanced lung compliance and 
low alveolar surface tension, but also play an important part in the innate immunity of the 
lungs. SP-A and SP-D are hydrophilic, in contrast to SP-B and SP-C which are hydrophobic. 
After secretion into the alveolar space, SP-A is located in the corners of the tubular myelin 
lattice and represents a first line defence against alveolar pathogens. There are extensive 
sequence similarities in structural configuration and functions in innate immunity between 
MBL, SP-D and SP-A, and particularly between SP-A and MBL(152;153). Their genes are 
also closely located on chromosome 10q (MBL2 at 10q11.2-q21 and SP-A (SFTP1) and SP-D 
(SFTP4) at 10q22.2-q23.1). 
MBL and complement activation, MBL deficiency and pneumococcal disease 
MBL activates complement through the lectin pathway (Figure 18). Low levels of MBL 
results in an infantile illness characterized by recurrent infections, persistent diarrhea and 
failure to thrive(153-156). Homozygosity for certain MBL variant alleles has previously been 
shown to correlate with an increased frequency of invasive pneumococcal disease (157;158).  
Previous MBL genotyping of 100 Norwegian blood-donor controls showed that 3 % were 
homozygous deleterious for MBL variants (159) 
MBL and Candida albicans
MBL is an important component of innate resistance to candidiasis. MBL binds to Candida  
albicans, inhibits C. albicans growth directly and activates complement(160). Parenteral 
administration of MBL increase resistance to hematogenously disseminated candidiasis in 
mice studies, suggesting that MBL therapy may prevent disseminated candidiasis in high-risk 
patients(161). MBL binds C. albicans via its lectin domain, resulting in agglutination of  
organisms with outgrowth of hyphae(160). MBL does not facilitate opsonophagocytosis by 
monocyte-derived dendritic cells. MBL inhibits the growth of C. albicans independent of 
complement activation. Upon complement activation, further inhibition is observed. In 
conclusion, MBL plays an important role in the first-line defense against C. albicans without 
the need for opsonophagocytosis by dendritic cells.
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Figure 18 Complement pathway 
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Streptococcoccus pneumonia and immune defence 
The antibody response to pneumococcal capsular polysaccaride has been called a T cell 
independent process (TI type 2) with a predominant B-B cell interaction (162). Yet T cells 
and CD40 ligand contribute to regulation of this process (163;164). Wild-type infections or 
nasopharyngeal carriage normally induce pneumococcal antibodies, while vaccines (plain 
polysaccharide or conjugate) induce a more secondary response (165). Naturally occurring 
IgM antibodies to pneumococcus are polyreactive, while class-switched antibodies are 
serotype-specific (166). Oligoclonal pneumococcal antibodies of isotypes IgG2 and IgA 
predominate after vaccination and infection. Pneumococcal vaccines are capable of inducing 
antibodies within the IgG1 subclass (167).  Specificity, avidity and protective efficacy depend 
on V(D)J rearrangements and somatic hypermutations. Certain V regions (VH3 and Vκ2) 
dominate the repertoire, and specific V region genes, such as Vh3-48, are linked to high 
avidity and opsonic activity against a variety of pneumococcal serotypes (163;168;169). 
Several PIDs exhibit defective protection against Streptococcus pneumonia, including both 
immunodeficiencies caused by defects in adapted immunity (i.e. agammaglobulinemia or 
DNA repair disorders), and defects in innate immunity (i.e. IRAK4 deficiency or MBL 
deficiency). The use, utility and efficacy of pneumococcal vaccines and other vaccines in 
PIDs have been controversial. Vaccine responses are used in the diagnostic work-up of 
primary antibody deficiencies. 
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Aims of the study 
Collect information on all PID patients in Norway  
• to describe the incidence and prevalence of the various primary immunodeficiency 
diseases and their regional distribution in Norway, and 
• to increase knowledge of the care and treatment of PID patients in order to 
• facilitate better healthcare planning and care of patients.   
Study of coping, quality of life and hope in a selected group of adults with PID  
• To elucidate two main issues: 
a)     How do adults with primary antibody deficiency manage their condition?  
b)     What kinds of factors influence coping, quality of life and hope? 
Studies in a selected group of PID, the patients with ataxia-telangiectasia 
• To characterize the immunodeficiency in ataxia-telangiectasia: 
a)    Find potential genotype-phenotype correlations in the immunodeficiency in A-T  
b)    Test the response to conjugated pneumococcal vaccine in A-T 
• To study alpha fetoprotein levels over time and assess for correlations with genotype, 
neurologic deterioration and liver enzyme serum levels. 
Studies in other PID patients 
• To study immunological abnormalities in patients with familial CMC with 
hypothyreosis, APECED excluded.  
• To describe a patient originally considered to have A-T, but in whom genetic and 
immunological studies confirmed a chromosomal microdeletion of 14q and MBL 
deficiency 
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Material and Methods 
Patients: 
Patients with PIDs – epidemiology (Paper I)  
Information concerning patients with PIDs were collected through their hospital physicians. 
Questionnaires were sent to all hospital departments taking care of PID patients. As of 1999, a 
total of 372 PID patients (303 living) were registered (Paper I).  We were allowed to keep and 
update the Norwegian PID research registry until 2005. As of December 2004, a total of 566 
PID patients (456 living) were registered. These data are presented in Results 2 (Table 5, 
Table 6 and Figure 1).  
Patients with antibody deficiencies 
- selected for the coping, quality of life, and hope study (Paper II) 
Studies of coping strategies, scales for measuring different aspects of quality of life and hope 
are designed for and need to be tested on adult persons with a more or less consolidated 
personality. The largest group of adult PID patients is found within the group of antibody 
deficiencies. The adult PID patients diagnosed with primary antibody deficiency and served 
by Rikshospitalet as of 1999 were selected for the coping, quality of life, and hope study. 
Based on data from the national PID registry (Paper I), we knew that a total of 122 patients ≥
20 years of age had primary antibody deficiency, and that Rikshospitalet served 75% of these 
patients. After excluding one person with mental retardation, the cohort included 91 persons; 
50 men and 41 women, aged 20–82 years, with various types of antibody deficiencies: 
Common variable immunodeficiency (n = 66), X-linked Bruton’s agammaglobulinemia (n = 
8), selective IgA deficiency (n = 16) and hyper IgM syndrome (n = 1). Twenty three patients 
had hepatitis, and of these 21 had verified HCV hepatitis. These 91 persons received the 30 
page questionnaires by ordinary mail. Fifty five responded. Responders were representative of 
the original cohort of 91 persons with regard to specific PID diagnoses, gender and age.  
PID patients selected for the interviews  
The questionnaire study was supplemented with selected interviews of extreme cases. Cases 
were selected for interviews to detect possible patterns within two groups: patients with high 
QLI (quality of life) scores and patients with low QLI scores. The selected cases represented a 
strategic sample of patients with the lowest and highest QLI scores (n = 21). Originally, we 
wanted to interview all 21 extreme cases. Ten patients consented to participate in the 
interview study. Based on power calculations, 10 cases were regarded as sufficient to detect 
patterns within the different groups. One person, H.M.H. Sigstad performed the interviews. 
The different authors’ contributions to this study are described in detail elsewhere 
(Acknowledgements). 
Patients with Ataxia-Telangiectasia (Paper III-V)
A total of 14 patients with A-T have been studied prospectively studied during the 
immunological study, vaccine study and alpha fetoprotein study.  
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We were in contact with eight of the nine living Norwegian A-T patients registered per 
January 2000. These eight were first included in the immunological study. After initiation of 
the A-T immunological study, the last patient and two newly diagnosed A-T patients were 
also included. Similarly, after initiation of the pneumococcal vaccine study, an additional 
three newly diagnosed patients were included via their paediatricians. Information about the 
ongoing A-T studies had reached the new families through the A-T family meetings at 
Frambu Center for Rare Disorders and the Pediatric Rehabilitation Unit in Hedmark County. 
One patient had problems with repeated blood sampling and declined to participate in the 
vaccine study. His parents decided to withdraw him from the study. Two patients died after 
the immunological study was finished and before the vaccine study was initiated. After 2004 
an additional three patients with A-T were diagnosed in Norway. As of 2006, we knew of a 
total of 32 persons diagnosed with A-T in Norway during the last 50 years, 14 living and 18 
deceased, including the five patients reported by Smeby (61). Updated epidemiological and 
genetic data on A-T in Norway are presented in Result 2: Table 7, Table 8 and Figure 20 
- and their parents (Paper III-V)  
Twenty two parents were studied. The A-T patients’ parents were included in the 
immunological study for two main reasons. Firstly, we wanted to check for possible 
immunological consequences of their carrier status, especially to see if the twelve parents who 
were carriers of the Norwegian founder mutation differed in immunological status from 
parents carrying other ATM mutations. Secondly, knowledge of the parents’ immune status 
allowed us to assess the need for extra vaccines to prevent exposure of their immunodeficient 
child to certain infectious diseases. The results of the serum alpha fetoprotein measurements 
from these 22 parents are included in Paper V.  
Ethical issues in the immunological studies of A-T patients 
Oral and written information was given to patients and their parents. Written informed 
consent was obtained from the parents on behalf of each patient included in the study. The 
parents signed the vaccination consents on behalf of their children, and the older patients had 
to orally agree in the vaccination before participation. The vaccinee or a parent answered a 
questionnaire concerning adverse reactions after each vaccination. Information about 
pneumococcal vaccination status was documented in each person’s medical record. The 
Regional Committee for Medical Research Ethics and the Norwegian Data Inspectorate 
approved the immunological study, and The Norwegian Medicines Agency approved the 
vaccination study protocol. Written informed consents were obtained for all collection and 
storage of biological material and ATM related genetic testing.  
Control persons in the vaccine study (Paper IV)
Control persons for the vaccine study came from Rikshospitalet. We originally wanted to 
recruit healthy children, but this is difficult in a hospital setting. Persons with no to minor 
heart disease were selected from the Pediatric Outpatient Clinic at Rikshospitalet. Twenty-five 
individuals (13 males and 12 females) with no or minor heart disease served as sex and age 
matched controls. All controls had followed the national pediatric vaccination program. 
Exclusion criteria were: current infection, cancer/cancer treatment, corticosteroid treatment, 
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previous adverse reactions to other vaccines including diphtheria, other vaccinations six 
weeks prior to or after administration of the study vaccines.  
Ethical issues control persons for vaccinations 
The Norwegian Medicines Agency, the Regional Committee for Medical Research Ethics as 
well as the Norwegian Data Inspectorate, approved this study. Oral and written information 
was given to controls and their parents. Signed consent was obtained from each vaccinee or 
his/her parent.   
Patients with Chronic mucocutaneous candidiasis (Paper VI)
Most of our patients with chronic mucocutaneous candidiasis CMC had APECED with 
verified mutations in the AIRE gene (170). Thirty eight patients have been registered with 
CMC in the PID registry (Update PID report, Results 2: Table 5), 23 had APECED (2 
deceased), 4 had CMC linked to hypothyroidism and 9 had CMC without endocrinopathy. 
Recently, an additional 13 Norwegian APECED patients (3 deceased) have been reported 
(171). For several years, we have followed two families with several affected members with 
CMC associated with acquired, primary hypothyroidism, and where the disease does not
segregate with the AIRE gene. Clinical and laboratory data on these two families are reported 
in Paper VI. 
Ethical issues in the chronic mucocutaneous candidiasis study 
The CMC study was approved by the Western Norway Regional Committee for Medical 
Research Ethics. 
14 q deletion and MBL deficiency (Paper VII)
This patient was originally referred to us because ataxia-telangiectasia was suspected on the 
basis recurrent infections and neurological symptoms. He was investigated as part of our A-T 
study. He had a normal serum AFP level. No mutations in the ATM gene were found, and a 
constitutional chromosomal aberration was found. His proximal interstitial 14q microdeletion 
included the TITF1 gene, a transcription factor for SP-A. The SP-A and SP-D collectins are 
structural homologues to MBL protein, and their coding regions are close to the MBL2 locus. 
Since MBL deficiency was found in his serum, a family study was initiated to investigate if 
his MBL protein deficiency was caused by familial MBL2 variant alleles or associated with 
the TITF1 haploinsufficiency. 
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Methods 
The epidemiological PID study 
The simple PID questionnaire 
In order to register all detected PID cases in Norway, a simple, two-page questionnaire was 
sent to all relevant hospital departments. Physicians were asked to classify each patient’s 
disease as: antibody deficiency, T cell or combined B and T cell deficiency, phagocyte 
deficiency, complement deficiency, or other immunodeficiency. Since PID consists of a 
variety of different subtypes, subgroup categories were useful epidemiologically and allowed 
for simplification of the questionnaire. When necessary, additional information, such as 
laboratory results, was obtained at a later stage of the study. The questionnaire permitted 
reporting patients in whom PID was suspected, but not established. In April 1998 the 
questionnaires were mailed to 140 departments in 60 hospitals. All non-psychiatric hospitals 
in Norway were contacted. The patient organization, The Norwegian Immunodeficiency 
Association, distributed the questionnaire to its members. One reminder, with relevant ICD-9 
numbers, was sent to non-responders. In addition, several departments were contacted by 
telephone to clarify information already given and to repeat the request for responses. The 
investigators arranged lectures, seminars and presentations for health personnel about PID and 
this particular study during the study period. All PID patients’ medical records accessible at 
our hospital were reviewed, and the diagnoses were confirmed or reclassified.   
The PID registry update report 
After January 1999 we continued to receive reports of new PID patients from other hospitals 
and other departments within our hospital. Relevant medical information concerning these 
patients and all new PID patients referred to and registered at our paediatric department were 
consecutively included in the registry until January 2005 (Results 2).  
The PID Research Registry Database  
The collected data were registered in a non-network-connected database.  In order to meet 
legal requirements, all patient administrative and personal data were coded when entered into 
the database. We were granted permission to keep a list with the database identification 
numbers linked to the patients’ names and dates of birth. This list allowed us to update the 
database and avoid double registration. As initially recommended from the Norwegian Data 
Inspectorate, the decode list was stored separately from the PID research database.  
Demographic statistics for calculating prevalences and incidences of PID 
Children were defined as individuals below 16 years of age. Demographic statistics were 
obtained from Statistics Norway (31). The point prevalences in paper I were calculated using 
geographical population data from January 1999. Population data from January 2005 were 
used in the updated report. The regional prevalence results were based on the patients’ home 
addresses. C1- inhibitor deficiencies and other complement deficiencies were reported to us 
with no more personal information than gender and year of birth, and these patients were 
therefore excluded from calculations of geographical prevalence. Incidences of some of the 
specific PID diagnoses, such as ataxia-telangiectasia, were calculated related to livebirths 
using national population data for the last four to five decades.  
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Coping, quality of life, and hope study in adults with PID  
The comprehensive questionnaire 
Five different scales were incorporated into one comprehensive 30-page questionnaire. Four 
standardized scales had previously been translated and tested in Norwegian populations. The 
standardized scales were: Ferrans and Powers Quality of Life Index (QLI), Short Form-36 
(SF-36), Jalowiec Coping Scale (JCS), and Nowotny Hope Scale (NHS). An additional scale 
designed for this project (RPP Scale), focused on resources and pressures in the past. Factor 
analyses were used to assess the empirical support for each subscale in all instruments. 
Internal consistency was estimated using Cronbach's alpha coefficient. 
The questionnaire together with an information letter was sent to each patient’s home address. 
Definitions of the following concepts: coping, coping strategies, locus of control, resilience 
against stress, closeness, competence, and hope are defined in Paper II. In Paper II, the 
difference between global and health-related quality of life; QLI versus SF-36, is discussed. 
The personal interviews 
The questionnaire study was supplemented with selected interviews of ten extreme cases, five 
with low and five with high quality of life scores based on results from the questionnaire. The 
interviews were included as a supplement to the survey to elucidate preconditions for coping, 
good quality of life, and hopefulness. The interview study was designed to probe and to aid in 
the interpretation of some of the results from the questionnaire. Cases were selected for 
interviews to detect possible patterns within two groups: patients with high QLI scores and 
patients with low QLI scores. The selected cases represented a strategic sample of patients 
with the lowest and highest QLI scores. Ten patients consented to participate in the interview 
study, and the size of the cohort was regarded as sufficient to detect patterns within the 
different groups. The qualitative interviews were based on significant results related to QLI in 
the survey. The interviews were semi-structured with a pre-written interview guide, and lasted 
nearly two hours. The interviews took place at the patient’s home and were performed by the 
same person.  
Ethical issues in the coping, quality of life, and hope study 
Participants were guaranteed anonymity and the right to withdraw from the study at any time. 
A letter to respondents provided information about the potentially sensitive items in the 
questionnaire. For each of the ten patient interviewed, the interviewer defined beforehand the 
content of the interview and explained her role. The coping, quality of life, and hope study 
was approved by the Norwegian Regional Committee for Medical Research Ethics and the 
Norwegian Social Science Data Services. 
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A-T studies - Longitudinal follow-up of a selected cohort 
Blood sample collections – Repeated blood samples 
Paper III, IV and V are based on results from repeated blood samples and clinical 
investigations. The blood samples were collected and consultations with the patients, parents 
and control persons were provided as an integrated part of the regular follow-up at the 
Pediatric Outpatient Clinic at Rikshospitalet.  
The studies in paper III, IV,V and VII were conducted in collaboration with a variety of 
professionals from different hospital departments. The first author was responsible for the 
project planning, clinical investigations, vaccinations, sample collection and evaluation of the 
results of the laboratory tests. In this chapter (Materials and Methods) the principles of the 
methods used are outlined. Detailed descriptions are given in each paper. 
Vaccination method 
The seven-valent pneumococcal conjugated vaccine (PCV7, Prevenar® Wyeth Lederle) was 
given as 0.5 mL injection in the deltoid muscle. Prevenar contains polysaccharides from seven 
serotypes [serotype 4 (2 μg), 6B (4 μg), 9V (2 μg), 14 (2 μg), 18C (2 μg), 19F (2 μg) and 23F 
(2 μg)] which are conjugated to a carrier protein (CRM197 from diphtheria toxin, about 
20μg). After 6-12 months, the patients received 0,5 mL of the 23-valent pneumococcal 
polysaccharide vaccine (PPV23, Pneumovax® Aventis Pasteur MSD) intramuscularly. 
Pneumovax contains polysaccharides from following 23 serotypes (25 μg of each): 1, 2, 3, 4, 
5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F. All 
vaccinations were performed at our hospital by one trained person. PCV7 and PPV23 were 
used in paper IV. Diphtheria and tetanus vaccines (0,5 mL containing 15Lf Diphtheria toxin 
and 3.8 Lf Tetanus toxin) in addition to the PCV7, were used in Paper VII. Prior to each 
vaccination and six weeks after, a blood sample was collected. The serum samples were 
stored at -20°C until antibody testing analysis, and pre- and postimmunization samples were 
assayed simultaneously.  
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Immunological tests   
Immunoglobulins/antibodies 
Quantitation of serum immunoglobulins, total IgG, IgA, IgM, IgE and IgG subclasses was 
performed by nephelometry (Dade Behring, Illinois, US). Lowest detection limits were 0.06 
g/L for IgA and 3 kU/L for IgE. Age specific reference values were developed and are 
presented here in Materials and Methods and in the supplement of Paper III (172). IgD was 
measured by immunodiffusion (Behring) with reference values according to Haraldsson et al. 
(173).  
Specific antibodies 
An in vitro toxin neutralisation test was used for detection of diphtheria antibodies (174). The 
detection limit was 0.01 IU/mL, and the protective limit previously defined to 0.1 IU/mL 
(174). Tetanus antitoxin was measured with enzyme linked immunosorbent assay (ELISA), 
and the detection and protective limit were 0.1 IU/mL IgG (175). Antibodies to the capsular 
polysaccharide of Hemophilus influenzae type b (Hib) were measured with ELISA using an 
antigen composed of Hib oligosaccharides conjugated to human serum albumin (HbO-HA) 
The protective limit was defined to 1.0 microg/mL(176). Antibodies to viral antigens were 
measured using enzyme immunoassay (EIA) for anti-varicella-zoster virus (VZV) IgG, anti-
herpes simplex virus (HSV) IgG, and anti-measles IgG. The microparticle enzyme 
immunoassay (MEIA) was used for detection of anti-rubella virus IgG and anti-
cytomegalovirus (CMV) IgG. EIA was employed for detection of the anti-Epstein-Barr virus 
(EBV) nuclear antigen (EBNA) and anti-EBV virus capsid antigen (VCA) IgG.   
IgG antibodies to Streptococcus pneumoniae
IgG antibodies to Streptococcus pneumoniae were tested against the 23-valent polysaccharide 
vaccine (PPV23) and measured with ELISA (177), levels given in arbitrary units (U/mL). We 
compared our results to historical controls of healthy, unvaccinated adults (178), and levels of 
pneumococcal antibodies below 2.5 U/mL were regarded as low and non-protective. IgG 
antibodies to individual pneumococcal serotypes 4, 6B, 14, 18C, 19F and 23F and also to a 
mix of PPV23, were measured with ELISA after CPS adsorption of sera (Statens Serum 
Institut, Denmark) (177;179). For each serotype an IgG level > 1 microg/mL were regarded as 
protective (178).   
Autoantibodies 
Antibodies against thyroperoxidase (TPO-Ab), thyroglobulin (TG-Ab) and thyroid-
stimulating hormone receptor (TSHR-Ab) were assayed by a competitive lumino-
immunoassay method with kits from B.R.A.H.M.S, Diagnostica GmbH, Berlin. Antibodies 
against the enzymes 21-hydroxylase (21OH), side-chain cleavage enzyme (SCC), 17α-
hydroxylase (17OH), aromatic L -amino acid decarboxylase (AADC), and glutamic acid 
decarboxylase (GAD) were measured with a method based on the in vitro transcribed and 
translated protein as described by Ekwall et al.(180). 
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Investigation of complement and mannose-binding lectin 
The complement components C3 and C4 and total haemolytic complement activation 
products (CH50 and C-alternative way) were measured as described by Nielsen et al. (181).    
Mannose-binding lectin (MBL) 
Serum concentrations of MBL were quantified using ELISA (Antibodyshop/Statens Serum 
Institut, Copenhagen, Denmark) with detection limit at 5 nanogram/mL. Low MBL levels 
were defined as  <400 ng/mL and extremely low if <100 ng/mL. To further characterise the 
role of MBL, a functional ELISA measuring the lectin pathway activation capacity of 
exogenously added purified complement C4b-binding capacity was performed as described by 
Petersen et al (182;183).   
Surfactant protein D (SP-D) 
SP-D was measured by ELISA as described in (184). Briefly, microtitre wells were coated 
with F(ab´)2 prepared from rabbit anti-SP-D antibody, incubated with dilutions of test serum, 
later incubated with monoclonal antibody anti-human SP-D, and then peroxidase was added. 
Serum samples were tested simultaneously in 1:5 and 1:10 dilutions and the mean value 
calculated. Reference values for SP-D are 370-1300ng/mL according to (185). Three biallelic 
polymorphisms at the SP-D codons for the amino acids in position 11, 160, 270 in the mature 
SP-D were genotyped using an in house PCR-sequence specific priming method. 
Alpha fetoprotein 
Quantitation of alpha fetoprotein was performed in serum samples with AutoDELFIATM
hAFP (Wallac Oy, Turku, Finland). The AutoDELFIATM hAFP assay is a solid phase, two-
site fluorimmunometric assay with immobilized monoclonal antibodies and fluorescent 
urorium-labeled monoclonal antibodies technique. Reference value for AFP is < 14 kU/L with 
both techniques. 
Flowcytometry for immunophenotyping/lymphocyte quantification 
Flowcytometry is the generic term for techniques which involve analysis and/or separation of 
particles in a flowing stream by quantification of optical parameters. Flowcytometry allows 
analysis of various properties of cells or particles suspended in a fluid, which flows past a 
detector point, where the stream is illuminated by a focused laser beam. Cells are usually 
labelled using fluorescent probes/antibodies which bind to specific cell associated molecules. 
As the cells flow past the detector point and are illuminated, the probes fluoresce, the emitted 
light is detected and converted into proportional electronic signals. In this way measurements 
of various phenotypic, biochemical and molecular characteristics of individual cells are 
possible. In all our immunological studies, flowcytometric immunophenotyping of peripheral 
blood leukocytes was performed using the TruCount technique (Becton Dickinson, San Jose, 
California) with lysed heparinized blood. The monoclonal antibodies used were: anti-CD3, 
anti-CD4, anti-CD8, anti-CD19, anti-HLA-DR, anti-CD16, anti-CD56, anti-CD14, anti-TCR-
αβ and anti-TCR-γδ. Age-adjusted ranges for the lymphocyte subpopulations were used. 
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Mitogen stimulation of lymphocytes 
Mitogens are agents that are able to induce polyclonal cell division (mitosis) in a high 
percentage of T or B cells. There are T and B cell mitogens. A number of common mitogens 
are lectins, proteins which bind to glycoproteins on the surface of the lymphocytes and cause 
activation. Importantly, lectins do not act via conventional TcR-epitope or Ig-epitope 
interactions. The lectins concanavalin-A (ConA), and phytohemagglutinin (PHA) are T cell 
mitogens while pokeweed mitogen (PWM) activates both T and B cells. Another important 
mitogen which is NOT a lectin is LPS (lipopolysaccharide).  This polysaccharide component 
of the outer membrane of gram negative bacteria is also known as endotoxin.  LPS is a very 
potent mitogen for B cells. Mitogen stimulation in our immunological study of A-T patients 
was performed with ConA, PHA and PWM. Stimulation index was defined as counts per min 
(cpm) divided with the spontaneous proliferation.  
REFERENCE VALUES for immunoglobulins and lymphocyte counts 
As part of our study, age specific reference values were developed and defined for IgA, IgM 
and IgG with subclasses and also for some of the lymphocyte subclasses. Reference values for 
IgE were taken from Compendium in Laboratory Medicine, Denmark, and Fürst AS med-lab, 
Oslo, Norway (internet address: www.furst.no) and for IgD from (173). Age specific 
reference values in percentage for lymphocyte subsets were calculated from the absolute 
counts given in reference (186). The age specific reference values used in our study when 
measuring immunologlobulins and lymphocyte subsets are presented here and are also 
available at: 
http://www.blackwellpublishing.com/products/journals/suppmat/CEI/CEI2492/cei2492tableS1.doc
http://www.blackwellpublishing.com/products/journals/suppmat/CEI/CEI2492/cei2492tableS2.doc
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Genetic tests 
ATM genotyping 
Several mutation analysis techniques have been used to locate the disease causing ATM 
germline mutation in A-T probands as the Norwegian AT study has been ongoing for more 
than a decade. Mutation analyses of DNA prepared from peripheral blood cells had been 
performed using several different techniques: protein truncating test (PTT), denaturing 
gradient gel electrophoresis (DGGE), heteroduplex analysis, denaturing high performance 
liquid chromatography (dHPLC) followed by sequencing in both directions using DyeDeoxy 
Terminator Cycle sequencing kits (Applied Biosystems, Inc., Foster City, CA) using an ABI 
3100 DNA sequencer (Applied Biosystems, Inc) as previously described (187;188).  
dHPLC is a high-resolution method for separating large molecules and is often used as an 
automated method for the detection of DNA sequence variants. dHPLC-based mutation or 
single nucleotide polymorphism (SNP) screening relies on different DNA thermodynamic 
properties between perfectly matched base pairs in homoduplex molecules and mismatches in 
heteroduplex DNAs. dHPLC analysis is conducted on a WAVE machine and detects about 
70% of ATM mutations. 
AIRE genotyping 
Sequencing of coding regions of the AIRE gene was done in one affected CMC patient from 
each family in Paper VI after publication. Reported in Paper VI are results of the microsatelite 
analyses excluding segregation with the AIRE gene locus. 
MBL genotyping 
Detection of mutations and promoter polymorphisms in the MBL gene was performed by 
polymerase chain reaction (PCR) according to (189). The following polymorphisms were 
studied: three point mutations in the promoter region (position -550 (H/L variants), -221 (X/Y 
variants), -70 (nt C or T)), one point mutation in the 5' untranslated (UT) region at position +4 
(P/Q variants) and three point mutations located at codons 52, 54 and 57 in exon 1, at 
nucleotide positions 223, 230 and 239. 
HLA haplotyping 
Patient samples were typed for HLA-DQB1 using a reverse dot blot kit (Amplicor, Dynal, 
Oslo, Norway). The DQA1 alleles and HLA-DRB1-DQA1-DQB1 haplotypes were deduced 
based on known patterns of linkage disequilibrium in the Norwegian population. 
Microsatellite marker analysis 
Three highly polymorphic microsatellite markers (D21S268, D21S1224 and D21S1890) 
located near the AIRE gene were used as markers for the transmission of the AIRE locus in the 
two families. Fluorescence labelled PCR products were analysed on an ABI 310 Genetic 
analyser and the Genescan Analysis software (PE Applied Biosystems, USA). 
Fluorescent in situ hybridization FISH 
Fluorescent in situ hybridization (FISH) is based on chromosome region-specific, fluorescent-
labelled DNA probes. Probes are cloned pieces of genomic DNA that are able to detect their 
complementary DNA sequences, and produce a fluorescent signal against background stained 
chromosomes. The technique requires prior knowledge of the type and location of expected 
aberrations and can only be used for the analysis of a limited number of chromosomal loci at 
one time. The efficacy of FISH is limited in some applications by low-resolution sensitivity. 
FISH is used to confirm findings on microarray CGH, MLPA etc. For the 14q deletion study, 
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cosmids covering TITF1 and one covering PAX9 (190) were biotinylated by nick translation. 
Labeling and FISH were performed as described (191). 
Multiplex ligation-dependent probe amplification MLPA 
The MLPA technique is used for the relative quantification of up to 40 different DNA 
sequences. Each MLPA probe consists of two oliginucleotides that are ligated by a 
thermostable ligase if they bind to the target sequence. Target sequences are small (50-70 
nucleotides). The ligated probe is then amplified by polymerase chain reaction (PCR) rather 
than the target sequence as in conventional assays. Each MLPA probe is designed to have a 
specific size so that, when run on a gel, the product of each probe can be identified by its size. 
This technique can be used to identify exon deletions and duplications and, potentially, the 
copy number of any unique sequence. MLPA is used to confirm findings on microarray CGH, 
FISH etc.  Neither FISH nor MLPA can determine sequence alterations and chromosomal 
break points with precision.  
Microarray CGH  
With the introduction of microarray-based comparative genomic hybridization (microarray 
CGH), it is possible to overcome the main limitation of conventional CGH, low resolution. 
Microarray CGH has more and more become the method of choice for studying genome-wide 
DNA copy number changes (191). With microarray CGH, the metaphase chromosomes are 
replaced by cloned DNA fragments (±100–200 kb) of which the exact chromosomal location 
is known. This allows the detection of aberrations in more detail and, moreover, makes it 
possible to map the changes directly onto the genomic sequence. Microarray-based CGH 
builds upon the conventional CGH procedure, by the use of differentially labelled test and 
reference DNAs. Both DNAs, then, are hybridized to cloned fragments, most often genomic 
DNA or cDNA, which are spotted on a glass slide (the array). The DNA copy number 
aberrations are subsequently measured by detecting intensity differences in the hybridization 
patterns of both DNAs. A high-density miniaturized array of oligonucleotides spotted onto a 
glass slide. Expression arrays hybridize mRNA to quantify gene expression. Genomic arrays 
hybridize DNA to identify cryptic deletions and duplications, and are useful for determining 
which genes are involved. CGH enables analysis of all chromosomes in a single experiment 
and, in contrast to conventional karyotyping, no dividing cells are required. A main 
disadvantage of conventional CGH is its inability to detect mosaicism, balanced chromosomal 
translocations, inversions, and whole- genome ploidy changes. For the detection of these 
types of abnormalities, other techniques, such as spectral karyotyping and (multiplex) FISH, 
can be used. 
Statistics 
The data leading to Paper I, III, IV and V was collected in Microsoft Access 97 databases; one 
database for the PID registry, one for the A-T patients and carriers, and one separate database 
for the control persons in the vaccine study. To meet legal requirement, the patient 
administrative data were coded when registered. SPSS programs for Windows (SPSS 9.0 or 
SPSS 11.0) were used for the statistical analyses performed in paper II-V. To compare two 
groups, t-tests were used, while one-way ANOVA models were used to compare more than 
two groups. Bonferroni corrections were performed to accommodate multiple tests. To study 
the linear relationship between two continuous variables, Pearson coefficients and linear 
regression components were computed. Associations between categorical variables were 
studied with Fisher’s exact test. The programme SamplePower 2.0 was used to calculate 
statistical power of the data prior to and after the studies. Reliability analyses (Cronbach 
alpha) were performed for the factors in each subscale of the Hope/QLI/Coping questionnaire. 
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Results 1 
Paper I  
PID in Norway – epidemiology 
The objective of this study was to perform a national epidemiological survey of PIDs. 
Questionnaires were sent to all hospital departments taking care of PID patients. As of 1999 a 
total of 372 PID patients were registered, 303 were alive, yielding a prevalence of 0.7 per 
10.000 inhabitants in Norway. Distribution between the main immunodeficiency diagnoses 
was as follows: 
(a) antibody deficiencies (n=189) 50.8%,  
(b) combined deficiencies included other immunodeficiency syndromes (n=46) 12.4%,  
(c) complement deficiencies (n=78) 21.0%,  
(d) phagocytic disorders (n=25) 6.7%,  
(e) immunodeficiency associated with other congenital diseases (n=34) 9.1%.  
We were able to calculate more accurate incidences of the specific diagnoses, such as Wiskott 
Aldrich Syndrome, X-linked SCID, Bruton's X-linked agammaglobulinemia and ataxia-
telangiectasia. When incidence and prevalence of each specific PID is compared, our results 
with some exceptions correspond to estimates from other countries. Compared to reports from 
other European countries, the proportion of combined deficiencies is larger compared to 
antibody deficiencies because we had fewer patients with selective IgA deficiency. We also 
had a large proportion of complement deficiencies because of the prevalence of hereditary 
angioedema. 
Paper II 
Coping, quality of life, and hope in adults with primary antibody deficiencies 
Questionnaires were sent to all patients > 20 years of age with primary antibody deficiencies 
served by Rikshospitalet. The questionnaires consisted of several standardized scales: Ferrans 
and Powers Quality of Life Index (QLI), Short Form-36 (SF-36), Jalowiec Coping Scale 
(JCS), Nowotny Hope Scale (NHS), and one scale we designed with questions about 
resources and pressures in the past. Fifty five of 91 patients (aged 23-76 years) replied. 
Among the 55, low quality of life scores were related to unemployment, infections in more 
than four organs, more than two additional diseases, or more than two specific occurrences of 
stress in the last 2-3 months. Previous experiences related to the immunodeficiency such as 
episodes of illness, absence from school and psychosocial consequences were important. 
Persons with selective IgA deficiency had significantly higher QLI scores than those with 
other antibody deficiencies. Other differencies between the various antibody deficiencies were 
not found. HCV infection had no influence on QLI or SF-36 scores. An optimistic coping 
style was most frequently used, and hope values were moderately high. The questionnaire 
study was supplemented with selected interviews of ten extreme cases, five with low and five 
with high quality of life scores. Based on these interviews, the patients could be divided into 
three groups: 1) low QLI scores, low hope values, and reduced coping, 2) low QLI scores, 
moderate hope values, and good coping, and 3) high QLI scores, moderate to strong hope 
values, and good coping. Coping was related to the patients' sense of closeness and 
competence.  
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In conclusion, low quality of life scores in adults with primary antibody deficiencies were 
linked to unemployment and disease-related strains. Closeness and competence were 
preconditions for coping, quality of life and hope.  
Paper III 
A-T and Immunology 
During the epidemiological study it became evident that some patient subgroups including A-
T had been less well characterized immunologically than others. All living A-T patients were 
localized via the national PID registry, included in the study and thoroughly characterized 
immunologically. In addition we looked for possible immunological correlations to ATM 
genotypes. Despite normal leukocyte counts and normal to subnormal levels of lymphocytes 
in peripheral blood, the A-T patients had low numbers of B cells (CD19+) and T cells, 
especially CD4+ cells. Among the 11 A-T patients, we found a variable degree of IgG2 and 
IgA deficiency, as well as low/undetectable IgE values. The five patients homozygous for the 
Norwegian ATM founder mutation had the lowest IgG2 levels. All 11 patients had very low 
levels of antibodies to Streptococcus pneumoniae. There was a significant positive linear 
relationship between pneumococcal antibodies and IgG2 levels. Previous vaccinations with T 
cell dependent diphtheria, tetanus and Hemophilus influenzae type b (Hib) vaccines had 
induced protective antibodies in most patients. There was a striking discrepancy between the 
pathological immunological findings in the laboratory and the sparse clinical symptoms of 
immunodeficiency in the patients. No age related progression of the immunodeficiency was 
found. 
Patients’ parents were included in the immunological study, because of evidence which 
suggests that ATM carriers may be radiosensitive and have a moderately increased risk of 
cancer. Twenty-two parents were included, half of them heterozygous for the ATM founder 
mutation. Some abnormalities in immunoglobulin levels and/or lymphocyte subpopulations 
were observed but there was no correlation to ATM genotype. 
Paper IV 
A-T and pneumococcal vaccine 
This study was a follow-up of Paper III.  Others have previously vaccinated A-T patients with 
the “old type” 23-valent pneumococcal polysaccharide vaccine (PPV23) without a significant 
pneumococcal antibody response. In Paper II we documented that A-T patients are capable of 
making protective antibodies to other vaccines, such as diphtheria and tetanus toxin. These 
vaccines are designed to trigger a more T-cell dependent immunological response, compared 
to the polysaccharide vaccines. The fact that A-T patients had antibodies against Hib, 
diphtheria and tetanus, suggested potential for effect of the “new type” seven-valent 
pneumococcal conjugated vaccine (PCV7). After protocol approval from the Norwegian 
Medicines Agency, the Regional Committee for Medical Research Ethics and the Norwegian 
Data Inspectorate, all Norwegian A-T patients were invited to participate in the vaccine study. 
Nine A-T patients and 25 age and sex matched controls were vaccinated with PCV7 and 
PPV23, and three A-T patients were vaccinated with PCV7 only. No significant increases in 
pneumococcal antibody levels were observed among the A-T patients after the single PCV7. 
Subsequent PPV23 vaccination resulted in a significant increase in antibody levels to the 
PPV23 mix, as well as to some of the serotypes. The vaccinations induced a 1.5- to 7-fold 
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increase in antibodies to the six different serotypes tested. The increases in pneumococcal 
antibody titres were lower than those observed in the controls (9- to 34-fold increase) The 
results of the vaccination study are valuable in planning care of A-T patients.  PCV7 can be 
used to trigger and PPV23 to booster immune response and possibly preventing severe 
pneumococcal disease. To prevent severe pneumococcal disease in A-T is important since 
older patients tend to suffer from chronic respiratory failure and to be susceptible to 
pneumonias. 
No correlation between mannose binding lectin (MBL) levels and pneumococcal antibody 
levels was found. Six A-T patients had low levels of serum MBL. The four patients with the 
highest MBL levels were not prone to respiratory infections. Low MBL levels may represent 
a separate additive effect of the immunodeficiency in these patients. 
Paper V 
A-T and alpha fetoprotein 
By closely following A-T patients with repeated blood samples for years, we have 
documented an increased level of alpha fetoprotein and a continuous increase in AFP serum 
levels with increasing age. This observation has not been published previously. The role of 
AFP in A-T remains to be elucidated and different theories of why AFP is increased in A-T 
are discussed in the paper. 
Paper VI 
Chronic mucocutaneous candidiasis and hypothyroidism 
We describe the clinical and immunological features of two families with chronic 
mucocutaneous candidiasis (CMC) and primary hypothyroidism. Family A includes three 
siblings with both candidiasis and hypothyroidism and four individuals with hypothyroidism 
only.  Family B includes four members with candidiasis, including one male child with 
hypothyroidism. All individuals with CMC had oral candidiasis and onychomycosis from 
infancy. Facial seborrhoeic dermatitis, generalized folliculitis and scaling blepharitis were the 
main manifestations. Hypothyroidism became evident during childhood. No thyroid 
antibodies were present in the affected siblings in family A, while the male with 
hypothyroidism in family B had antibodies against thyroid peroxidase at diagnosis.  
Immunological evaluation revealed intra-individual variations in serum immunoglobulin 
levels, lymphocyte subsets and proliferative responses, but no consistent abnormalities. An 
elevated serum MBL level was found in all patients. Vaccine responses were normal. The 
disease showed no HLA haplotype association. AIRE gene region microsatellite markers did 
not segregate with disease nor were autoantibodies typical for autoimmune polyendocrine 
syndrome type 1 detected. The link between hypothyroidism and chronic mucocutaneous 
candidiasis remains to be identified. 
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Paper VII 
Proximal 14q Deletion and MBL deficiency 
We report an eight year old boy with developmental delay, ataxia, choreoathetosis, muscular 
hypotonia, thyroid dysfunction and severe pulmonary problems characterised by recurrent 
episodes of respiratory distress and pneumonia. He had a heterozygous deletion of proximal 
chromosome 14q resulting in haploinsufficiency of NKX2.1 (TITF1) and PAX9. He was also 
homozygous for the mannose-binding lectin (MBL) haplotype B, a variant in codon 54 in the 
MBL2 gene on chromosome 10q causing absence of functional serum MBL. The 14q deletion 
was confined to the index patient, while the MBL deficiency and corresponding MBL2
genotypes were found in his mother and his younger sibling.  
We conclude that the TITF1 haploinsufficiency is causative for his neurological disease and 
respiratory distress, and his susceptibility to infections is intensified by the coexistence of 
MBL deficiency. 
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Results 2 
  
Update report – PID epidemiology and treatment 
PID epidemiology 
We were allowed to keep and update the national Norwegian PID research registry until the 
end of 2004. As of January 2005, a total of 566 PID patients (456 living) were registered. 
With a population of 4.6 millions, the prevalence of PID was 1.0 per 10.000 inhabitants in 
Norway. These updated results are not published elsewhere. The number of patients according 
to specific PID diagnoses is presented in the table below, compared with the numbers from 
1999, and with the specific diseases sorted by the same categories as in 1999. The distribution 
of PID and differences in prevalence between counties and regions are presented here in the 
Table 5 and Figure 19. 110 persons had another family member registered in the PID registry.
PID update report - Treatment 
PID patients on treatment with subcutaneous (ScIg) and intravenous immunoglobulins (IVIg) 
are included in this update report, as are patients treated with hematopoietic stem cell 
transplantation.  
As of January 2005, a total of 127 persons including 17 children were being treated with 
immunoglobulins. 113 were on ScIg, 24 of whom also received IVIg infusions periodically or 
parallel to ScIg. Fourteen individuals were treated with IVIg only. 
Since Rikshospitalet is the national referral centre for stem cell transplantations in PID 
patients, the table of stem cell transplantation outcome in patients with PID is recent, from 
June 2007. The outcome of hematopoietic stem cell transplantation in patients with PIDs 
(Table 6 in Results 2) is presented with permission from Senior Consultant Anders Glomstein, 
Section of Pediatric Hematology, Department of Pediatrics, Rikshospitalet.      
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  Table 5      Primary immunodeficiency diseases in Norway – Update report year 2005 
Primary immunodeficiency diseases in Norway Jan   2005
Jan 
1999 
Main PID Diagnoses Specific PID diagnoses Living Deceased Total Total 
Antibody deficiency Bruton’s X-linked agammaglobulinemia 25 6 31 15 
 Common variable immunodeficiency (CVID) 103 32 135 117 
 Hyper IgM syndrome type 1,2,3,5 8 5 13 11 
 IgG subclass deficiency 15 15 10 
 Selective IgA deficiency 48 2 50 36 
 Other sorts of antibody deficiencies 4 1 5 
Total Antibody deficiencies 203 46 249 189 
Phagocytic disorders Severe congenital neutropenia 3 2 5 3 
 Cyclic neutropenia 18 1 19 8 
 Idiopatic neutropenia 10 1 11 7 
 Interferon gamma receptor 1 deficiency 7 1 8 2 
 Chronic granulomatous disease 6 1 7 4 
 Leukocyte adhesion defects (LAD1) 1 1 1 
Total Phagocytic disorders 45 6 51 25 
Complement deficiencies C2 deficiency 10 10 7 
 C4 deficiency 1 1 1 
 C5 deficiency 2 2 2 
 C8beta deficiency 1 1 1 
 C1 inhibitor deficiency 70 70 67 
Total Complement deficiencies 84  84 78 
Severe combined Immunodeficiency (SCID) a 6 15 21 12 
Ataxia-Telangiectasia 12 17 29 17 
Del 22q11, DiGeorge anomaly with immunodeficiency 33 5 38 8 
Trisomy 22q11 1 1 
IPEX* (192) 1 1 
Wiskott Aldrich syndrome 8 3 11 8 
T-cell defects, combined  
B- and T-cell deficiencies  
and other well-defined 
immunodeficiency 
syndromes
X-linked thrombocytopenia 1 1 
 Other T-cell defects 1 1 1 
Total T-cell deficiencies and combined B- and T-cell deficiencies 62 40 102 46 
Other immunodeficiencies Autoimmune lymphoproliferative syndrome 7 7 
 Hyper IgE syndrome 2 2 1 
 Chronic mucocutaneous candidiasis (CMC) b 36 2 38 23 
 Ivemark syndrome with asplenia 5 6 11 3 
 XL EDA-ID*/NEMO (193) 4 4 3 
 NKX2.1 haploinsuffiency 1 1 
 Pearson syndrome 1 1 
 Schimke immunosseus dysplasia (194) 2 1 3 
 Shwachman Diamond Syndrome 4 0 4 
 Hoyerall–Hreidarsson syndrome 1 2 3 
 X-linked immunoproliferative syndrome 2 2 1 
 Chromosomal defects combined with immunodeficiency  3 3 3 
Total Other immunodeficiencies 61 18 79 34 
  Total PID Norway 456 110 566 372 
a) SCID includes T- B+ NK- SCID, T- B- NK+ SCID, Omenn syndrome and other types of SCID such as reticular dysgenesis.  
b) CMC includes patients with APECED*, CMC patients with hypothyreosis and also CMC patients without endocrinopathy. 
*Abbreviations:  
IPEX; immune dysregulation, polyendocrinopathy, enteropathy, X-linked caused by FOXP3 gene mutations 
XL EDA-ID; X-linked ectodermal dysplasia anhidrotic immunodeficiency caused by NEMO gene mutations 
APECED; autoimmune polyendocrinopathy, candidiasis, ectodermal dystrophy caused by AIRE gene mutations 
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Ataxia-Telangiectasia in Norway,  
epidemiology and genetics 
Disease incidence and A-T carrier frequency in Norway:  
As of 2006, we knew of 32 patients born between 1951-2003 with A-T. The birth rate in 
Norway the last 50 years has been approximately 60.000 livebirths per year (Statistics 
Norway; http://www.ssb.no/). The incidence of A-T based on these figures is about 1:100.000 
livebirths. The A-T carrier frequency is calculated to be 0.6 % in the general population. With 
4.600.000 inhabitants per 2006, approximately 30.000 persons will be A-T carriers. 
Nine of the 32 patients were born in Hedmark County which has a birth rate of 1800 per year 
(Statistics Norway; http://www.ssb.no/). In Hedmark County, the incidence of A-T is 
therefore 1:10.000 live births. The frequency of A-T mutant heterozygous alleles may be as 
high as 2 % in this area of Norway. The nine patients from Hedmark county were either 
homozygous or compound heterozygous for the Norwegian founder mutation, which 
originated in “Rendalen”valley in the northern part of Hedmark county. These data are 
presented in Results 2 (Table 7, Table 8, and Figure 20 Rendalen A-T Pedigree) 
Eighteen of our 32 patients (born 1951-1985) are deceased; mean age of survival was 19,9 
years (95% CI, 17.1-22.6) with three outliers: one patient died at 8, one at 9 and one at 23 
years of age. Table 7 includes ATM mutations and cancer occurrence in 25 patients. In five 
families, two siblings were affected. Seven patients were homozygous and six compound 
heterozygous for the Norwegian ATM founder mutation.  
Norwegian founder mutation from Rendalen in Hedmark County 
Genealogical studies have identified a common ancestor for six of the Norwegian A-T 
families with the founder mutation. The common ancestor was born in 1495 in Rendalen, 
Hedmark County. The Figure 20 shows how the families are related. Further genealogical 
studies would most likely reveal common descent in more families given the allele frequency 
in Norwegian A-T probands.  
Other mutations in ATM  
and possible relationships between the Norwegian A-T families 
Including the founder mutation a total of five mutations recur in the Norwegian families. 
These five mutations are responsible for 75% (30/40) of the parental ATM mutations. The 
mutation spectrum is presented in Table 8. The father in family NOAT 7 and mother in 
NOAT8 carry the same mutation and haplotype (187). They were born in the same 
community. The mother in NOAT7 carries the same mutation found in the mother of 
NOAT21, and this mutation was also found in both parents in family NOAT13 who were not 
aware of consanguinity prior to mutation analyses. The maternal and paternal grandfathers of 
NOAT13 carry the same mutation. These families originate from Southwest Norway. The 
father in NOAT3 and mother in NOAT20 carry the same mutation. The mother in NOAT9 
and NOAT18 and father of NOAT15 carry the same mutation, and their families are probably 
originally from the same valley in Oppland County. In one family only one disease causing 
allele has been found (NOAT5). Linkage studies have concluded that the other mutation is de 
novo (187). Six of the mutations are also found outside of Norway, in Denmark, the US, the 
Netherlands, Great Britain, Germany, Poland and Brazil (187;195-201) 
75
Predicted consequences of mutations 
The mutations found in the Norwegian AT families (Table 8) have different consequences for 
the ATM protein: 27 (19 Rendalen + 8 other) of the 40 parental branches have frameshift 
mutations that lead to truncation of the protein, 5/40 have splice site mutations that lead to 
skipping of exons, 5/40 have nonsense mutations causing skipping of exons or inducing stop 
codons at the mutation site, 1/40 has a double substitution and 1/40 has a missense mutation.  
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Table 8       Parental mutations in ATM  
           and predicted ATM protein alterations 
Identity cDNA  exon PREDICTED EFFECT protein 
NOAT3 mother c.1931C>A    15 p.S644X  
NOAT3 father c.2880_2880delC c.2880delC 21 p.P961CfsX10 
NOAT20 mother c.2880_2880delC c.2880delC 21  p.P961CfsX10 
NOAT15 mother c.2938delT(fs) 22 p.Y980IfsX12 
NOAT1 father c.3245_3247delATCinsTGAT 24 p.H1082LfsX14 
NOAT1 mother c.3245_3247delATCinsTGAT 24 p.H1082LfsX14 
NOAT2 father c.3245_3247delATCinsTGAT 24 p.H1082LfsX14 
NOAT2 mother c.3245_3247delATCinsTGAT 24 p.H1082LfsX14 
NOAT5 father c.3245_3247delATCinsTGAT 24 p.H1082LfsX14 
NOAT6 father c.3245_3247delATCinsTGAT 24 p.H1082LfsX14 
NOAT6 mother c.3245_3247delATCinsTGAT 24 p.H1082LfsX14 
NOAT8 father c.3245_3247delATCinsTGAT 24 p.H1082LfsX14 
NOAT10 father c.3245_3247delATCinsTGAT 24 p.H1082LfsX14 
NOAT10 mother c.3245_3247delATCinsTGAT 24 p.H1082LfsX14 
NOAT11 father c.3245_3247delATCinsTGAT 24 p.H1082LfsX14 
NOAT11 mother c.3245_3247delATCinsTGAT 24 p.H1082LfsX14 
NOAT14 father c.3245_3247delATCinsTGAT 24 p.H1082LfsX14 
NOAT14 mother c.3245_3247delATCinsTGAT 24 p.H1082LfsX14 
NOAT16 father c.3245_3247delATCinsTGAT 24 p.H1082LfsX14 
NOAT16 mother c.3245_3247delATCinsTGAT 24 p.H1082LfsX14 
NOAT17 mother c.3245_3247delATCinsTGAT 24 p.H1082LfsX14 
NOAT18 father c.3245_3247delATCinsTGAT 24 p.H1082LfsX14 
NOAT24 father c.3245_3247delATCinsTGAT 24 p.H1082LfsX14 
NOAT9 father c.4110_4110delG c.4111delG 30  p.G1371GfsX16 
NOAT15 father c.4110_4110delG c.4111delG 30 p.G1371GfsX16 
NOAT18 mother c.4110_4110delG c.4111delG 30 p.G1371GfsX16 
NOAT24 mother c.4588G>T(ns) 32 p.E1530X 
NOAT9 mother c.4632_4635delCTTA(ns) 33 p.Y1544X  
NOAT20 father c.5932G>T(ns) 42 p.E1978X  
NOAT21 father c.6838C>T(ns) 49 p.Q2280X 
NOAT17 father c.6890A>C(ms) 49 p.Q2297P 
NOAT4 mother c.7875_7876delTGinsGC 55 p.DA2625EP 
NOAT7 father c.8264_8268delATAAG 58 p.Y2755CfsX12 
NOAT8 mother c.8264_8268delATAAG 58 p.Y2755CfsX12 
NOAT7 mother c.8432_8432delA c.8432delA 60 p.N2811TfsX46 
NOAT13 father c.8432_8432delA c.8432delA 60 p.N2811TfsX46 
NOAT13 mother c.8432_8432delA c.8432delA 60  p.N2811TfsX46 
NOAT21 mother c.8432_8432delA c.8432delA 60  p.N2811TfsX46 
NOAT4 father c.8978_8981delGAAAinsAT 64 p.R2993HfsX4  
NOAT5 mother Unknown - de novo? -  
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General Discussion 
The presented papers (I-VII) all focus on collecting information concerning PID patients. We 
ascertained the number of PID patients (Paper I), and investigated how they were coping with 
their chronic disease and life in general (Paper II). The epidemiological study (Paper I) also 
revealed that there were some patients with uncharacterized immunodeficiency syndromes. In 
Paper III and IV we describe a cohort of patients with a specific PID, ataxia-telangiectasia. 
During the epidemiological study (Paper I) it came clear that the genotypes, but not the 
immunological phenotypes, had been defined in most A-T patients. We initiated the 
immunological study, searched for genotype-phenotype links, and were able to draw some 
interesting conclusions (Papers II-IV). When counting patients and sorting them into 
diagnostic categories and specific PID diagnoses, new and unclassified entities may appear. 
We found two families with CMC linked to hypothyroidism but without APECED (Paper V). 
Closer scrutiny of the A-T group revealed one patient with a new and different disorder 
(Paper VII).  
Epidemiological studies in rare disorders and medical quality registries in Scandinavia  
The great advantages of performing epidemiological studies in Scandinavia are our relatively 
small and surveyable populations, and our National Health Services with universal social 
healthcare (202). We also have a long tradition of national disease registries in Norway i.e. 
Cancer Registry of Norway http://www.kreftregisteret.no/, the Medical Birth Registry of 
Norway, and also medical quality registries for particular diseases such as the National 
Porphyria registry at the Norwegian Porphyria Centre (NAPOS) http://www.helse-
bergen.no/avd/napos/. Using population-based registry data to calculate incidence and 
prevalence is contingent upon high detection rates. In the case of rare disorders official 
national-wide patient registries are necessary to ensure that all, or nearly all, patients are 
counted. 
PID epidemiology - Not all PID registered  
A main issue to discuss after Paper I is that not all Norwegian PID patients are likely to be 
recognised, diagnosed or registered. The geographical variation in prevalence of PID supports 
likely underdiagnosis. The true occurrence of PID may vary between regions (e.g., as for A-T) 
or medical professionals from some districts may not have reported all their PID patients, 
because of lack of awareness of the national PID registry. It is, however, very likely that the 
results reflect a difference in awareness of PID among medical professionals from different 
health regions and in different medical centres. PIDs are rare disorders and advanced 
immunological or specific molecular genetic investigations are often needed for accurate 
diagnosis. These tools are not available in all medical centres. Regional differences in 
primary, secondary and tertiary healthcare services including access to specialists may also 
have influenced the number of diagnosed and reported cases. Research activity and medical 
interests may influence the pattern of distribution of diagnoses causing overrepresentation of 
patients from certain medical centers. Half of the reported patients with primary neutropenia, 
for example, lived in the same county, and were referred or reported from the same hospital 
(Figure 19)(203). A similar example is the high frequency of hereditary angioedema in 
Northern Norway (Paper I). A special interest in PID research may contribute to the high 
prevalence of PID in the catchment of our hospital, Rikshospitalet, but does not explain all the 
geographical differences in PID incidence and prevalence. We have updated the PID research 
registry after the first publication, but this work was not done systematically. We only added 
81
new PID referrals to the registry. An even more skewed PID distribution between regions was 
present in the latest update from January 2005 (Results 2 Figure 19). Some PIDs, such as 
APECED, are pleiotropic and require a multidisciplinary approach, Sometimes the 
immunodeficiency is not the clinically most important element of multiorgan disease, and 
reporting to the PID registry may very well be overlooked. The reported incidence of SCID 
based on recognized cases is 1/100.000 per live births, but is an underestimate due to death in 
infancy before diagnosis. SCID patients are missed and autopsy findings are nonspecific 
unless specific lymphocyte counts have been done prior to death. On the other hand, in some 
cases only autopsy could have had detected the PID. At least five factors cause 
underestimation of the true prevalence of PID: 1) lack of clinical recognition, 2) death before 
recognition, 3) variable access to cellular and molecular diagnostics, 4) lack of reporting to 
the PID registry, and 5) lack of standardized diagnostic criteria.   
Classifications and definitions of PID are dynamic   
One of the difficult challenges was to diagnose and classify PID patients correctly. 
Many patients registered as CVID may have had other PIDs, e.g., WAS, leaky BTK, XLP. 
Re-evaluation of each patient’s complete medical record and laboratory results was necessary.  
After we started our epidemiological survey new PIDs have been defined as a result of 
molecular genetic research. X-linked Hyper IgM type 1 caused by CD40 ligand defect is a T 
cell defect, but this disease was previously classified as an antibody deficiency. Our former 
classification of female patients with agammaglobulinemia (combined with decreased or 
absent B cells) into the CVID group may therefore be incorrect. Some of these females may 
instead have one of the autosomal recessive µ heavy chain deficiencies, BLNK deficiency, 
Igalpha deficiency, λ(lambda)5 deficiency or other antibody deficiencies(204). The patients 
with hypogammaglobulinemia, low IgG and IgA and various levels of IgM have until now 
been classified into the CVID group, but may in reality have CD19 deficiency, ICOS 
deficiency, BAFF deficiency or defects in Ig subclass switching like AID deficiency, UNG 
deficiency, CD40 deficiency, the more comprehensive immunodeficiency CD40 ligand 
deficiency or another undefined immunodeficiency. Most of the agamma- and 
hypogammaglobulinemic patients are treated with immunoglobulin infusions, and one can 
argue that the new classifications into specific PIDs are of academic interest only. But for 
some of these PIDs knowledge about specific molecular genetic disease mechanisms may 
confer risk of additional diseases/complications and susceptibility to infection with specific 
microorganisms and have prognostic implications that should influence clinical management. 
For instance, it is important to know that patients with the CD40 ligand deficiency have a high 
risk of severe infection with cryptosporidiosis causing biliary canal stenosis and liver failure, 
or that lymphoproliferative and autoimmune signs are part of ALPS and WAS and that 
splenectomy may not resolve WAS patients’ thrombocytopathia. The earlier classification of 
specific PIDs into the five groups of antibody deficiencies, combined deficiencies, 
complement disorders, phagocyte disorders or the groups of other PIDs/syndromes including 
PID was confusing. Recently classification has changed. For example, WAS classified as a 
predominantly antibody deficiency may cause neutropenia and T cell deficiency in addition to 
thrombocytopenia (205;206).  
Medical records - from paper to electronic charts 
Medical records were kept as paper charts during the study period. To collect and read 
thoroughly a large number of medical records was time-consuming and ineffective. Some 
patients with PIDs causing multisystem diseases, such as APECED, had multiple medical 
records within the same hospital; one medical record for each department. Today, at our 
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hospital and at most hospitals in our country, medical records are electronic and old 
documents are scanned to the chart. There is only one medical record for each patient. A 
given patient chart is accessible for more than one user at the same time. However laboratory 
results, results of radiological investigations and records for the same patient from multiple 
hospitals may not be easily accessible and searchable.  When searching for new patients in the 
hospitals registry, the ICD-numbers have limited value as long as many of the specific PID 
diagnoses do not have their own ICD-10 numbers. For genetic diseases, OMIM numbers are 
of greater value because they are much more specific. It would be an advantage if these 
numbers were used in patient reporting hospital data systems.  
Change in organisation of health care system in Norway – implications for management 
of PID patients and disease awareness 
After we began to register PID patients, the five health regions in Norway were reorganised 
into five new regional health trusts (207), and more recently fused into four regional health 
trusts. The proportion of patients receiving medical treatment across regional health trusts was 
only 0.9% in 2003 (208). Since we have indirectly shown that awareness of PID differs 
among medical professionals, this reorganization of specialized healthcare services and 
hospitals may have consequences for the diagnosis and follow-up of new PID patients.  
Our epidemiological data has been useful for others
Despite the limitations of our epidemiological survey and report update we collected a fairly 
large number of PID patients compared to studies from other countries. This may be 
consistent with variance in rates of detected/reported PID patients, rather than true differences 
in frequency of PID between the countries. Our population based calculations of frequencies 
of PID have already been valuable in planning healthcare services for PID patients in our 
country as well as in other countries, in documenting the need for PID awareness among 
healthcare professionals, and has also been useful comparing PID frequencies in different 
populations(209;209;210). Our results have been used by the US’ Department of Health and 
Human Services’ Centers for Disease Control and Prevention (CDC) in their 
recommendations and report “Applying Public Health Strategies to Primary 
Immunodeficiency Diseases” January 2004: 
http://www.cdc.gov/genomics/hugenet/reviews/tables/SCID_Tables.htm
Other national PID registries and the ESID registry
In paper I our data were compared with the data published from other countries and the data 
from the old ESID (European Society for Immunodeficiencies) registry. After our publication 
in 2000 there have been some reports or update reports from other countries: Spain in  
2001(211), Ireland in 2005 (212), Israel in 2002 (213), Iran in 2002 and 2006(214;215), 
Australia/New Zealand in 2007(216), and a second report from the Latin American PID 
registry in 2007(217). A new report calculating the population prevalence in US was 
published in 2007. This study was based on telephone calls to 10.000 random households, 
trying to find the true prevalence of PID(218). The internet based registry from Australia and 
New Zealand (2007) showed a geographic variation in PID registration from 1 to 12.5 per 
100.000 living individuals (216). We had a mean registration of 7 PID patients per 100.000 
(Paper I), increasing to 10 per 100.000 in our update report (Table 5). We also found 
substantial variation in PID registration between the different regions in our country (Paper I 
and Update report: Figure 19). The true frequency of certain diseases may vary between 
countries. Of a total of 1209 reported PID patients, only ten had A-T in Australia and New 
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Zealand (216). In the PID report from Iran (2002) a higher proportion of A-T patients were 
reported; (48/440). The report of PID from Australia and New Zealand was based on a single 
time point registration, while PID registries from other countries have included deceased 
patients. In comparison, our first PID epidemiology report (Paper I) contained 17 A-T patients 
including 10 deceased individuals. During our clinical immunological A-T studies newly 
diagnosed patients were referred to us (Papers III-IV), and we also received information about 
previously deceased A-T patients. This information was included until end of year 2004 in the 
national PID registry (Table 5). Recently, even more A-T patients have been diagnosed in 
Norway and our summary from year 2006 (Results 2) contained 32 known A-T patients (14 
living, 18 deceased). Our first PID registry report (Paper I) was based on single time point 
registration combined with collection of retrospective data.  This allowed us to register 
deceased patients, such as patients with fatal SCID. The epidemiological results emerging 
from our A-T studies illustrates the advantage of longitudinal collection of data, both 
retrospectively and prospectively, compared to single time point registration.  
The A-T report from Iran 2007 (219), corresponds in many ways to what we have done based 
on our national PID registry. Characterizing and following cohorts of patients increases our 
knowledge of the specific disease. National multicenter registries, such as the CVID cohort 
study from Italy (220), can be used for follow-up of cohorts of patients with the same PID 
diagnosis. For assessing outcome of treatment, e.g., bone marrow transplantation, national and 
international collected medical data are important for formulating treatment recommendations 
for specific PIDs (23).  
It is necessary to emphazise that prevalence and incidence of specific PID diagnoses, and not 
groups of PID such as “antibody deficiencies” or “phagocyte defects”, should be used in 
making comparisons between countries. For example CMC patients in some national PID 
reports may have been classified as “T cell deficiencies” or “other immunodeficiencies”, 
while new research shows that CMC is a phagocyte disorder. In contrast to the old ESID 
registry, specific PID diagnoses are available the in new internet based ESID registry (221-
223). As we do in Paper I, the report from Australia states that the access to 
cellular/immunological and molecular diagnostic tests seem to lead to more patients being 
recognized and correctly categorized. Mutation registries, such as Bruton’s X-linked 
agammaglobulinemia registry from Argentina 2003(224), represent a basis for future PID 
cohort studies.  
Mutation databases for specific PID are already established (225) with a connection to the 
internet based European PID registry(221). The new ESID database has been designed for 
supporting continuous long-term documentation of patients, in order to improve diagnosis, 
classification, prognosis and therapy of PIDs. The ESID Online Database is a web-based 
system aimed at data storage, data entry, reporting and import of pre-existing data sources. It 
fulfills requirements of high-standard security and complies with present EU data protection 
laws and the demands of a modern research platform. The IDRbase (PID mutation databases) 
integrate clinical, biochemical, genetic, genomic, proteomic, structural, and computational 
data of primary immunodeficiencies.  
International collaboration: National PID registry  ESID registry 
Strictly speaking, few data from registries or large case-series have been published in the past 
5 years in international journals and there should be a greater focus on international 
collaboration and pooling of data (212;213;215;226). The present and future updated reports 
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of all PID patients in one country will be of national interest, but of more minor international 
significance. Some of the recent updated national registry reports are published in national 
languages, not in lingua franca (211;213). It seems no longer relevant to publish separate 
updated reports of all PIDs from each country in Europe. However, it is still very important to 
collect information about all PID cases in each country, collaborate with the ESID registry 
and with other international databases for specific PIDs and publish national updated reports 
collectively, as part of an international clinical scientific effort.  
Focus on particular groups within the PID registry 
Using the PID registry, we were able to focus on particular groups and study more closely 
areas of special research interest e.g., psychosocial factors such as coping, quality of life and 
hope. Studies of coping strategies, scales for measuring different aspects of quality of life and 
hope are designed for and need to be tested on adults with a more or less consolidated 
personality. The largest group of adult PID patients is found within the group of antibody 
deficiencies. Even the selected group consisted of patients with different PIDs and represented 
a rather heterogeneous group of disorders. However, some common denominators were 
present. Including subjects with other immunodeficiencies would have increased the sample 
size at the cost of homogeneity.  
Coping, quality of life, and hope study in adults with PID 
The main purposes of the study reported in Paper II were to examine how adults with primary 
antibody deficiency manage their condition and to identify factors which are conducive to 
coping, good quality of life, and hopefulness. We found that low quality of life scores in 
adults with primary antibody deficiencies were linked to unemployment and disease-related 
strains. Previous experiences related to the immunodeficiency such as episodes of illness, 
absence from school, psychosocial consequences were important. Individuals with selective 
IgA deficiency had significantly higher QLI scores than those with other antibody 
deficiencies. Those with IgA deficiency had higher QLI scores in the socioeconomic and not 
surprisingly as expected in the health function domain. Other differences between the various 
antibody deficiencies were not found. During the years 1987-1993 the immunoglobulin 
preparation for intravenous administration (IVIg) was contaminated with hepatitis C virus.
Several of the patients with antibody deficiency who had been treated with IVIg during that 
period were infected with HCV with subsequent significant morbidity. We found that HCV 
infection had no influence on the QLI or SF-36 scores.  
Closeness and competence 
The concept “competence” encompasses an individual’s skills and experience of usefulness.  
“Closeness” is defined on three levels: 1) dyadic relationship with one competent adult, 2) 
family, and 3) social network. Closeness and competence contribute to self confidence and 
thereby to resilience against stress. We found that closeness and competence were 
preconditions for coping, quality of life and hope. Closeness and competence emerged as 
areas where psychosocial interventions may contribute to better quality of life in adults with 
antibody deficiencies. The results from the adult PID study confirm Lazarus and Folkman’s 
universal theory of coping and resilience against stress. Our results should influence the 
organisation of medical care and follow-up for this patient group. 
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Why 60% represented a satisfying response rate 
The questionnaire used in the coping, quality of life, and hope study was comprehensive and 
over 30 pages long. It was time-consuming and potentially challenging to answer. In order to 
perform statistical analyses and formulate conclusions of general validity in the study of 
“soft” factors such as coping, hope and quality of life, standardized comprehensive 
questionnaires and a high response rate are essential. A 60% response rate may be considered 
low, but is average for comprehensive quality of life questionnaires (227;228) That more than 
60% completed and returned the questionnaire, may indicate that our adult PID patients, on 
the whole, were motivated. The distribution of gender, age, types of antibody deficiency and 
presence of HCV was similar in non-responders and responders. The response rate was judged 
sufficient for the statistical analyses. Including subjects with other immunodeficiencies would 
have increased sample size at the cost of homogeneity. 
Triangulation  – combining quantitative and qualitative studies 
Triangulation, combining quantitative and qualitative methods based on different theories of 
coping, hope, quality of life, was a fruitful strategy. Triangulation of different methods 
strengthens the validity of research findings (Patton) (229). Our interview study supported the 
theoretic basis and constructs in the questionnaire, thereby strengthening the study as a whole. 
The interviews probed the individual’s and general results from the questionnaire. However, 
the interview study also raised some new questions and hypotheses, which were not covered 
by the questionnaire. The interviews contributed to more nuanced knowledge and 
complemented the questionnaire, increasing the relevance of the project as a whole. The 
combined findings strengthened the validity and utility of our results.  
Researchers have long debated the relative value of qualitative and quantitative inquiry. 
Phenomenological inquiry, or qualitative research, uses a naturalistic approach that seeks to 
understand phenomena in context-specific settings. Quantitative research uses experimental 
methods and quantitative measures to test hypothetical generalizations. Where quantitative 
researchers seek causal determination, prediction, and generalization of findings, qualitative 
researchers seek instead illumination, understanding, and extrapolation to similar situations. 
Qualitative analysis results in a different type of knowledge than does quantitative inquiry. 
Some researchers claim that qualitative and quantitative research can be effectively combined 
in the same research project, giving insights that neither type of analysis can provide alone 
(229;230). Also in medical science qualitative studies may be relevant (231). 
The triangulation of methods, combining quantitative and qualitative studies and finding 
coherence with theories of human behaviour and attitude, is elegant and has been used in 
other recent quality of life studies in various patient groups(230). For example Lukkarainen 
studied health-related quality of life in people with coronary artery disease with this approach. 
Significantly, the qualitative approach provided an explanation for the poor psychosocial 
health-related quality of life scores obtained by the quantitative approach (232). Interviews 
and the application of phenomenological psychology helped us to gain insight into the 
informants’ situational experiences of health-related quality of life and life course. This 
information was not elicited by questionnaire. Merkouris studying patient satisfaction found 
that the combination of qualitative and quantitative methodology appeared to contribute to the 
completeness of description and understanding of phenomenon (233). Anderson and Ferrans, 
in 1997, reported that indepth interviews provided a more complete understanding of the 
quality of life in their patient group and clarified the low ratings that were found on the 
quality of life index(234). 
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Choice of Instruments 
Quality of life and patient reported outcome studies depend a great deal on the choice of 
appropriate instruments. Tools must be selected according to the domains they measure and 
the populations and pathologies for which they are designed. Practical issues, such as the 
availability of different translations, copyrights, and access to instruments are additional 
major criteria in the choice of instruments. In our project following instruments were used: 
Ferrans and Powers Quality of Life Index (QLI), Short Form-36 (SF-36), Jalowiec Coping 
Scale (JCS), Nowotny Hope Scale (NHS). These instruments had been used in similar studies 
of other patient groups and had been translated into Norwegian and previously validated in 
our country (235;236). In addition, past events in the patients’ life needed to be documented. 
The first author (H.M.H.Sigstad) devised a new scale to measure resources and pressure in the 
past. Similarly to the JCS, this RPP Scale was founded on and Lazarus and Folkman’s theory 
of stress and coping(237).  
Coping Scale 
Jalowiec Coping Scale (JCS) were used to assess coping (238). JCS is based on Lazarus and 
Folkman’s theory of stress and coping. Other coping scales include, for example, the Coping 
Strategies Questionnaire (CSQ) that has recently been translated, cross-culturally adapted 
from an American to a German version. The reliability and validity of the translated version 
has been tested(239), but this coping scale is not yet ready to be used in the Norwegian 
population. Multicenter, multinational studies of psychological and social consequences of 
disease require questionnaires in the patients’ own languages and the scales must be cross-
culturally adapted, tested and validated on sample cohorts. 
Hope Scales 
As with social network and support, being able to hope may be helpful in the adaptive process 
and promote good quality of life. Hope has not been investigated in the other quality of life 
studies of PID patients. Different instruments can be used to study hope. Scales have been 
developed within various healthcare disciplines. Researchers with nursing background, in 
particular, have made important contributions. Examples of instruments used to study hope in 
patient groups are: Stoner Hope Scale (240), Miller Hope Scale (241), Nowotny Hope Scale 
(236), Herth’s Hope Scale (HHS) and Herth’s Hope Index which is a short version of HHS, 
recently translated and tested in a Norwegian population (242). The various hope scales have 
been developed based on different definitions of hope. For instance, Herth’s Hope Scale and 
Index are based on Daufalt and Martocchios theories and understanding of hope. We chose 
Nowotny Hope Scale. Nowotny identified hope as an important factor in the quality of life of 
individuals with cancer and found that hope was present in all aspects of life and could vary 
over time, as difficult situations evolved. Nowotny defined hope as a multidimensional 
dynamic attribute of the individual which includes future orientation, active involvement, trust 
that what is hoped for is possible, belief that other people or a higher being are involved, and 
importance of outcome for the individual. Hope may act as a buffer against decreased quality 
of life and can be regarded as an expression of personal resources. In spite of having ‘‘the 
same diagnosis,’’ disease progression and quality of life vary between individuals and 
settings. We estimated that hope was responsible for 1/5 of the total variance of QLI in our 
adult patients with antibody deficiencies. A low hope score was found in patients with 
extensive disease. The subscales of the NHS provide a framework for the development and 
implementation of strategies to maintain, reinforce, and facilitate hope. Sources of hope, as 
well as divergence in the hopes of health care providers and patients with chronic diseases, 
could also be discussed. 
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Quality of life scales: QLI or SF-36 
The validity and reliability of the instrument we used to measure global quality of life, the 
Ferrans and Powers Quality of Life Index, has recently been reassessed (243;244). SF-36 
which measures health-related quality of life is well-known and widely used in health care 
assessments. It is available and has been tested in almost all languages and populations. The 
SF-36 Scale has recently been implemented in the ESID internet registry as well, and is well-
suited for longitudinal follow-up reports of individual PID patients. 
SF-36 versus measuring global QLI 
As a rule, in quality of life studies of patient groups only the SF-36 scale is used. This also 
applies to older and recent studies of patients with PIDs (30;245;246). Health care 
professionals including nurses and physicians are primarily focused on the health-related 
quality of life, and can forget that life is more than concerns about disease and treatment. 
Other factors may contribute substantially to coping and good quality of life. These factors are 
easily missed with a focus limited to SF-36 scale scores. Some non-medical factors have 
implications for how patients and families handle their lives, deal with disease and treatment, 
and interact within the family. Therefore, to focus on the global factors related to quality of 
life is important for all types of patient groups. Patients with symptomatic selective IgA 
deficiency are usually healthier than other patients with antibody deficiencies and, as 
expected, they achieved a higher global QLI score (247-251). But very interestingly, the QLI 
differences were not found in the health/function domain, but in the socioeconomic, family 
and psychological/spiritual domains. If only SF-36 had been used, this finding would not have 
been evident. We need to be cognizant of factors than strictly medical issues when planning 
interventions which can have a positive impact on how patients and families cope with disease 
in the long-term. In addition to developing effective medical treatment strategies, it is 
important to support independence from an early age, focus on school achievements and 
ability to work, prevent social isolation and personal financial problems. 
Health-related quality of life and treatment methods 
The SF-36 scale measured health-related quality of life. Our study also focused on global 
quality of life. Answers about the immunoglobulin treatment regimens were not fully 
informative. We observed a difference in quality of life between those who treated themselves 
(ScIg) compared to those who were treated by others (IVIg), but the difference was not 
statistically significant. Patients who treated themselves (ScIg) had a significantly higher 
score in social functioning as assessed by SF-36 compared to the others. Gardulf found 
significantly increased health-related functioning, and improved self-rated health among 
patients with antibody deficiencies after initiation of ScIg infusions. This finding has been 
confirmed by others (30;31;245;252;253). In contrast to most other recent quality of life 
studies of patients with antibody deficiencies our study was not designed to detect differences 
before and after introduction of ScIg. In Norwegian patients, ScIg is the primary and initial 
immunoglobulin treatment for adults and children with hypogammaglobulinemia. Patients are 
put on IVIg only if they need high doses of immunoglobulins to maintain adequate serum IgG 
levels, or intermittently for other practical reasons, such as travelling. Studying implications 
on quality of life of a change from IVIg to ScIg is therefore less relevant.  
In contrast to hypogammaglobulinemia, selective IgA deficiency is usually not treated with 
immunoglobulins because of the potential for allergic reactions. Individuals with selective 
IgA deficiency do not have fewer intercurrent infections during adolescence or less of a health 
burden from autoimmune disease, but are perhaps less absent from school due to 
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hospitalisations for routine investigations and IVIg treatment. These factors may reduce the 
tendency to define oneself as sick. We found that individuals with selective IgA deficiency 
had significantly higher QLI scores in the socioeconomic but not the health-function domain 
compared to individuals with other antibody deficiencies including hypogammaglobulinemia. 
Selective IgA deficiency may have less psychosocial consequences and fewer implications for 
education, ability to work, employment opportunities and income. Other differences between 
the various antibody deficiencies were not found in our study, and surprisingly HCV infection 
had no influence on the QLI or SF-36 scores. 
Further discussion of results of the coping, quality of life, and hope study    – 
implications for follow-up 
Avoid unemployment  
The sum of medical problems, such as infections and additional diseases, were important for 
scholastic achievement. Based on the interviews a state of unemployment and, quite 
unexpectedly, a close bond to mother were noted as two important negative factors for coping. 
Our medical interventions should reduce the patient’s burden of illness, and support his / her 
chances of employment. Finding that work is an important independent external determinant 
of quality of life, is in agreement with results from recent studies of other chronic 
diseases(228). Adolescent patients must be encouraged to continue their educations in order to 
increase their flexibility in the employment market. Practically speaking, in caring for patients 
with antibody deficiencies, appointments should be planned to minimize absence from work 
and school. Self-administered subcutaneous treatment with immunoglobulin administered at 
home reduces travelling time to hospital for intravenous treatment. Appropriate pre-filled 
prescriptions for antibiotics and avoidance of unnecessary consultations may reduce sick 
leave. Medical interventions aim to reduce health related strains, but may not necessarily 
influence the patient’s perception of disease. A focus on coping, taking into account factors 
that have been defined as relevant, is an extra tool when planning health care strategies for the 
group and for each individual. Non-medical interventions can also have implications for the 
patients’ global QLI (30;31;222;253-255). Treatment and interventions may have 
consequences in other areas than anticipated. Health care providers can play an important role 
in enhancing the quality of life for patients with chronic illness through developing 
appropriate, individualized, coordinated and compassionate medical management.  
Support independence in adolescence 
Interpretation of the results from the interviews must be interpreted with some caution, since 
individuals were selected for interview based on QLI scores. The two elusive factors 
“closeness” and “competence” were found to be important for coping in PID patients. This 
was thought provoking, but consistent with Lazarus and Folkmans’ theories (237). Of 
particular note was that a complicated relationship to an intervening mother was related to low 
QLI scores. This raises a more universal issue for individuals with congenital and/or chronic 
disorders. Parents of children with chronic disorders may feel primarily responsible for the 
medical care of their children for many years. Particularly in children with rare disorders, 
parents may experience that healthcare providers may have less knowledge of the disease than 
they themselves have. Helping parents to withdraw from having total responsibility for an 
adolescent or adult child’s health, is an important management issue. Supporting 
independence already in childhood may be achieved by arranging training courses i.e. for 
introducing and promoting self-injection of ScIg at an early age. Attention to the transition 
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through adolescence, family dynamics and other psychological issues is required for 
successful management. Transfer of care to adult services should be planned carefully within 
the context of a multidisciplinary team.  
Optimistic coping style – also found in other studies 
An optimistic coping style was the most frequently used strategy found in our cohort of 
antibody deficient patients. In studies of other groups of patients, a majority have been found 
to employ an optimistic coping style (256-259).  
Ethical issues relating to the questionnaire and interviews  
Ethical issues can arise when patients are asked to complete questionnaires about coping, 
quality of life and hope. Answering such a questionnaire may lead to emotional distress and a 
feeling of being intruded upon. However, reflecting around these issues may also lead to 
increased insight, personal growth and better adjustment. The introductory letter, which 
accompanied our questionnaire, warned patients of the potentially sensitive nature of some 
items in the questionnaire. The interviews took place in the patient’s home with his / her 
consent. This may have felt intrusive, but on the other hand, may have been perceived as 
considerate and positive. The interviewer strived to be professional, empathetic and respectful 
and if necessary, provided information about follow-up support available through the National 
Health Service. 
Studies of coping, quality of life, and hope in other PID patients 
Quality of life studies are needed in patients with PID diagnoses other than antibody 
deficiences. In particular, there is a major need for psychosocial and behavioural studies in 
children with PIDs. There are additional ethical issues which arise with psychosocial testing 
and intervention studies in children. The childrens’ welfare should be given priority. 
Clinical studies based on the PID registry 
Clinical studies are time-consuming and will eventually occupy a part of the health centre 
capacity. However, the dividends from systematically following groups of patients with rare 
disorders have substantial value for patients and professionals. Health care professionals 
increase their knowledge of medical aspects of the disease, and patients are met by 
professionals with relevant clinical experience. Research results can be translated into practice 
directly and can be used for rational planning of health care and social services. Practical 
strategies for follow-up care, increased awareness and competency among health care 
professionals and results of the clinical studies could all have carry-over benefit for other 
patient groups. With the A-T studies (Papers II-V) we have shown that national registries can 
be used for clinical research and follow-up of cohorts of patients with the same PID.  
A characteristic immunological pattern in A-T patients 
A very characteristic immunological pattern is recognizable in A-T patients, and reflects 
underlying disturbances in T cell and B cell development including immunoglobulin 
formation. The A-T patients’ levels of immunoglobulin isotypes situated at the beginning of 
the constant region's reading frame are increased and then successively reduced downstream 
the genetic reading frame. This is compatible with the role of ATM protein in the end joining 
repair machinery in CSR. Patients usually have low IgE, IgA and/or IgG2 levels, and 
oligoclonal-/monoclonal increase in IgM and/or IgG can be present in A-T patients without 
signs of hematological malignancy (210;260). Quantitation of lymphocyte subsets is required 
to detect the specific pattern of cellular immunodeficiency. Routine leukocyte counts will 
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rarely, if ever, detect these lymphocyte subclass defects. The low T cell number in A-T 
patients has been observed by others (81;261), but we also call attention to the low B cell 
numbers (Paper III), a phenomenon which had not been reported previously. Lymphocyte 
flowcytometry can be performed as a diagnostic tool when A-T diagnosis is suspected in a 
child and will usually reveal both low B cells and low T cell numbers, with normal NK cell 
number. Not all patients are lymphopenic. Note that age-specific reference values should be 
used. Consistent differences in immunological status between patients can be found. The 
overall pattern is the same, but the severity of the immunodeficiency varies. The 
measurements in each patient showed variation over time, but interestingly, there was no 
significant progression of immunological abnormalities with age. We performed a 
longitudinal study, but only followed each patient for two to three years in the first study. If 
we include the subsequent years during which we conducted the pneumococcal study and 
measured alpha fetoprotein, we have followed seven patients for six to seven years each and 
not seen major progression of the immunological aberrations, however, an age effect over 
decades cannot be completely excluded. However, in a cross-sectional analysis of 100 A-T 
patients Lederman et al showed that the immune defect is not age-related (262).  
Laboratory immunological evaluation 
The defects in immune response are more quantitative than qualitative in A-T (42;263) and 
there is a discrepancy between patients’ modest clinical symptoms and the abundance of 
immunological laboratory abnormalities. The effectiveness, not only the numbers of B cells 
and T cells is important(262). We investigated the immunological status in our A-T patients 
using repeated blood sampling for quantitation of lymphocyte subsets and immunoglobulin 
levels. We did not determine the specific degree of deficiency in V(D)J recombination, 
isotype switch (CSR) or somatic hypermutation (SHM). However, the low T cell and B cell 
numbers as well as the signs of reduced ability to make certain immunoglobulin classes such 
as IgE and IgA, point indirectly to a deficiency in certain processes in the development of 
secondary immunocompetence. Investigation of presumed restricted V-region usage and 
oligoclonality of T cells and B cells requires methods not used in our studies (264;265). 
Others have shown that ATM is involved in V(D)J recombination and CSR, but not in SHM 
(120;266). A theoretical explanation for the extremely low B cell numbers in A-T is that B 
cells undergoes both V(D)J recombination and isotype switch, both of which are processes 
involving ATM. T cell precursors only undergo V(D)J recombination involving ATM, not 
CSR. This may be the reason why we found low T cell numbers and even lower B cell 
numbers (Paper III). A limitation of V(D)J repertoire of T cells and also B cells is to be 
expected in A-T and has been described by others (89;264;267-270). Recombination is an 
important step during development of B- and T-lymphocytes. Failure to perform appropriate 
recombination may lead to early apoptosis resulting in a low number of mature cells (89;94). 
The resulting few circulating B cells and T cells may be effective enough to prevent severe 
invasive infections in A-T in the absence of impaired respiratory function.  
Clinical immunodeficiency 
The A-T patients’ immunodeficiency was of less clinical significance than anticipated based 
on the laboratory abnormalities. In a nutshell, we found a severe immunodeficiency in the 
laboratory with mild clinical immunodeficiency in children. Despite low T cell numbers, 
opportunistic infection with Pneumocystis jerovici was not a problem. Common warts, 
molluscum contagiosum, paronychia/onychomycosis, seborrhoeic eczema were present. 
These are considered clinical signs of minor T cell deficiency and frequently described in A-T 
patients (84). Some correlation between laboratory and clinical findings was observed, 
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however: Low IgA values were for example found in patients with diarrhoea, and decreased 
IgG2 levels were noted in patients with recurrent respiratory tract infections. This 
reproducible discrepancy between laboratory and clinical immunological findings in A-T 
patients had been recognized previously (42;42;263;263), but had been overlooked in some 
recent literature. Lederman et al also recently described this peculiar discrepancy(262). Our 
laboratory investigations represent fragmented snapshots of ongoing immunological processes 
and underscore that laboratory results should be interpreted in a clinical context. 
Immunoglobulin supplementation in A-T 
None of the A-T patients in our studies were treated with immunoglobulin substitution. 
Internationally IVIg is recommended in A-T patients, while we consider home-based 
subcutaneous therapy the better alternative when Ig substitution is indicated. In Norway we 
generally reserve supplemental gammaglobulin for PID patients with verified symptomatic 
hypogammaglobulinemia. None of our A-T patients had hypogammaglobulinemia defined as 
low serum IgG1 levels (Paper III). We have followed a small number of A-T patients, and 
may have a restrictive policy compared to others with larger cohorts who estimate that 10% of 
A-T patients require immunoglobulin supplementation (262) 
Frequency and severity of infections – interpretation difficulties 
Recording and categorizing infections was challenging, especially in retrospect. Even when 
we tried to use annual summaries, it was difficult to get a clear picture of frequency and 
severity of infections. Microbiological evaluations were often sparse. Chest x-rays had not 
been done in all cases of clinical pneumonia because of radiosensitivity. One reliable measure 
of infections was information about the prescription and effect of antibiotics. Another 
objective measure was hospitalisation for infection. Also in the Iranian study of 104 A-T 
patients as many as 25% had no more infections than predicted for the population in general. 
63% had somewhat more infections than average, but within this group only one admission to 
hospital was registered. Only 12% of 104 suffered from suppurative lung disease or severe 
infections (219). Moin et al found a positive correlation between immunological symptoms 
and immunoglobulin deficiencies in A-T patients. Because one of our main conclusions is that 
immunodeficiency is generally not a major clinical issue, we are able to reduce parents’ 
anxiety concerning the risk of severe and life threatening infectious diseases in children. 
However, increasing risk of lung infections with age is an issue. If increased vulnerability to 
pulmonary infection is not mainly caused by a progressive immunological defect, it may be 
the result of progressive lung failure secondary to microaspiration from dysfunctional 
swallowing or other reasons such as interstitial changes due to ATM protein deficiency in the 
lung cells. These research questions remain to be addressed (39;74;262).
Vaccination in A-T  
PCV7 vaccine induced, and PPV23 vaccine boostered, pneumococcal antibodies in our A-T 
patients (Paper IV). Six of nine achieved protective antibodies to the PPV23 mix. The PCV7 
containing diphtheria CRM197 induced an increase in diphtheria antibody levels. Pre-existing 
protective antibody level to diphtheria and tetanus seemed to be predictive of capability to 
make protective pneumococcal antibodies, which was both interesting in itself and illustrative 
of the variable nature of immunodeficiency. The results of the vaccine study were important 
for the A-T group, because they show that vaccination may partially circumvent 
immunodeficiency. The clinical immunological study revealed that many children had 
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received the MMR vaccine prior to being diagnosed with A-T and that no adverse reactions to 
the living vaccine had occurred (Paper III). We have gone from advising against vaccines, to 
advising that children follow the standard vaccination program, excluding only vaccination 
against BCG (Mycobacterium bovis Bacille Calmette-Guerin). In addition to the vaccines in 
the national vaccination programme, we recommend vaccination against chickenpox and 
annual vaccination against influenza. Based on our study, as well as the Turkish and the 
German study of antibody responses to pneumococcal vaccines, we now recommend two 
successive PCV7 vaccinations plus a booster vaccination with PPV23.(85;271;272). 
Revaccination with PPV23 is recommended every five to ten years in splenectomized 
individuals. This should also be recommended in A-T patients in an effort to prevent 
pulmonary pneumococcal disease in the longterm. After we completed our study, the PCV7 
vaccination became a part of the national pediatric vaccination program. All children born in 
Norway after 1st January 2006 presently receive PCV7 vaccinations at 3, 5 and 12 months of 
age. Introduction of PCV7 vaccine in the general population can cause a shift in 
pneumococcal serotypes causing severe pneumococcal disease. Our recommendation for 
pneumococcal vaccination in A-T may therefore need to be modified with time.  
Reference values and protective antibody levels 
The importance of using age-adjusted reference values for serum immunoglobulins and 
lymphocyte populations needs to be stressed (Paper III). Immunoglobulin levels and 
lymphocyte counts vary with age in early childhood. The problems arising from undefined 
protective levels for specific antibodies to microbial antigens are discussed in Paper IV for 
pneumococcal antibodies, and illustrate a more general problem. For many of the antibodies 
detected, protective levels are not clearly defined. Undetected differences in antibody 
specificity may exist, or protective levels may only have been defined based on animal 
studies.  
Antibody responses, not clinical outcomes, have been studied 
To test the response to conjugated vaccines in A-T, a study of the incidence of pneumococcal 
infections or pneumococcal carrier status is necessary. Only antibody response, not clinical 
effect, has been studied to date. Determination of protective antibody levels is associated with 
uncertainty because antibody specificity may vary at the same antibody level. Why A-T 
patients have difficulty specifically with making protective antibodies against polysaccharide 
antigens and pneumococcal polysaccharide, in particular, remains an unanswered question. 
Our patients with A-T had extremely low levels of pneumococcal antibodies (Paper III and 
Paper IV). The difficulties in ligation of DNA strands after excision of larger loops in CSR 
(Figure 5) are demonstrated by low levels of IgE, IgG2 and IgA compared to more normal 
IgG1 levels. The same mechanism may also be responsible for the difficulties in making B-
cells with certain V-regions during V(D)J recombination. Certain V genes present particular 
conformations suitable for certain types of antigen. Successful clones in the memory response 
to pneumococcal polysaccharide use VH with high numbers, requiring sufficient DNA ligation 
after excision of large loops. Assessment of TCR repertoire and use of specific V regions 
(Figure 5, Figure 7) could have been investigated, before and after vaccination. 
Nasopharyngeal carrier status for pneumococcus could have been ascertained (273).  
BCG vaccination in A-T 
BCG vaccination in A-T patients is still somewhat controversial. In countries where BCG 
vaccination is administered routinely shortly after birth, active BCG infection has not been 
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observed in individuals subsequently diagnosed with A-T (Prof. Ozden Sanal, Turkey, 
personal communication) (274). However, there is a recent publication showing impaired 
interferon-gamma production in response to BCG in T cells and NK cells in patients with A-T 
(275). Granulomatous lesions have been reported in A-T patients (276;277). Some of these 
reports are from countries were BCG vaccination is routinely given in early childhood 
(278;279). Even in the absence of mycobacteria in granulomatous lesions or absence of 
evidence of disseminated BCG infection, the safety of BCG vaccination in A-T remains 
uncertain.  
Vaccination in other PIDs 
Vaccines represent an extra therapeutic tool in the treatment of patients with primary 
immunodeficiencies other than A-T and can reduce effects of specific immunological defects. 
For instance, in patients with cyclic neutropenia vaccines are safe and may effectively prevent 
certain diseases. Whether or not to vaccinate patients with hypogammaglobulinemia, 
including CVID, is under debate. Effects are expected to be modest, but given that vaccines 
are safe in this population, they are not medically contraindicated.  
The thymus is underdeveloped 
The term “thymus atrophy in A-T” is inappropriate, because lack of thymus tissue is not a 
primary cause of immunodeficiency in this disease. The thymus appears underdeveloped on 
MRI and ultrasound scanning because of a paucity of T cells. Measurements of TRECs (T cell 
recombination excision circles) demonstrate low thymic output (264). However, there is no 
primary thymic aplasia or hypoplasia as in DiGeorge/deletion 22q11 syndrome. Thymus 
aplasia or hypoplasia is not a distinct diagnostic criterion for A-T. 
Using immunological laboratory findings to support the diagnosis of A-T 
Characterization of the immunodeficiency in A-T should be done as part of the diagnostic 
work-up because a characteristic pattern of abnormality is supportive of the diagnosis prior to 
molecular genetic confirmation. Although the degree of immunodeficiency on immunological 
testing is variable, the overall immundeficiency pattern is very characteristic. These 
immunological findings have consequences for management. Only a minority of the A-T 
patients appear to need immunoglobulin treatment.  
Revising the ESID diagnostic criteria for A-T 
The ESID diagnostic criteria for A-T (Table 1) should be revised to not only include IgA 
deficiency, but also the other typical immunological findings. Only half out patients had IgA 
deficiency. IgG2 deficiency and IgE deficiency were much more common. Low numbers of B 
cells and CD4+ T cells were an even more consistent finding. 
A-T and phenotype - genotype correlations 
We have a large cohort of A-T patients, relative to population size, which we have followed 
closely for several years.  We have noted some phenotype-genotype correlations in IgG2 
serum levels, and in the debut age of telangiectasias (Paper III)(63). The patients homozygous 
for early truncating mutations (two null mutations) had relatively lower IgG2 and earlier 
debut of telangiectasias. We also found a correlation between serum IgG2 levels and 
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pneumococcal antibody levels (Paper II). A correlation between IgG2 levels and early 
truncation mutations in ATM has been noted in a subsequent and on-going pneumococcal 
vaccination study from the UK (http://www.atsociety.org.uk/newsletter12.06.pdf., preliminary results 
presented as a poster at the 12th ESID Biennial Meeting, Budapest Oct 2006). However, a 
correlation between IgG2 levels and pneumococcal antibody levels was not shown in a recent 
Brazilian study of ten A-T patients (274). The A-T mutation spectrum in our country is 
heavily skewed towards truncating mutations.  
Ideally, genotype-phenotype comparisons for immunological phenotype, neurological 
phenotype, eye findings including debut of telangiectasias and AFP levels should be 
performed in individuals with milder disease (63). In the UK several individuals with 
atypical/mild A-T have been diagnosed. They have a less severe neurological course than 
classic A-T patients. Ataxia is milder and starts later in life while other neurological features, 
such as extrapyramidal signs are more apparent. These British patients with a milder 
phenotype have missense mutations in ATM predicted to produce altered ATM protein with 
residual function. Comparison of immunodeficiency between typical and atypical A-T 
patients with measurement of ATM protein levels and ATM protein functional activity, could 
determine whether complete loss of ATM protein or ATM kinase activity, causes more severe 
immunodeficiency than partial loss.  In 2004, Trimis et al. reported an interesting, unusual A-
T case; a 6 year old girl without any neurological symptoms. She was homozygous for a 
mutation in one of the terminal exons in ATM, had classical immunodeficiency (280) and only 
moderately increased AFP. This case highlights that a possible broader disease spectrum than 
previously recognized may be associated with ATM mutations.  
Our study was the first to find a correlation between the degree of immunodeficiency and 
mutation type (Paper III). A correlation between cancer incidence and mutation type may also 
exist. The immunodeficiency and hematological cancers in A-T represent the bi-faceted result 
of defective ATM functional activity in T cell and B cell maturation. Of the five Norwegian 
patients who had developed leukemia/lymphomas, three were homozygous for the founder 
mutation and one was compound heterozygous for null mutations in proximal exons (Results 
2, Table 7).
Non-allelic polymorphisms may contribute to variation in phenotype  
Sequence alterations/variations in genes other than ATM may explain some of the phenotypic 
differences. MBL deficiency may have a separate additive effect on the immunodeficiency 
and further increase the risk of infections (Paper IV). In contrast to the risk of hematological 
cancers, leukaemia and lymphomas, the increased risk of other solid tumours in A-T patients 
and carriers are unexplained. Increased cancer risk may be related to reduced TP53 function. 
Li Fraumeni syndrome patients have germ line TP53 haploinsufficiency and a greatly 
increased risk of cancer (solid tumours, sarcomas). A common polymorphism in the MDM2
gene is linked to earlier cancer debut in Li Fraumeni patients. MDM2 inhibits TP53. This 
specific SNP309MDM2 polymorphism causes gain-of-function of MDM2. ATM kinase 
inhibits MDM2 and stimulates TP53 as part of the cells’ cancer protection machinery (Figure 
8). High levels of MDM2 could theoretically exaggerate the effect of ATM deficiency and 
increase cancer risk. Studies of cancer incidence, especially for solid tumours, in A-T patients 
and A-T mutation carriers correlated to co-existence/prevalence of SNP309MDM2 have not 
yet been carried out. 
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Alpha fetoprotein in A-T 
The role of alpha fetoprotein in A-T is still not clear. Serum AFP is elevated, and increases 
with age (Paper V). It might be useful as surrogate marker in clinical trials. We will continue 
to monitor serum AFP in our cohort.  The AFP study originated from long term systematic 
study of A-T patients. AFP measurement is reliable and reproducible. Our simple observation 
provides important knowledge about the disease. However, in order to assess the value of 
AFP as a biomarker, we would have needed to have done standardized neurological 
assessments in parallel with serum AFP measurements. Interestingly, AFP is also increased in 
AOA2 and vitamin E deficiency, but not in Mre11 and NBS. The process leading to increased 
AFP expression in A-T is different from the process leading to immunodeficiency, in light of 
the common the immunodeficiency pattern in Mre11, NBS and A-T. Theoretically, liver cells 
may be affected by ATM deficiency, and reduced TP53 activity may be the linked to 
increased AFP expression. Common for ATM deficiency, AOA2 and vitamin E deficiency is 
increased ROS (reactive oxygen species) and reduced cellular antioxidative capacity. If and 
how ROS in hepatocytes is related to AFP expression in A-T is not clear.  
  
The genes which code for AFP, albumin, vitamin D binding protein and alpha-albumin are 
located close to each other at chromosome 4q11-q13 and share considerable sequence 
homology (281)(MIM+104150). These four three-domain gene family proteins are all 
synthesised in liver and secreted in serum. Their half-life in serum is 5 days.  
Human AFP was previously thought to be fetal albumin. Similarly to albumin, AFP binds and 
transports a multitude of ligands, including bilirubin, retinoids, steroids, heavy metals, dyes, 
flavonoids, phytoestrogens, dioxins, and various organic drugs and fatty acids. In contrast to 
albumin, AFP reversibly binds with high affinity and transports polyunsaturated fatty acids, 
mainly docosahexaenoic acid (282-285). AFP is first synthesised by the embryonic yolk sac 
cells, and later by the fetal liver. High AFP levels persist until birth when they decrease 
rapidly, and reach levels typical for adults (< 14 kU/L) by the end of the first year (286). After 
birth and in adult life, extremely high levels of AFP are linked to malignant liver and germ 
cell tumours. Lectin binding studies of serum AFP from patients with A-T reveal a profile 
characteristic for AFP of hepatic origin (287) which is similar to that seen in benign chronic 
liver disease and neonatal hepatitis. Increased serum AFP levels are not indicative of severe 
liver disease. Autopsy of A-T patients usually show no or sparse liver damage (287;288). 
However, cirrhosis has been reported in a few A-T patients, as has hepatocellular carcinoma 
and hepatic veno-occlusive disease (289-291). Mild elevation of serum liver enzymes was 
reported in nine of 20 A-T patients in one series (Waldmann 1972) (292). Other fetal proteins 
are not increased in A-T (293). Serum AFP level is lower in patients with A-T than with yolk 
sac derived tumours and liver cancers, and similar to the levels observed in hepatitis.   
ATM deficiency, AFP and signs of liver damage. TP53 inhibits AFP expression 
ATM deficiency may induce an inflammatory and regenerative process in the liver cells 
analogous to the changes that can be seen in hepatitis and other benign liver disease. Increased 
oxidative stress has been reported in Atm-/- mice and is linked to growth retardation (Ziv et 
al). (294). AFP expression can be induced in experimental animal model systems by partial 
hepatectomy and by administration of hepatotoxic agents (295). Increased expression of AFP 
mRNA correlates with liver regeneration (296). Study of Atm function in a liver regeneration 
model system showed that Atm is required for survival of hepatocytes, that liver regeneration 
is impaired in Atm-/-mice, and that AFP expression during liver regeneration can be observed 
both in wild-type and Atm-/-mice (Shu Lu et al)(297). Increased AFP expression in A-T 
patients may be caused by a constant hepatic regenerative response to genotoxic 
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insults/oxidative stress. AFP has also been identified as a novel downstream target of NF-
kappaB. Repression of IKK-2 activity in hepatocellular carcinomas promotes down-regulation 
of AFP gene expression, linking AFP directly to apoptotic pathways (298) 
The tumour suppressor TP53 acts downstream of the ATM protein kinase in cell cycle DNA 
damage checkpoint control. In response to DSBs, ATM phosphorylates TP53 and induces 
processes leading to cell cycle arrest at the G1-S transition (44). Recently, it has been 
documented that TP53 and its family members act as repressors of AFP gene expression 
during liver cell development (299-301). Increased AFP expression may be related via TP53
to ATM deficiency. 
Large cohort of A-T patients for population size 
In the primary immunodeficiency registries in Iran and Turkey (219), A-T is more prevalent 
than in most countries. However, consanguinity was found in the majority of Iranian and 
Turkish patients, and consanguineous marriages are common in both countries. In contrast, 
the majority of the parents of our A-T patients with homozygous ATM mutations were not 
aware of consanguinity. Hence, not consanguinity, but a high carrier frequency is responsible 
for the rather large cohort of A-T patients compared to our population size. People in Norway 
have traditionally lived most of their lives in their birth counties. Our universal national 
healthcare system is well developed. It is safe to assume that all diagnosed A-T patients in 
Norway are included in our report. This gives us the opportunity and the obligation to 
undertake longitudinal studies on all aspects of disease progression. The Norwegian A-T 
cohort is well suited for participation in future clinical trials. In contrast to other groups of 
PID, our cohort is well characterized molecular genetically. Participation in clinical trials for 
specific ATM mutations (i.e. read-through aminoglycoside trials) are feasible (302). 
A-T Clinical Care Centers 
The centralisation of some medical care and follow-up of patients with a rare disorder such as 
A-T is highly desirable. It allows a few people to collect information and to develop 
knowledge about the disease and to build a team with expertise. The expert team may then be 
able to give evidence-based as well as experience-based advice to medical and 
multidisciplinary teams around each patient. In the US and Israel A-T clinical care centers 
have been established. The population in our country is scattered, and it is not practical for a 
single central clinical center to cover all medical aspects, serve acute medical needs or to 
provide frequent follow-up of each patient. To have the opportunity to see each patient 
infrequently but regularly, and to be able to follow patients with rare disorders over time, 
would confer great advantages for the development of multi-specialist teams and good patient 
care. Taken into account the great distances in our country, a Norwegian A-T Clinical Care 
Network with extensive collaboration across health care regions, is probably the best 
approach for us. 
Longitudinal follow-up is needed for rare disorders. 
Longitudinal follow-up of our small patient group has already led to increased knowledge of 
the disease. Some previous misconceptions have been cleared up. For example, the typical 
immunological findings in A-T patients no longer result in emergency telephone calls to 
parents and colleagues. We now advise completing the routine pediatric vaccination program 
instead of avoidance of vaccines 
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Prior to the death of one of our oldest patients because of unexpected cerebral hemorrhage 
Paper III), we did not know that older A-T patients may have microangiopathy of the brain. 
Only after our patient died, did we became aware of the few reports of similar autopsy 
findings in patients with this rarely described complication. If the eyes are a mirror of the 
cerebrum, the findings from the ocular studies of our A-T patients are interesting. The 
conjunctival biopsies revealed increased blood vessel tortuosity (telangiectasias) and also 
increased number of cross-sections of neurons. The difference between light-exposed areas 
(rima) and less light-exposed areas (fornix) points to an UV-effect. Telangiectasias regularly 
found on sun-exposed areas in the skin such as hands and ears also support the theory of an 
UV-effect on blood vessel tortuosity in A-T. Since the brain is not UV-exposed, there must be 
additional factors as well which promote increased vessel tortuosity. On post-mortem, brains 
from radiation treated patients resemble brains from older A-T patients.  
Awareness of the risk of interstitial lung disease in A-T has increased. The immunodeficiency 
alone does not explain the lung problems which increase with age. In the future, we need to 
follow A-T patients’ lung function regularly. Prolonged or recurrent pulmonary infections 
need to be documented and treated aggressively to prevent further lung damage. There is also 
a need to standardize neurological assessment for use in future drug intervention studies. 
Immunological status should be assessed intermittently in order to check for development of 
hematological malignancies or hyperimmunoglobulinopathy. We observed individual patients 
over a period of years, without detecting worsening of immunological laboratory findings. It 
would have been interesting to see if immunological findings may change over decades and if 
any changes have predictive value relative to cancer risk or other longterm outcomes. In 
general, the advantages of longitudinal studies in small cohorts of patients with rare disorders 
should not be underestimated. Repeated observations at the individual level have more power 
than cross-sectional observational studies. 
Children and adolescents with a neurodegenerative disease and participation in                          
clinical research studies – Ethical issues
Frequent blood sampling or other unpleasant investigations for research purposes only, may 
be an extra stress factor for children and adolescents with a neurodegenerative disease. The 
cumulative blood sample collection of 50-100 ml represented proportionally large volumes 
for the smallest children. One family did not want to participate in the AFP study because of 
frequent blood sampling. Consultations were coordinated with other planned medical 
examinations in order to minimize disruptions in daily life. Parents consented for participation 
on behalf of young children. Adolescents and adults gave written informed consent. Since it 
was physically impossible to obtain proper written consent from the oldest A-T patients, oral 
consent was accepted. Parents and patients older than 10 years knew that withdrawal from the 
studies was possible at any time, without consequence for their routine medical management.  
On one hand, participation in research studies may be an extra burden, because of the focus on 
disease rather than health. On the other hand, in rare diseases without curative treatment the 
families and patients are often extremely motivated to participate in clinical studies, 
representing hope for future therapy and improved quality of care (303;304). There is also a 
remarkable willingness to contribute to research which can help other families.
Study humans in human disease, in addition performing animal studies  
Further basic and clinical research are a means of building knowledge that can be used for 
development of therapy. Clinical studies often represent substantial intervention in a patient’s 
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life, but it is important to study humans in human diseases. Scientific knowledge from mouse 
models has contributed, and will continue to contribute, substantial knowledge to every 
medical field, especially in the areas of immunodeficiency, DNA repair and 
neurodegenerative disease. Mouse models are extremely practical. However, there are 
numerous examples of differences between humans and knock-out mice as well as mice 
knocked-in for human mutations (305). In the future, the optimal strategy would be to study 
effects in mice and humans in parallel. More collaboration between clinical and laboratory 
researchers is needed. 
Caring for A-T carriers and other relatives of PID patients 
Special attention should be given to the susceptibility of adult members of families with A-T 
to malignant neoplasms and to the importance of regular examinations for cancer detection. 
Relatives of patients with other kinds of PID may also need to be offered genetic counselling. 
Investigation of other family members for the same disease may be an issue. In our CMC 
patients (Paper VI), the younger family members were diagnosed and treated more promptly 
after debut of symptoms than their older relatives. In our recent publications of autosomal 
dominant IFNGR1 mutation the youngest family member received prompt antimycobacterial 
treatment only because of awareness of PID in the family (Glosli et al, See other 
publications). In Paper VII the results of MBL testing had implications for understanding the 
susceptibility for infections also in other family members. Genetic counselling can be 
important for parents planning new pregnancies, for families with multiple consanguineous 
couples and for female relative of individuals with X-linked PIDs. 
MBL deficiency, IgA deficiency and cancer risk in A-T, CVID and other PIDs  
We have studied MBL levels in A-T patients. MBL deficiency contributes to their clinical 
immunodeficiency by causing an increased risk for certain infections, such as mycoplasma 
pneumonia. In patients with other PIDs, for example CVID, coexistence of MBL deficiency 
may increase pre-existing susceptibility to infections, and explain some phenotypic variation 
(306). The IgA deficiency in A-T seems to be related to defective DNA repair processes in Ig 
class switch recombination, while the cause of selective IgA deficiency in CVID families can 
not be explained by identical defects. An increased risk of cancer is observed in A-T patients, 
and, to a lesser extent, in A-T carriers. In patients with other PIDs an increased risk of cancer 
has been observed, e.g., leukemia in severe congenital neutropenia, lymphomas in WAS and 
in CD40 ligand deficiency. There have been reports of an increased risk of cancer in CVID 
patients, but this is controversial. The heterogeneous CVID group may consist of a wide 
variety of different specific PIDs. 
   
Immunological study of patients with familial CMC with hypothyroidism  
-but without APECED  
Patients with chronic mucocutaneous candidiasis (CMC) are selectively unable to clear the 
yeast Candida, which results in persistent debilitating infections affecting the skin, nails, and 
mucous membranes. The underlying defect is unknown. Studies in Aire-/- knockout mice 
highlighted the importance of type 1 cytokines in protection against Candida, and previous 
work suggested that CMC patients may exhibit altered cytokine production in response to 
Candida.  Protection against C. albicans infection is generally considered to be T cell 
mediated. Therefore, it is surprising that CMC patients suffer from chronic mucocutaneous 
candidiasis in spite of an exaggerated T cell mediated destruction of endocrine organs. A 
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dysregulation of T cell responses, both Th1 and Th2, in APECED and other CMC disorders 
has been suggested. Th2 responses are related to IgE and IgG4 production. Low IgE and IgG4 
levels, as we found in our CMC patients (Paper VI), points to a lowered Th2 response. The 
low NK cell numbers found in some of our patients together with the low serum IgG4 and IgE 
levels (Paper VI) may also fit into this pattern of low Th2 response, since also NK cells have 
been shown to be involved in Th2 responses. On the other hand, clearance of Candida is 
dependent on an appropriate Th1 response. Specifically, it has been shown that Th1 type 
response, characterized by antigen stimulated lymphocyte production of cytokine IL-12 and 
interferon gamma and delayed-type hypersensitivity reactions, are associated with protection 
against Candida in animal studies(150), but the role of the Th1 response is less well 
understood in humans. Cytokine IL-12 is produced by myeloderived dendritic cells and 
macrophages.  IL-12 plays a key role in regulating the type of adaptive immune response 
produced, whether Th2 or Th1 type responses are induced. In general, Th2 responses are 
linked to induction of humoral immunological responses and Th1 responses to cellular 
responses. The clinical autoimmunity accompanied by various autoantibodies present in 
APECED patients, suggests an overactive and dysregulated Th2 response. APECED may 
result from biased Th2 responses to self-antigens and defective protective Th1 responses 
against C. albicans. In four of seven of our CMC patients we found low levels of CD8 T cells 
(Paper VI) which may be consistent with a low Th1 response. Others have tested cytokine 
production in CMC patients in response to Candida and found impaired production of IL-12 
in parallel with increased levels of IL-6 and IL-10. Their results suggest that patients with 
CMC have impaired production of Th1 inducing cytokines and an inability to mount 
protective cell-mediated responses and a failure to clear Candida (307). Decreased interferon 
gamma production has been found in whole blood from CMC patients (APECED excluded) 
after in vivo stimulation with C. albicans (308). Taken together, these data suggest that 
although cell-mediated Th1 immunity is essential for protection against fungal infections, the 
link between type 1 inducing cytokines, induction of Th1 responses, and fungal clearance is 
more complex than initially appreciated. 
If T cell deficiency, why not warts and molluscs? Lessons from APECED 
Usually in patients with minor signs of T cell deficiency (i.e. as in A-T), candidial 
onycomycosis and seborrhoeic dermatitis are accompanied by warts and molluscum 
contagiosum. The altered T cell responses could be explained by a defect in the antigen 
presenting cells (APC) including the dendritic cells. Faulty dendritic cell function may lead to 
autoimmune disease. The trigger for inappropriate immune reactions may be Candida, as 
proposed for Hyper IgE syndrome (309). Chronic candidiasis may on the other hand only be 
another sign of the specific immunological defect. These diseases (APECED + other CMC 
disorders) may serve as models for understanding the pathogenesis of organ-specific 
autoimmunity in general. The question of what skews cytokine responses remains 
unanswered, while the candidate cells that harbour the defect could be dendritic cells or 
macrophages by virtue of their cytokine-producing function and role in orchestrating Th1 and 
Th2 responses. These findings have bearing on understanding CMC itself, as well as on our 
understanding of the mechanisms involved in protective immunity to fungi in general, a 
subject which is still poorly understood. Lessons from APECED may help us further since the 
genetic defect in the other CMC disorders, including our CMC families, is not yet known. 
Importantly, the AIRE gene is expressed in the peripheral monocyte/dendritic cell lineage 
(310). Brannstrom et al found both a defect internalization of Candida and kinase activation 
in monocytes derived from APECED patients. The total number of monocytes in mice with 
Aire -/-  is increased roughly two-fold. (311). A recent paper by Peltonen et al (2007) 
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mentioned monocytosis in CMC in humans, but to our knowledge there is no published data 
on the subject. 
Compensatory responses but no distinct immunological defect found in our CMC study 
We were not able to find an underlying immunological defect in our CMC patients (Paper 
VI). Perhaps we failed to detect or oversaw laboratory signs of an immunological defect. 
Monocyte numbers were somewhat high in family B, but still within the normal reference 
range and are not commented upon in our report. The disease showed no specific HLA 
haplotype association. Even the autoantibody evaluations that are valuable and disease-related 
in APECED were not conclusive in our study. Usually in AIRE deficiency autoantibodies are 
present, however, we found no autoantibodies in our CMC affected family A. TPO-
Antibodies and TG-Antibodies were found in the patients with newly diagnosed 
hypothyreosis in family B. APECED patients tend to have anti-thyroid antibodies which are 
detectable several years after the onset of overt hypothyroidism. It is also possible that our 
two families represent two distinct CMC disorders, autosomal dominant inheritance was 
evident in family B, but a recessive inheritance pattern can not be excluded in family A. 
Candida antigen responses were not investigated in our project, but three of the patients had 
been tested previously and two had shown anergy on skin-test reactivity against Candida 
antigen (Paper VI). Increased MBL levels and complement activation (Paper VI) may be part 
of a compensatory response to the immunological defects. MBL plays an important role in the 
first-line defense against C. albicans without the need for opsonophagocytosis by dendritic 
cells. MBL inhibits the growth of C. albicans independent of complement activation. With 
complement activation, further inhibition is observed (160). 
If monocyte/APC/dendritic defect, why the absence of susceptibility to mycobacteria? 
Mouse Aire is expressed both in thymic medullary epithelial cells and in peripheral antigen-
presenting cells, suggesting a role in both central and peripheral tolerance. Very interestingly, 
T cells from Aire deficient mice show a competent in vitro response against C. albicans.  
APC-mediated T cell activation is not decreased, but increased both in mice and humans 
deficient in this autoimmune regulator. Maturation time for monocytes in bone marrow is 
decreased in Aire deficient mice. Monocytes from APECED patients have defective 
internalization and intracellular signalling after exposure to Candida antigen. Evolving 
evidence points to one or more immunological defects within the APCs. However, in contrast 
to other inherited disorders of macrophage function, there is no obvious susceptibility to 
mycobacterial infection in CMC patients (144). None of our CMC patients had had 
mycobacterial infections. 
Inherited thyroid diseases: Autoimmune thyroiditis versus congenital thyroid disease  
and response to treatment. 
In contrast to the autoimmune thyroiditis in CMC patients, the thyroid problem in TITF1 
deficiency is congenital. Patients with CMC and hypothyreosis, respond to treatment with 
thyroxin, while patients with TITF1 deficiency do not. The mild elevation of TSH with 
normal thyroid hormone secretion points to a functional thyroid defect in our patient with 14q 
deletion (Paper VII). There is a reduced activation of TITF1 targets, such as the thyroglobulin 
promoter in the thyroid follicular cells (312). Other TITF1 targets are TSH receptor and 
thyroid peroxidase gene (313;314). Thyroid dysgenesis has been found in other patients with 
TITF1(NKX2.1) haploinsufficiency (315), but ultrasound of the thyroid gland in our patient 
showed a thyroid of normal size and shape. As expected, he did not respond to thyroxin. 
101
Recurrent pulmonary problems, related to MBL deficiency  
and IgG2 deficiency? 
We suggest that the MBL deficiency and probably also the IgG2 deficiency explain why our 
patient described in Paper VII had more severe and recurrent pulmonary problems than 
previously reported for TITF1 haploinsufficiency. The mother and younger brother who also 
had MBL deficiency, had history of respiratory infections, although the infections were fewer 
and less severe than in the index patient. The 14q deletion involved PAX9 and probably also 
haploinsufficiency for other genes that may have contributed to his cleft lip-palate, clubfeet 
(as case 777 in (316)) and feeding difficulties with gastrooesophageal reflux.  
Contiguous gene syndromes and the contribution of single genes 
It has become increasingly evident that the clinical consequences of chromosomal aberrations 
are linked to the excess or reduction of involved genes. The phenotype in known 
chromosomal syndromes is dependent on which genes are involved. However, phenotypic 
variation is also observed between patients with identical single gene mutations. Further 
studies of patients with single mutations in genes within the region may further elucidate 
genotype-phenotype correlations of proximal 14q deletions. Polymorphisms located outside 
this chromosomal region may also influence the clinical phenotype. 
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Conclusions 
We have shown many advantages of collecting information on PID patient cohorts. We have 
been able to document prevalence and incidences of the various types of PIDs in our country 
(Paper I), which in turn has facilitated estimation of the need for different treatment 
modalities. Baseline statistics are important for securing subgroups of PID patients nation-
wide drug-availability, e.g. immunoglobulins. Using the national registry we have been able 
to focus on particular PID groups and to study more closely areas of special interest, e.g., 
coping, quality of life and hope in adult patients with antibody deficiency and genotype-
phenotype correlations in A-T cohort. We have shown that national registries can be used for 
clinical research and follow-up of cohorts of patients with specific PID diagnosis. Previously 
unrecognized disease manifestations may also be detected when data are systematically 
registered, e.g., increasing serum AFP levels with increasing age (Paper V). The 
epidemiological results emerging from our A-T studies illustrate the advantage of longitudinal 
data-collection, both retrospectively and prospectively, compared to single time point 
registration. Characterizing and following cohorts of patients with rare disorders increase our 
knowledge of specific diseases, and may uncover atypical patients with previously 
undescribed diseases entities, e.g., CMC patients in Paper VI and the patient with a 
microdeletion 14q and MBL deficiency in Paper VII. 
The prevalence of all types of PID taken together was 7 per 100.000 living population in 1999 
(Paper I), and 10 per 100.000 in our update report from 2005 (Table 5). Even in light of the 
geographic variation in PID registration within the country, the total prevalence estimate is 
high compared to other countries. Compared to other European countries, the proportion of 
combined deficiencies is decreased because we have fewer patients with selective IgA 
deficiency, and the proportion of complement deficiencies is increased because we have many 
patients with hereditary angioedema. Compared to international estimates we have a large 
proportion of ataxia-telangiectasia patients. Within Norway there is geographic variation in 
the incidence of A-T from 1 to 10 per 100.000 livebirths, due to a high heterozygote carrier 
frequency in certain areas of the country. 
Using the PID registry we were able to focus on particular groups and research questions. Our 
investigation of psychosocial factors in the adult cohort of patients with antibody deficiency 
showed that unemployment and disease-related strains were linked to low quality of life 
scores. Previous experiences related to the immunodeficiency such as episodes of illness, 
absence from school, psychosocial consequences were of importance, but the patients with 
hepatitis C virus infection had not lower scores on SF-36 or QLI scales than the others. 
Persons with selective IgA deficiency had significantly higher QLI scores than those with 
other types of antibody deficiencies. They had higher QLI scores in the socioeconomic and 
not in the expected health function domain. Other differences between the various antibody 
deficiencies were not found. Closeness and competence were preconditions for good coping, 
quality of life and hope. In addition to representing approaches for future interventions, the 
results from the adult PID study confirm Lazarus and Folkman’s universal theory of coping 
and resilience against stress. 
The immunological phenotype in A-T patients was characterized by low IgE, low IgG2 and/or 
low IgA levels. All patients had low levels of antibodies to Streptococcus pneumoniae. Low 
numbers of CD19+ B cells and CD4+ T cells were also typical as were normal numbers of 
NK cells (Paper III). The patients homozygous for early truncating mutations had relatively 
lower IgG2 levels than the others. Based on our results, a genotype-immunological phenotype 
103
correlation can not be excluded. The characteristic pattern of immunological abnormalities is 
consistent with defects in isotype switch and V(D)J recombination in B cell and T cell 
development, and can be supportive of diagnosis prior to molecular genetic confirmation.  
IgA deficiency was not a consistent finding in our patients, and we suggest that the ESID 
diagnostic criteria for A-T should be revised to also include the other typical immunological 
findings. There was a discrepancy between the abundance of immunological laboratory 
abnormalities and the patients’ more modest clinical symptoms. The immune defect was not
age related and cannot be the sole explanation for the increased frequency of pulmonary 
infections in older A-T patients. Vaccination with the pneumococcal vaccines PCV7 plus 
PPV23 resulted in a significant increase in the patients’ pneumococcal antibody titres, but 
lower than those observed in the controls (Paper IV). The results of the vaccination study are 
valuable in planning the care of A-T patients, using PCV7 to trigger and PPV23 to booster the 
immune response and possibly prevent severe pneumococcal disease.  
Serum AFP increases with age in A-T and may be useful as surrogate marker in clinical trials. 
Our study showed a possible link between AFP and general A-T disease progression 
including hepatic pathology (Paper VII). In our cohort of patients a link between AFP level 
and the degree of neurological disease was not confirmed, and no correlation between serum 
AFP levels and ATM genotypes was found. All our patients had a classical A-T phenotype and 
20 of 24 mutations were truncating. Genotype-phenotype correlations that we were unable to 
detect because of nature of our population, may well exist.  
Low MBL levels have an additive effect on the immunodeficiency in A-T. MBL deficiency 
explains why our patient in Paper VII had more severe and recurrent pulmonary problems 
than previously reported in other patients with proximal 14q deletions and/or TITF1 
haploinsufficiency. The increased MBL levels and complement activation found in familial 
CMC with hypothyroidism (APECED excluded) may be part of a compensatory response to 
immunological defects.  
We were not able to find an underlying immunological defect in our CMC patients (Paper 
VI).  In contrast to APECED patients, our patients in family A had no autoantibodies. TPO-
Antibodies and TG-Antibodies were only found in the patients with newly diagnosed 
hypothyroidism in family B. Decline in autoantibodies with time is an explanation we have 
not be excluded. The patients’ immunoglobulins, various lymphocyte subclasses and 
monocyte numbers were all within normal references limits. Candidiasis, onycomycosis and 
seborrhoeic dermatitis were not accompanied by classical signs of T-cell deficiency such as 
warts, molluscum contagiosum, other viral or opportunistic infections. APECED studies in 
mice suggest immunological defects within the monocyte derived APCs, but an HLA 
association was excluded in our families. The general mechanisms involved in protective 
immunity to fungi are still poorly understood, and we still do not know why CMC patients 
(APECED included or excluded) are particularly susceptible to candida. 
Characterizing the immunological phenotype in all PIDs thoroughly, both in the clinic and in 
the laboratory, provides increased diagnostic precision in general, better understanding of the 
individual patient’s immunodeficiency and may allow more targeted treatment for PID 
subgroups in the future.  
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Future Perspectives 
Establishment of a permanent national PID registry 
With continuous registration of PID cases in Norway, it will be possible to obtain population-
based knowledge of the natural course of PIDs and contribute to the ongoing and expanding 
international research effort. National and international data are important for future 
recommendations for treatment such as Ig supplementation and bone marrow transplantation 
(23). A permanent national registry of PID patients will be of great value to healthcare 
professionals and families alike. A likely spin-off will be increased awareness of PID among 
pediatricians and other physicians. We need to establish a network linking all involved 
parties, professionals and patients, in order to increase sharing of information and to improve 
diagnostics and management. We should strive to assure that all patients have access to the 
best possible follow-up and treatment. This means shortening time to specific PID diagnosis 
with the aid of immunologic and molecular genetic analyses. 
Ethical considerations in conjunction with a future PID registry 
Informed consent from patients or parents was not obtained directly before inclusion in our 
previous, temporary national PID registry. However, the registry questionnaire was 
distributed to members of the Norwegian PID patient organization, who subsequently 
consulted their physicians to ensure that they were included. A substantial proportion of 
patients were registered via this route. Future medical quality of care registries will require 
informed consent from all participants. All individuals will have the right to withdraw from 
the registry and remove his / her personal information at any time. How deceased patients, 
patients without the ability to give consent and first degree relatives should be registered must 
be discussed. First degree family relatives may give consent for living individuals who are not 
competent to give informed consent themselves, i.e. parents may sign on behalf of their 
children. For deceased PID patients, however, informed consent may be difficult to obtain via 
distant relatives. Information concerning deceased PID patients can be very important for 
living relatives. Confidentiality for registered individuals, secure data storage and access are 
important issues. It is important to ensure that information is accessible only to authorized 
individuals. Semi-identification or pseudo-anonymization rather than complete anonymization 
of personal information will facilitate updating data on each patient and allow for 
longitudional studies of subgroups of PID patients. Easily accessible, frequent reports with 
non-identifiable/non-personalized/anonymous data from the registry can be made available 
for research and patient management. Obtaining informed written consent, registering patients 
with the correct PID diagnosis, and revising and adding data over time, will require 
involvement of local physicians and pediatricians. Systematic longitudinal registration should 
increase collaboration between primary, secondary and tertiary healthcare levels and increase 
general awareness of PID. National established registries should have a coordinating role, and 
transfer patient data to the ESID registry or other international PID databases. Local 
physicians may report their PID patients directly to ESID either via the internet based registry 
or via a national PID registry and mechanisms for avoiding registering the same patient more 
than once are required. International mutation registries linked to the ESID registry represent 
a basis for future PID cohort studies. The PID registries are gold mines for the discovery of 
new diseases. A nation-wide registry may function as a medical quality registry, by 
facilitating evaluation of different treatment methods and securing equal access to appropriate 
follow-up and treatment regimens irrespective of place of residence.  
105
A permanent national PID registry would: 
• increase knowledge and awareness of PID and promote clinical and basic research of 
PID disorders 
• be an important support for clinical research assuming that semi-identification of the 
patients is permitted. Semi-identification gives clinical researchers the opportunity to 
go back to individual patients and to offer participation in clinical research projects.  
• allow for more systematic collection of information, including detection of true 
disease incidences and prevalences  
• be made known to all diagnosed PID patients who would be offered the opportunity to 
register.  
• include a quality of care registry which would allow us to keep track of the current 
numbers of patients on special treatments and to evaluate results and effects of 
longterm treatments or lack of treatment.  
• allow longitudinal collection of data.  
• be continuously updated. Treatment and diagnostics change. New treatment methods 
need to be evaluated and compared with results from other countries because 
individual PIDs may be exceedingly rare. International collaboration and pooling of 
data is vital for both research and good patient care in rare disorders. 
• provide updated, accessible and reliable information for health care providers.  
• allow transfer of relevant information to international patient registries such as the 
internet based ESID Registry (222) or the international neutropenia registry SCNIR 
(http://www.severe-chronic-neutropenia.org/). The questionnaire for our former 
epidemiological study was a simple two-page form which was easy to complete. 
Updating information on individual patients can be achieved with one reminder every 
year, or via internet registration of new data. The Euro Huntington Disease Network 
(EHDN) is a good example of a multi-national collaborative treatment and research 
network. (http://www.euro-hd.net/). Active patient and family interaction via internet is an 
integrated feature of EHDN. 
• be linked to a team of professionals with clinical experience in caring for PIDs. The 
registry would facilitate arranging meetings and conferences, establishing local and 
regional networks and disseminating evidence-based knowledge on all aspects of 
diagnosis and treatment.  
• hopefully promote collaboration instead of competition between medical centers and 
departments caring for PID patients. 
• allow for detection of factors with possible clinical implications. Hypotheses can then 
be tested in larger cross-sectional studies. 
   
For some rare, multisystem disorders, such as A-T, not only collection of medical data, but 
closer follow-up with collaboration between medical professionals across health care regions 
is needed. Creation of a Norwegian A-T Clinical Care Network may be an alternative which 
can secure equal access and state-of-the-art management of all patients irrespective of home 
address.  Finally, longitudinal studies and systematic medical follow-up of cohorts of few 
patients with rare disorders are valuable because they provide knowledge about the natural 
course of rare diseases. This information is much in demand among families and professionals 
alike. 
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“Not only add years to life, also add life to the years” 
Quality of life studies are needed in patients with PID diagnoses other than antibody 
deficiencies. In particular, there is a major need for psychosocial and behavioural studies in 
children. To perform this type of necessary study in patient groups with neurodegenerative 
disorders such as ataxia-telangiectasia is especially challenging. Triangulation of methods, 
combining quantitative and qualitative studies and finding coherence with theories of human 
behaviour and attitude may prove fruitful in future studies. Future studies and interventions 
should be guided by the philosophy: “Add not only years to life, but life to the years”  
Availability of genetic testing must improve and the immunological phenotype must be 
characterized. 
Research has begun to clarify the genetic defects underlying the different immunodeficiencies 
and mechanisms predisposing to autoimmunity and cancer. Clinical applications of research 
findings will include the identification of the causative genetic defect which in turn may allow 
for the options of prenatal testing and testing of relatives at risk. The availability of genetic 
tests must be improve so that delays in diagnosis are reduced. As of 2007 the Norwegian 
genetic laboratories only offer diagnostic sequencing of coding regions of following genes: 
BTK, RAG1/RAG2, IL2RG, JAK3, ELA2, WAS, NEMO, AIRE and ATM. Intragenic mutation 
analysis for other PIDs must be performed at laboratories abroad, and availability of genetic 
testing is dependent on the individual physician. In families with more than one affected 
member, genetic linkage analyses, SNP base genome-wide scans and microsatelite analyses 
may be helpful in ruling in or excluding candidate genes. In the future it will become 
increasingly important to study the immunological mechanisms in PIDs with known genetic 
causes, and to perform appropriate molecular genetic testing in all patients, including adults. 
Mode of inheritance, susceptibility to infections with specific pathogens, as well as 
immunological profile, are clues to the type of immunodeficiency and should guide genetic 
testing. Even single families with only a few affected members may be valuable for genetic 
linkage analyses in the search for PID associated genes. Case reports and reports of small 
families (193), demonstrate that PIDs are “spotlight disorders”,  point to the important role of 
specific factors within the immune system, and show how important genetic verification can 
be for patient care and family planning. Inherited immunological diseases with specific 
genetic causes, may be amenable to targeted therapy (317). There are evidences that mutated 
genes in rare disorders may represent important target genes for treatment of other common or 
rare disorders. Therefore, rare monogenic disorders, in particular, may be of interest for drug 
development (318). With the advent of clinical implementation of microarray CGH, a 
substantial number of new microdeletion /-duplication syndromes are expected to be 
discovered (191). In patients with constitutional chromosomal abnormalities, the chromosome 
abnormality often encompasses many genes of which only one or a few contribute 
significantly to the phenotype (319). The laboratory immunological findings and 
characteristics of the clinical immunodeficiency may determine which genes are putative. 
Careful immunological characterisation of patients with chromosome abnormalities and 
susceptibility to infection may uncover new PID genes. And the other way around, further 
studies of patients with single mutations in genes within the specific chromosomal regions 
may clarify genotype-phenotype correlations, not forgetting that sequence variations in other 
genes located outside the particular chromosomal region also may influence the phenotype.  
Future perspectives A-T immunological research 
The immunological findings in the A-T patients are valuable in planning care. Characterizing 
the immunodeficiency in A-T should continue to be a part of the diagnostic process. 
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We have developed new recommendations for vaccination in A-T. The clinical effects 
(reduction in frequency of infections/ nasopharyngeal carrier status) of pneumococcal 
vaccines remain to be studied. We also need to determine the immunological mechanism 
underlying low immune responses to lipopolysaccharides and Pneumococcus, in particular. 
Studies of the presumed restricted V-region usage and oligoclonality of T and B cells in 
response to pneumococcal vaccine in A-T are needed. We should also study the effect of early 
childhood PCV7 vaccinations as part of the national vaccination programme and degree of 
persisting pneumococcal antibodies in new A-T patients. There is a general need to define 
absolute protective levels for specific antibodies to other, various microbial antigens in 
humans. The immunodeficiency alone does not explain increasing lung problems as a 
function of age. ATM deficiency and a possible direct, local effect on lung tissue need to be 
studied.  We know that susceptibility to aspiration may increase the risk for and consequences 
of lung infections. Early management and monitoring of lung function is necessary to 
minimize lung damage(320): We should in the future follow lung function closely and treat 
pneumonia promptly. 
Future genotype-phenotype A-T studies 
Our patients who were homozygous for proximal truncating mutations (i.e. two null 
mutations) had relatively lower IgG2 and earlier debut of telangiectasias. The relationship 
between null mutations and severity of immunodeficiency had not been detected before. To 
confirm our results larger studies are needed: Genotype-phenotype comparisons for 
immunological phenotype, neurological phenotype, eye findings including debut of 
telangiectasias and AFP levels should be performed between patients with classical A-T with 
null mutations and those with atypical/milder A-T disease and leaky/missense mutations. The 
spectrum of ATM mutations is limited in Norway, but there is a large cohort of patients with 
atypical/milder A-T disease in UK who will be interesting to study.  
Detect factors early that can predict increased risk for leukaemia, lymphoma and solid 
tumors in A-T 
- relevance for detecting mechanisms leading to cancer in general. 
Immunological status should be assessed regularly in all A-T patients in order to check for 
development of haematological malignancies or hyperimmunoglobulinopathy. It would have 
been interesting to see if immunological findings have predictive value relative to cancer risk 
or other longterm outcomes. Advanced immunological tests like molecular genetic 
characterisation of BCR and TCR in various clones may be required to document the 
mechanisms behind oncogenic BCR and TCR translocations in A-T, and could also elucidate 
mechanisms leading to leukemia and lymphoma in general. Studies of incidence and risk of 
other cancers including solid tumours in patients and of cancer risk in mutation carriers are 
necessary. We have shown that coexistence of MBL deficiency exacerbates the clinical 
immunodeficiency in A-T patients. The same phenomenon was seen in the patient with a 
constitutional 14q deletion. Similarly, sequence variation in other genes, such as MDM2, may 
modify the risk of solid tumors in A-T and cancer in A-T carriers. 
A-T is a multisystem, pleiotropic disorder and ATM deficiency may have different or similar 
effects on epithelial derived cells, hepatocytes in the liver, alveolar cells in the lungs and 
neurons in cerebellum. The relationships between ATM deficiency, ROS, TP53 and cell 
damage have been studied in in vitro and in Atm -/- mice, and need to be studied in various 
tissues from human patients. Promising treatments will be developed that aim to either 1) 
increase ATM levels, or 2) reduce ROS and subsequent DNA damage, or 3) circumvent the 
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ATM repair mechanism to increase DNA repair.  Effects in vitro and in mouse studies have 
been promising, but the various compounds remain to be tested in patients.  
Develop standardized neurological assessments. AFP may be a surrogate marker. 
Repeated standardized observations of neurological function over years are needed to chart 
disease progression. Longitudinal studies of gait function correlated with other neurological 
findings in larger cohorts of A-T patients should be done. Some standardized clinical 
measurements of the neurological deterioration in A-T exist  (321) or are being developed, 
e.g. instrumental tracking of eye movements. There is a pressing need to standardize 
neurological assessment for use in international collaborative drug intervention studies.  
One of the main difficulties in clinical research in A-T has been the lack of markers of disease 
progression. The immunologic variables are relatively constant, the neurologic markers 
difficult to validate, and occurrence of cancer is a seemingly random event. Thus, the 
elevation of AFP over time, even if only an epiphenomenon, may have potential as surrogate 
marker if correlates with a clinical outcome such as disease progression. The cause of AFP 
elevation remains to be determined. A possible connection between lower AFP levels and 
milder neurological disease needs to be studied. Measuring ATM protein levels and functional 
activity should be done in future studies to compare patients with classical A-T and those with 
milder disease.   
An optimal strategy would be to study effects in mice and humans in parallel. 
It is currently possible to study treatment effects, of for example antioxidants such PARP 
inhibitors(322), on Atm -/- mice with human mutations knocked-in combined with luciferase 
linked to genes of interest, i.e. genes involved in oxidative stress or apoptotic pathways. 
Bioluminescent assays with luciferase transgenic murine models permit demonstration of 
gene expression in an in vivo (323). Mouse APECED studies have suggested a primary 
monocyte/APC defect causing autoimmunity. In vitro functional autoimmunity studies of 
CMC patients’ monocytes and dendritic cells are currently underway. The unexplained 
susceptibility to candidial infections requires study in human cells, since APECED mice do 
not develop candidiasis. There are numerous examples of differences between humans and 
knock-out mice as well as mice knocked-in for human mutations. Information from mouse 
models has contributed and will continue to contribute substantial knowledge to every 
medical field, especially to the study of immunodeficiency and DNA repair defects (305).  
Finally, research collaboration between clinical scientists and laboratory scientists has brought 
us far and will continue to be fruitful in many aspects of PID research. Studies linking basic 
medical research and molecular genetics to clinical practice will play an increasing role in the 
future.   
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Supplement 
 
Supplement 1 
Presented here is a comprehensive list of various PIDs (Supplement Tables 1–9). The PID 
diagnoses can be classified into eight categories based on the immunologic phenotype. The 
tables are a modified version of information presented in the IUIS PID ESID-PAGID report 
(1;2). In addition, an algorithm which is helpful in diagnostic workup of SCID is included 
(Supplement Table 2). All SCID variants either lack T lymphocytes or have dysfunctional T 
cells. Some of the SCID variants can be classified by the number of B cells and/or NK cells 
present (Supplemental Table 2) 
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                                                                                                                                                        Appendices -  i 
Abbreviations 
 
AFP alpha fetoprotein 
AID activation-induced cytidine deaminase 
ALPS autoimmune lymphoproliferative syndrome 
AOA1 ataxia oculomotor apraxia syndrome 1 
AOA2 ataxia oculomotor apraxia syndrome 2 
APC antigen presenting cell 
APECED autoimmune polyendocrine candidiasis ectodermal dystrophy, caused by AIRE gene mutations 
APS I autoimmune polyendocrine syndrome type I 
A-T ataxia-telangiectasia 
ATG anti-thymocyte globulin 
ATLD A-T like disorder 
ATM ataxia telangiectasia mutated, the A-T gene 
ATR ATM and Rad3-related, member of PIKK family 
AVED ataxia with vitamin E deficiency 
BCG Mycobacterium bovis Bacille Calmette-Guerin 
BCR B cell receptor 
BER base excision repair 
BTK bruton tyrosine kinase 
Bu busulphan 
C.albicans candida albicans 
C2-C9 complement factors 2-9 
CD cluster of differentiation, a protocol for leukocyte cell surface molecules  
cDNA complementary DNA 
cer centromere 
CGD chronic granulomatous disease 
CGH comparative genomic hybridization 
CI confidence interval 
CMC chronic mucocutaneous candidiasis 
CMV cytomegalovirus 
CNS central nervous system 
ConA concanavalin-A 
CPS capsular polysaccharide 
CRM197 cross-reactive material 197 of diphtheria toxin 
CSR class switch recombination 
CVID common variable immunodeficiency 
Cy cyclophosphamide 
DC dendritic cell 
del deletion 
DGGE denaturing gradient gel electrophoresis 
dHPLC denaturing high performance liquid chromatography 
    
                                                                                                                                                        Appendices -  ii 
DNA deoxyribonucleic acid 
ds double substitution 
DSBs DNA double-strand breaks 
EBMT European Group for Blood and Marrow Transplantation 
EBNA anti-EBV nuclear antigen 
EBV Epstein-Barr virus 
EHDN Euro Huntington Disease Network 
EIA enzyme immunoassay 
ELISA enzyme linked immunosorbent assay 
ENT ear, nose, throat 
ESID European Society for Immunodeficiencies 
FAP familial adenomatous polyposis 
FAT FRAP, ATM, TRRAP 
FATC FRAP, ATM , TRRAP C-terminal 
FISH fluorescent in situ hybridization 
FRAP FKBP-12-rapamycin associated protein, also known as mTOR 
fs frame shift 
GAD glutamic acid decarboxylase 
G-CSF granulocyte-colony stimulating factor 
GVHD graft versus host disease 
HCV hepatitis C virus 
Hib Hemophilus influenzae type b 
HLA human leukocyte antigen 
HR homologous recombination 
HSV herpes simplex virus 
HVG host versus graft 
IFNGR1 interferon gamma receptor deficiency type 1 
Ig immunoglobulin 
IgA immunoglobulin A 
IGH immunoglobulin heavy chain 
IGK immunoglobulin kappa light chain  
IGL immuoglobulin lambda light chain 
IL-12 interleukin 12 
Ins insertion 
IPEX immune dysregulation, polyendocrinopathy, enteropathy, X-linked, caused by FOXP3 mutations 
IUIS International Union of Immunological Societies 
IvIg intravenous immunoglobulin 
JCS Jalowiec Coping Scale 
LAD1 leukocyte adhesion defect type 1 
LPS lipopolysaccharide 
MBL mannose binding lectin 
MEIA microparticle enzyme immunoassay 
    
                                                                                                                                                        Appendices -  iii 
MHC major histocompatibility complex 
microarray CGH microarray-based comparative genomic hybridization 
MIM Mendelian Inheritance in Man, the online version is called OMIM 
MLPA multiplex ligation-dependent probe amplification 
MMR mismatch repair 
ms missense 
mTOR mammalian target of rapamycin, also known as FRAP, member of PIKK family 
MTX methotrexate 
MUD matched unrelated donor 
NAPOS Norwegian Porphyria Centre 
NBS1 Nijmegen breakage syndrome 
NER nucleotide excision repair 
NHEJ nonhomologous end joining 
NHS Nowotny Hope Scale 
NK cells natural killer cells 
ns nonsense 
OMIM Online Mendelian Inheritance in Man, a database of human genes/genetic disorders 
p short arm of the chromosome 
PAGID Pan American Group for Immunodeficiency 
PCR polymerase chain reaction 
PCV7 seven-valent pneumococcal conjugated vaccine 
PHA phytohemagglutinin 
PI3K phosphoinositide 3-kinases 
PIDs primary immunodeficiency diseases 
PIKK phosphatidylinositol 3-kinase-like kinase 
PPV23 23-valent pneumococcal polysaccharide vaccine 
PTT protein truncating test 
PWM pokeweed mitogen 
q long arm of the chromosome 
QLI Ferrans and Powers Quality of Life Index 
ROS reactive oxygen species 
RPP Scale scale for measuring resources and pressures in the past 
RR relative risk 
SCAN1 spinocerebellar ataxia with neuropathy 
SCAR1 spinocerebellar ataxia recessive of non-Friedreich type 1 
SCC side-chain cleavage enzyme 
SCID severe combined immunodeficiency 
ScIg subcutaneous immunoglobulin 
SCN severe congenital neutropenia 
SCNIR Severe Chronic Neutropenia International Registry 
SCT stem cell transplantation 
SF-36 Short Form-36 
    
                                                                                                                                                        Appendices -  iv
SHM somatic hypermutation 
SI stimulation index; counts per min divided with the spontaneous proliferation 
SIR standardized incidence rate  
SNP single nucleotide polymorphism 
SP-A surfactant protein A 
SP-D surfactant protein D 
ss splice site mutation. 
TCR T cell receptor 
TDP1 tyrosyl-DNA phosphodiesterase 1 
ter terminal 
TG-Ab thyroglobulin antibodies 
TPO-Ab thyroperoxidase antibodies 
TRA T cell receptor alpha 
TRC T cell receptor beta 
TRD T cell receptor delta  
TRG T cell receptor gamma 
TSH thyroid stimulating hormone 
TSHR-Ab thyroid-stimulating hormone receptor antibodies 
TTPA alpha-tocopherol transfer protein 
UNG uracil-DNA glycosylase 
UT untranslated region 
V(D)J variable (diversity) joining 
VCA anti-EBV virus capsid antigen 
VZV varicella-zoster virus 
WAS wiskott aldrich syndrome 
XL EDA-ID; x-linked ectodermal dysplasia anhidrotic immunodeficiency, caused by NEMO gene mutations 
XLP x-linked lymphoproliferative syndrome 
AADC aromatic L -amino acid decarboxylase 
17OH 17a-hydroxylase 
21OH 21-hydroxylase 
 
    
                                                                                                                                                        Appendices -  v
Errata 
 
1. 14p11 corrected to 14q11 (Fig.7) 
 
2. the spelling of following words were corrected: opportunistic, tortuosity, seborrhoeic 
 
3. HLADR changed to HLA-DR (p.31) 
 
4. AutoDELPFIATM changed to AutoDELFIATM (p. 61) 
 
5. Brutons agammaglobulinemia (pp.10,11,66,71) and Bruton agammaglobulinemia 
SFKDQJHGWR%UXWRQ¶VDJDPPDJOREXOLQHPLD 
 
6. trombo- changed to thrombo- (pp.71,74,82) 
 
7. Due to black/white print,     with a red spot was changed to      in the Figure 20 legend. 
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Abstract
Background: Living with a chronic disease, such as primary antibody deficiency, will often have
consequences for quality of life. Previous quality-of-life studies in primary antibody deficiency
patients have been limited to different treatment methods. We wanted to study how adults with
primary antibody deficiencies manage their conditions and to identify factors that are conducive to
coping, good quality of life and hope.
Methods: Questionnaires were sent to all patients ≥20 years of age with primary antibody
deficiencies who were served by Rikshospitalet University Hospital. The questionnaires consisted
of several standardized scales: Ferrans and Powers Quality of Life Index (QLI), Short Form-36 (SF-
36), Jalowiec Coping Scale (JCS), Nowotny Hope Scale (NHS), and one scale we devised with
questions about resources and pressures in the past. Of a total of 91, 55 patients (aged 23–76
years) answered the questionnaires. The questionnaire study were supplemented with selected
interviews of ten extreme cases, five with low and five with high quality of life scores.
Results: Among the 55 patients, low quality of life scores were related to unemployment,
infections in more than four organs, more than two additional diseases, or more than two specific
occurrences of stress in the last 2–3 months. Persons with selective IgA deficiency had significantly
higher QLI scores than those with other antibody deficiencies. An optimistic coping style was most
frequent used, and hope values were moderately high. Based on the interviews, the patients could
be divided into three groups: 1) low QLI scores, low hope values, and reduced coping, 2) low QLI
scores, moderate hope values, and good coping, and 3) high QLI scores, moderate to strong hope
values, and good coping. Coping was related to the patients' sense of closeness and competence.
Published: 04 May 2005
Health and Quality of Life Outcomes 2005, 3:31 doi:10.1186/1477-7525-3-
31
Received: 26 January 2005
Accepted: 04 May 2005
This article is available from: http://www.hqlo.com/content/3/1/31
© 2005 Sigstad et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Health and Quality of Life Outcomes 2005, 3:31 http://www.hqlo.com/content/3/1/31
Page 2 of 13
(page number not for citation purposes)
Conclusion: Low quality of life scores in adults with primary antibody deficiencies were linked to
unemployment and disease-related strains. Closeness and competence were preconditions for
coping, quality of life and hope. The results are valuable in planning care for this patient group.
1. Background
Primary immunodeficiency diseases represent a heteroge-
neous group of rare disorders characterized by an
increased susceptibility to infections and autoimmune
diseases. Primary antibody deficiencies (PAD) constitute
the largest subgroup and include: Common Variable
Immunodeficiency, X-linked (Brutons) Agammaglob-
ulinemia, Selective IgA deficiency, IgG subclass deficiency,
and Hyper IgM syndrome [1]. Some patients need lifelong
replacement therapy with immunoglobulins and/or fre-
quent courses of antibiotics as treatment and/or prophy-
laxis. Patients with PAD have increased incidence of auto-
immune diseases and experience long-term complications
of infections and/or treatment [2]. Living with a chronic
disease, such as PAD, will often have consequences for
quality of life. Previous quality-of-life studies in PAD
patients have been limited to different treatment meth-
ods. After initiation of subcutaneous replacement therapy,
increased health-related function and improved self-rated
health have been reported [3]. We wanted to study wider
aspects of quality of life among adults with PAD: How do
they manage their condition? Which factors are conducive
to coping, good quality of life, and hope?
Coping, quality of life, and hope are important aspects
when the effects of a disease from infancy to old age are
examined. There are various partially overlapping per-
spectives on, and definitions of coping, quality of life, and
hope [4]. Coping reflects a process and includes active
involvement over a period of time [5,6]. Hope and quality
of life describe outcomes rather than processes. Hope and
quality of life are concepts which have several dimen-
sions. Coping also includes different strategies, but the
total sum of the strategies does not constitute a global def-
inition of the concept. Choice of strategies can influence
outcome variables such as hope or quality of life posi-
tively or negatively. Coping is of importance for quality of
life, and hope can be regarded as a coping strategy [7].
Hope can be seen as a variable that positively contributes
to the experience of quality of life.
Coping is defined by Lazarus and Folkman [[5]; p.141] as
"Constantly changing cognitive and behavioural efforts to
manage, reduce or tolerate external and/or internal
demands that are appraised as taxing or exceeding the
resources of the person". The coping process depends on
the situational context in which it occurs [5]. According to
Lazarus and Folkman's theory [5,6], resources and pres-
sures are linked to coping. We used resources and pres-
sures as concepts in the present study. Resources can be
divided in two groups; personal and socio-ecological
resources. Pressures, such as disease-related experiences,
may lead to stress and to reduced coping ability.
Locus of control is seen as a crucial factor in coping [8]. An
internal locus of control is present when a person explains
events by referring to causes within themselves. The per-
son perceives that the event is contingent upon his/her
own behavior or his/her own relatively permanent charac-
teristics. An external locus of control is present when a
person explains events by referring to causes in the situa-
tion or environment. Events and circumstances are typi-
cally perceived as the result of luck, chance, fate, under the
control of powerful others, or unpredictable because of
the great complexity of the forces surrounding the person
given an external locus of control.
Resilience predisposes for successful coping [9,10]. Longi-
tudinal studies in high risk children have showed positive
correlation between resilience and overcoming difficult
social circumstances as adolescents. Sommerschild [11]
developed a theoretical model which sums up of the key
points of resilience theory (see Figure 1). Resilience refers
to the person's latent resources which can be mobilized in
defense of the self in stressful situations. Resilience is
based on self confidence. Closeness and competence con-
tribute to self confidence. Figure 1 shows the concept
closeness explained at three levels; the dyadic relationship
with one competent adult, family, and the social network.
Competence encompasses the person's skills and experi-
ence of usefulness.
In the present study, quality of life was defined as a per-
son's overall satisfaction with life: "A person's sense of
well-being that stems from satisfaction or dissatisfaction
with areas of life that are important to him/her" [[12]; p.
15]. The global concept of quality of life is represented by
four domains: A health and functioning domain, a socio-
economic domain, a psychological/spiritual domain, and
a family domain. Health-related quality of life is defined
as a person's satisfaction or happiness within areas of life
that are affected by health or health care. Health-related
quality of life includes eight domains: physical function-
ing, role physical, bodily pain, general health perceptions,
vitality, social functioning, role emotional, and mental
health.
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Hope is future-oriented and described as a feeling, an
emotion, an experience, a need and a dynamic attribute
[13,14]. "A six-dimensional, dynamic attribute of the per-
son which orients to the future includes: active involve-
ment by the individual, comes from within, is possible,
relates to or involves others or a higher being, and relates
to meaningful outcomes to the individual" [[15]; p.89].
Two questions have been central in the present study:
1. How do adults with PAD manage their condition?
2. What kinds of factors influence their coping, quality of
life and hope?
2. Methods
The survey was the main investigation in this study, and
was analyzed quantitatively. The interviews were included
as a supplement to the survey, and did not represent a tra-
ditional qualitative study.
The survey
Sample
As of 2000, 122 patients with PAD were registered in Nor-
way [1]. All PAD patients ≥ 20 years and served by Rik-
shospitalet, in total 91 persons, received the
questionnaires, after excluding one cognitively impaired
person. The cohort included 50 men and 41 women, aged
20–82 years, with various PAD diagnoses: Common vari-
able immunodeficiency (n = 66), X-linked Agammaglob-
ulinemia (n = 8), Selective IgA deficiency (n = 16) and
Hyper IgM syndrome (n = 1).
55 of the 91 adults we approached completed the ques-
tionnaires (60% response rate), 31 men and 24 women.
The mean age was 41.6 (median 38, range 20–76) years.
Closeness and competence: preconditions for resilience against stressFigure 1
Closeness and competence: preconditions for resilience against stress. (Sommerschild, 1998 [11]).
CLOSENESS COMPETENCE
THE DYADIC RELATIONSHIP
A healthy, close relationship
with one competent adult
FAMILY
Consistency, confirmation, closeness
THE SOCIAL NETWORK
Corresponding values, social support
• skills
• areas of competence and perceived self-
efficacy, valued by oneself or others
• usefulness
• self-responsibility
• carefulness
• repertoire of problem-solving skills
• successful coping with stressful situations
SELF CONFIDENCE
RESILIENCE AGAINST STRESS
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The sample included 29 young adults, aged 20–39 years
and 26 older adults, aged 40–76 years. Distribution of the
specific PAD diagnoses was: Common Variable Immuno-
deficiency (n = 43), X-linked Agammaglobulinemi (n =
3), Selective IgA deficiency (n = 8) and Hyper IgM syn-
drome (n = 1). Nine of the responders reported previous
infection with Hepatitis C virus (HCV). Specific PAD diag-
noses, gender, and mean age, 47.2 (44, 20–82) years, were
similar and not significant different, when responders and
non-responders were compared. Responders (n = 55)
were reasonably representative of the original cohort (n =
91).
Measures
The survey included questions about the individual's past
and present situations, and about his/her thought con-
cerning plans for the future. Demographic variables
including age, gender, education, employment and mari-
tal status were requested. Information was elicited con-
cerning the following disease-related variables: specific
diagnosis, duration of clinical immunodeficiency state,
frequency of infections, in which organs the infections
(acute and chronic) occurred, other medical complica-
tions (including Hepatitis C virus infection), additional
diseases (including auto-immune diseases), treatment
with subcutaneous (ScIg) versus intravenous immu-
noglobulin (IVIg), other treatments (antibiotics) and
stressful events in the previous 2–3 months. Disease-
related strains were defined as the most problematic
strains linked to the PAD diagnosis, medical complica-
tions or additional diseases.
Five different scales were incorporated into one compre-
hensive 30-page questionnaire. Four of the standardized
scales had previously been translated and tested in Nor-
wegian populations [7,16,17]. The standardized scales
were: Ferrans and Powers Quality of Life Index (QLI) [18],
Short Form-36 (SF-36) [19], Jalowiec Coping Scale (JCS)
[20], and Nowotny Hope Scale (NHS) [13]. An additional
scale designed for this project (RPP Scale), focused on
resources and pressures in the past. Factor analyses were
used to assess the empirical support for each subscale in
all instruments. Internal consistency was estimated using
Cronbach's alpha coefficient.
Ferrans and Powers Quality of Life Index (QLI) has been
designed to measure quality of life in both ill and healthy
individuals, and this was based on Ferrans' definition of
quality of life [12,18]. The global construct quality of life
is represented by four underlying subscale domains/sub-
scales:
• Health/Functioning
• Socio-economic
• Psychological/Spiritual
• Family
The QLI consists of two sections. One section measures
satisfaction within various domains. The other section
measures the importance of each domain for the subject.
The items are scored according to a 6-point Likert scale
ranging from "very satisfied" to "very dissatisfied" for the
satisfaction items, and from "very important" to very
unimportant" for the importance items. The overall score
is the product of the satisfaction responses and the impor-
tance responses. The possible range for the overall and
subscale scores is 0–30, the higher the score the better
quality of life.
The validity and reliability of QLI has previously been
evaluated. Content validity of the original version was
assessed on the basis of a review of the literature [12,18].
Concurrent validity of the QLI was provided by a correla-
tion (r = 0.80) between the QLI and a measure of satisfac-
tion with life [12]. Construct validity was found to be
satisfactory in different patient populations, and was con-
firmed by factor analysis ("the maximum-likelihood
method" and "the direct oblimin method of rotation")
[12,21]. A four-factor solution had the best fit with the
data. Internal consistency reliability was 0.95 for the glo-
bal score, ranging from 0.66 to 0.93 for the subscales. The
test-retest reliability varied from 0.87 at two weeks to 0.81
at one month [18].
QLI has been translated and tested in a Norwegian popu-
lation of newly diagnosed cancer patients [7]. 131 cancer
patients participated in the test, 103 in the retest. The
Cronbach's alpha coefficient for the QLI was 0.93 for test
and 0.95 for retest. The coefficients for the subscales in
both tests ranged from 0.79 to 0.91 [7]. Test-retest-relia-
bility was r = .78 within three-four weeks (Pearsons corre-
lation coefficient). The correlation coefficients ranged
from r = .65 to r = .83 for the different subscales. Construct
validity was analysed by "the maximum-likelihood
method" and "direct oblimin method" of rotation (factor
analysis). Eight factors had an "Eigenvalue greater than 1".
Four factors explained only 45.4% of the variance in this
cancer patient cohort, in contrast to 91% in the study of
Ferrans and Power [21].
Reliability analyses in the present study with 55 PAD
patients showed a Cronbach's alpha of 0.81 for the total
QLI, and ranged from 0.54 to 0.92 for the four subscales.
The Family subscale had the lowest alpha value, and the
Health/Functioning subscale had the highest. Factor anal-
yses based on the four subscales were done by "the maxi-
mum-likelihood method", non-rotated method and
"direct oblimin method", rotated. Non-rotated method
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with "Eigenvalue greater than 1", resulted in one cluster
where only one of the factors appear, (2.571). All the sub-
scales could be related to this factor. The factor explained
64.3% of the variance in our sample. This result supported
a total scale with a common component.
The Short Form-36 (SF-36), one of several generic ques-
tionnaires developed to assess health-related quality of
life [19], consists of 36 items which measure eight concep-
tual domains:
• Self-reported General Health (GH)
• Physical Functioning (PF)
• Bodily Pain (BP)
• Mental Health (MH)
• Role limitations (Physical) (RP)
• Role limitations (Emotional) (RE)
• Vitality (VT)
• Social Functioning (SF)
In addition, one item assesses change in health in the past
year (HT). The scores in each domain are transformed into
0–100 scales. The higher score the better health-related
quality of life.
The reliability of the eight scales has been estimated using
both internal consistency and test-retest methods [22].
Reliability coefficients for each of the eight scales were
equal or greater than .80 (ranging from .81 in General
Health to .93 in Physical Functioning) with the exception
of Social Functioning, which had a reliability of .68. The
content validity of the SF-36 has been compared to that of
other widely used generic health surveys. Systematic com-
parisons reveal that the SF-36 includes eight of the most
frequently represented health concepts.
SF-36 has previously been translated and tested in 2323
persons from the general Norwegian population [17,23].
Reliability analyses (Cronbach's alpha) showed values
from 0.80 to 0.93 for the eight subscales, Role limitations
(Emotional) had the lowest and Bodily Pain the highest
value. Correlations between the SF-36-scales ranged from
r = .29 (Mental Health and Physical Functioning) to r =
.68 (Mental Health and Vitality).
Reliability analysis (Cronbach's alpha) of the SF-36 in the
present study (n = 55) yielded values from 0.74 to 0.92,
Role limitations (Emotional) had the lowest and Social
Functioning the highest value. Factor analysis is not usu-
ally performed when using SF-36. In spite of a relatively
small sample size, factor analysis was done in this study
by "Principal Component Analysis", non-rotated method
and "Varimax with Kaiser Normalization" rotated method
of the eight subscales. The analyses revealed two main fac-
tors. The scales which contributed the sum score of Phys-
ical Health, were one factor. The scales which contributed
the sum score of Mental Health, constituted the other fac-
tor. Compared with the original SF-36, there was one find-
ing of note in the present study: the Social Functioning
subscale was correlated with the sum score of Physical
Health. The Social Functioning subscale in the SF-36 is
originally included in the sum score of Mental Health.
The Jaloviec coping scale (JCS) is based on Lazarus and Folk-
man's theory of stress and coping [5,6,20]. The JCS has
been designed to measure how people cope with various
types of physical, emotional and social stressors. The JCS
measures the use and effectiveness of 60 cognitive and
behavioural coping strategies in a stressful situation. The
items describe cognitive and behavioural efforts in
response to stress. In our questionnaire, stress was speci-
fied as stress induced by living with PAD. The strategies
are grouped into eight coping dimensions:
• Confrontive – "tried to change the situation"
• Evasive – " put off facing up to the problem"
• Optimistic – "tried to think positively"
• Fatalistic – "accepted the situation because very little
could be done"
• Emotive – "worried about the problem"
• Palliative – "tried to keep busy and work harder"
• Supportive – "depended on others to help out"
• Self-reliant – "preferred to work things out yourself"
Item responses are rated on a 4-point scale from 0 (never
used) to 3 (often used), and a scale of helpfulness from 0
(not helpful) to 3 (very helpful). The higher score, the
more coping effort involved. The higher total coping score
the more alternation between different coping strategies.
The JCS has previously been tested in several studies
[20,24]. Its content validity has been assessed by an expert
panel and is supported by a broad theoretical and empir-
ical base. Construct validity has been evaluated. The 60
items are classified into eight subscales, with an agree-
ment ranging from 94% on the Supportive subscale to
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54% on the Emotive subscale. Reliability of the JCS,
assessed with Cronbach's alpha coefficients and based on
results from 24 different studies ranged from 0.48 to 0.81
for the use subscales and from 0.48 to 0.82 for the effec-
tiveness subscales.
JCS has previously been translated and tested in a Norwe-
gian population of 273 patients with psoriasis [16]. Cor-
relations between the eight subscales in JCS ranged from r
= .39 (p < .001) to r = .73 (p < .001). Reliability analyses
(Cronbach's alpha) of the eight subscales ranged from
0.55 to 0.88. The construct validity of the JCS was
analysed by "Principal Component Analysis" with orthog-
onal rotation (factor analysis). The analyses resulted in
three coping dimensions with sufficient internal consist-
ency: confrontive problem-solving coping, normalizing /
optimistic coping and combined emotive engagement. 37
% of the total variation in the Norwegian version of JCS
was attributed to these three factors [16].
Because few patients responded to the coping effective-
ness part of the JCS in the present study, we have only
included the coping strategy use part. Reliability analyses
(Cronbach's alpha) ranged from 0.41 to 0.75 for the eight
subscales (use-scores). The Confrontive, the Evasive and
the Optimistic subscales yielded the highest values from
0.73 to 0.75, and the Fatalistic subscale the lowest alpha
at 0.41. Our finding of three subscales with the strongest
internal consistency is in keeping with the results of
Jaloviec et. al. [20]. Factor analyses based on subscales,
done by "Principal Component Analysis", non-rotated
method and "Varimax with Kaiser Normalization",
rotated method, resulted in a three-factor-solution with
factor 1: Evasive, Fatalistic and Self-reliant coping; factor
2: Confrontive, Emotive, Palliative coping; and factor 3:
Optimistic coping. These analyses revealed that the Opti-
mistic scale could be considered a separate contributing
factor in the present study.
Nowotny Hope Scale (NHS) is designed to measure hope in
a general adult population after a stressful event [13,15],
and has been employed primarily in cancer patients. NHS
is a 29-item scale with items scored on a 4-point Likert
Scale ranging from 4, strongly agree, to 1, strongly disa-
gree. It consists of six subscales:
• Confidence
• Relates to others
• Future is possible
• Spiritual beliefs
• Active involvement
• Comes from within
The total score range is from 29 to 116, with a high score
indicating high hope. Cut-off scores are developed for
four levels of hope.
The content validity of the NHS has been evaluated by an
expert panel [13]. The concurrent validity was established
with the Beck Hopelessness Scale (r = -.47). The construct
validity of NHS was analysed by "Principal Components
Analysis" with orthogonal rotation (factor analysis). The
result supported the six dimensions and subscales of
hope. Cronbach alpha's reliability coefficient for this
instrument was 0.90. The concurrent validity has been
found to be satisfactory [13].
NHS has been translated and tested in the above-men-
tioned Norwegian population of newly diagnosed cancer
patients [25]. Correlations between different subscales
ranged from r = -.16 to r = .73. Factor analysis done by
"Principal Components Analysis", showed that the items
of the "Spiritual beliefs" subscale appeared as one factor,
and the "Comes from within" items as another factor
analogous to Nowotny's subscale items. With the excep-
tion of these two factors, the results of the NHS factor
analysis of Rustøen [25] diverged from Nowotny's origi-
nal six dimensions. At three-four week test-retest of NHS
correlation was high, Pearson's r = .81. Correlation coeffi-
cients ranged from r = .59 to r = .92 for the various sub-
scales. Cronbach's alpha for NHS was 0.89 both in the test
and the retest. The alpha coefficients for the subscales
ranged between 0.53 and 0.95.
Reliability analysis of NHS in the present study (n = 55)
showed a total Cronbach's alpha of 0.87. Cronbach's
alpha of the six subscales ranged from 0.54 to 0.94. Our
results were similar to Rustøen and Moum's results [25].
Factor analyses based on subscales were done by "Prinici-
pal Component Analysis", non-rotated method, and "Var-
imax with Kaiser Normalization", rotated method. Both
the non-rotated and the rotated variant of factor analysis
seemed to confirm only two explicit contributing factors:
factor 1; the Spiritual subscale, and factor 2; the five other
subscales.
The Resources and Pressures in the Past Scale (RPP Scale) was
theoretically founded on Lazarus and Folkman's theory of
coping [5,6] and consisted of 64 items divided into two
main categories: Resources and Pressures. The past was
defined as the period from adolescence to present time.
The distinction between different domains within the per-
son's resources was based on previous studies of coping
[9,10,26-28]. The concept of Resources included both per-
sonal characteristics / temperament and social support
resources. Pressures were defined as the person's individ-
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ual perception of his/her experiences, including immuno-
deficiency-related experiences and general events.
Resources consisted of four subscales:
• Personal characteristics / temperament
• Family and supporting adults
• Supporting persons in school and social network
• Public Health Service
Pressures in our scale consisted of four subscales:
• Immunodeficiency-related events (for example: many
hospitalizations because of the disease)
• General events
• Immunodeficiency-related experiences in school (for
example: significant absence from school because of the
disease)
• General experiences in school
The items were scored on a 5-point Likert Scale ranging
from 5, strongly agree, to 1, strongly disagree. The total
score range of Resources was from 29 to 145, and the total
score range of Pressures was from 35 to 175. A high score
indicated either a good availability of resources or a high
level of strain.
In the present study, missing was handled by the same
procedure as in the standardized scales JCS and NHS:
when more than 50% of the subscale is answered, the
missing value is replaced by the mean score of the rest of
the subscale.
This scale was evaluated by reliability analyses (Cron-
bach's alpha) and factor analyses. The aim behind using
reliability analyses was to evaluate in what degree the
individual items correlated with the main concepts in the
scale. Some items were excluded to attain highest possible
consistency. The Cronbach's alpha was 0.89 for Resources
and 0.90 for Pressures, with a range from 0.63 (Personal
characteristics/temperament) to 0.90 (Family and sup-
porting adults) in Resources, and a range from 0.59
(Immunodeficiency-related events) to 0.89 (Immunode-
ficiency-related experiences in school) in Pressures. Valid-
ity was tested by "Principal Component Analysis", non-
rotated method and "Varimax with Kaiser Normalization"
with rotation (factor analysis) based on the subscales.
With "Eigenvalue greater than 1", the non-rotated method
made only one contributing factor appear for the Pres-
sures scale to which 55% of the total variance could be
attributed. Likewise, the factor analysis (non-rotated
method) yielded only one contributing factor from the
Resources' scale, to which 46% of the total variance could
be attributed.
Statistical analyses of the survey data
The SPSS-PC statistical program (v 9.0) was used for data
analyses. Descriptive analyses were performed to assess
the characteristics of the sample. The impact of demo-
graphic and clinical variables on the dependent variables
was assessed by t-test for independent samples (two-
tailed). The effect sizes were measured by the difference
between the means of the samples divided by the mean of
the standard deviations of the samples [29]. The effect size
was defined by qualitative standardized values (small =
.25SD, medium = .50SD, large = 1.00SD). Both correla-
tion analyses and multiple regression analyses were per-
formed to assess the relationship between variables.
The interviews
The interviews were included as a supplement to the sur-
vey to elucidate preconditions for coping, good quality of
life, and hopefulness. The interview study was designed to
probe and to aid in the interpretation of some of the
results from the questionnaire. Cases were selected for
interviews to detect possible patterns within two groups:
patients with high QLI scores and patients with low QLI
scores. The selected cases represented a strategic sample of
patients with the lowest and highest QLI scores (n = 21).
Originally, we wanted to interview all these extreme cases
(n = 21). Ten patients consented to participate in the inter-
view study. Ten cases were regarded as sufficient to detect
patterns within the different groups. The qualitative inter-
views were based on significant results related to QLI in
the survey. The interviews were semi-structured with a pre-
written interview guide, and lasted nearly two hours.
The interview guide was based on the most central issues
in the survey: previous resources and pressures, the inter-
viewees' experience of coping and quality of life, and their
hope for the future. Questions about coping included
present challenges and choice of coping strategies. Ques-
tions about experience of quality of life were related to the
four dimensions in QLI: Health/Functioning, Socio-eco-
nomic, Psychological/Spiritual and Family. Questions
concerning hope, dealt with the patients' general experi-
ence of hope. All concepts were related to a lifespan per-
spective as the interviewees were asked to evaluate their
present situation related to their past. All interviews were
done by the same person and tape-recorded.
In accordance with Kvale's methodology [30], the inter-
views were analyzed on a thematic and a theoretical level.
Kvale distinguishes between three different contexts of
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interpretation of the interview statements. The thematic
level implies a condensed form of what the interviewees
themselves understand to be the content of their state-
ments. The interpretation is more or less based on the
interviewees' self-understanding as understood by the
researcher. The common sense level represents a critical
common sense understanding. The interpretations may
include a wider frame of understanding than those of the
interviewees themselves. The interviewer should be criti-
cal of what is said, and may focus on the content of the
statement. The theoretical level is a framework for
interpreting the meaning of a statement. These interpreta-
tions are likely to go beyond the interviewees' self-under-
standing and to exceed common sense understanding. In
this study, the theoretical level included the common
sense understanding.
The interviews were analyzed to identify interesting and
important themes. New themes appearing during the
interviews were included in the analyses (thematic level).
Similarities and differences were described within and
between the extreme groups. The expressed meanings
were summarized into shorter terms. Individual texts were
further analyzed with respect to meaning of the texts, and
to their respective categories. The categories were divided
into groups defined by contrasting elements within and
across the groups denoting high and low quality of life
[31]. When thematic analyses showed differences within
or between the extreme groups, further analyses were
done. Since some of these variants seemed to be in accord-
ance with previous studies in coping research, the results
of the first thematic analyses were reanalyzed according to
relevant theory about the constructs of coping, quality of
life, and hope (theoretical level).
According to Kvale [30] reliability pertains to the consist-
ency of the research findings, and validity to the truth and
correctness of a statement. Kvale emphasizes that issues of
verification do not belong to a separate stage of an inves-
tigation, but should be addressed throughout the entire
process. Validation is done at seven stages in the interview
process: 1. Thematizing based on the logic of derivations
from theory to the research questions of the study, 2.
Designing dependent on the adequacy of the design and
the methods used for the purpose of the study, 3. Inter-
viewing based on trustedness of the interviewees reports
and the quality of the interviewing itself, 4. Transcribing
dependent on the quality of the translation from oral to
written language, 5. Analyzing dependent on whether the
questions in the interview text are valid and whether the
interpretations are logical, 6. Validitating, based on reflec-
tive consideration of what forms are relevant to a specific
study and 7. Reporting dependent on to what degree a
given report is a valid account of the main findings of a
study.
3. Ethical aspects
The study was approved by the Norwegian Regional Com-
mittee for Medical Research Ethics and the Norwegian
Social Science Data Services. Participants were guaranteed
anonymity and the right to withdraw from the study at
any time. An information letter to respondents provided
information about the potentially sensitive items.
4. Results
The survey
t-tests were done on selected demographic and disease-
related variables and the results are presented in table
1(see Additional file 1). Other results and comparisons
are only presented in the text. Table 1 includes results of
total scores (means and standard deviations) of all scales
in the present study with one exception: the most signifi-
cant differences in SFscores were found in four out of the
eight domains. Only these are presented in the table (BP,
MH, RP and SF).
On the RPP, the 55 adults with PAD reported good avail-
ability of resources in the past (personally and support
from others) (mean 3.7, range 2.03–4.93, out of a possi-
ble total score of 5). Parents and other supporting adults
had been of major importance as social support (mean
3.8, range 1.69–5.00 out of a possible score of 5). Adults
with PAD had experienced moderate pressures (2.6, 1.27–
4.66, out of a possible total score of 5). Pressures related
to their immunodeficiency were the most burdensome in
the school context (3.09, 1.00–5.00). Four conditions in
present time implicated significantly more pressures in
the past: younger age (20–39 years) (p = .024), (Effect Size
(ES) = .77SD), living alone (p = .015), (ES = .84SD), hav-
ing more than two additional diseases (p = .005), (ES =
1.07SD), or suffering from infections in more than four
organs (p = .038), (ES = .69SD) (t-tests, two-tailed) (Table
1).
The mean score in global QLI (quality of life) was moderate
at 20.0 (range 12.3–27.6, out of a possible total score of
30.0). In addition to immunodeficiency, the following
conditions were associated with significantly lower QLI
scores: unemployment (p = .008), (ES = .80SD), infec-
tions in more than four organs (p = .020), (ES = .79SD),
the presence of more than two other diseases (p = .001),
(ES = 1.55SD), or more than two specific occurrences of
stress in the last 2–3 months (p = .007), (ES = 1.15SD) (t-
tests, two-tailed). These results are presented in table 1.
Unemployed men had lower QLI scores compared to
employed men (p= .020). The term "unemployed" was
defined to include currently/previously unemployed,
never employed and recipient of disability pension. Men
working full-time achieved significantly higher QLI scores
than men working part-time or unemployed men (p =
.016). These differences did not exist among the women.
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Variables without impact on QLI were: length of educa-
tion, type of treatment (subcutaneous Ig versus intrave-
nous Ig), frequency of treatments, self-administration of
treatment at home (ScIg), hospital based treatment (IVIg),
and HCV infection.
Compared to a Norwegian sample of newly diagnosed
cancer patients (n = 131) [7], the PAD patients (n = 55)
had a significantly lower total QLI score (p < .05), along
two dimensions: Health and Functioning (p < .05) and
Socio-economic (p < .01).
Health-related quality of life in different conceptual
domains on the SF-36, revealed that the adults with PAD
had their lowest mean score in General Health (37.8,
range 5.0–87.0, of a possible total score of 100.0) and
their highest mean score in Physical Functioning (81.1,
10.0–100.0, of a possible total score of 100.0) (SF-36).
The most significant differences in SF scores were found in
four of the eight domains, and these are presented in table
1. Gender, employment and disease-related pressures/
strains had significant influence. Men had a significantly
higher score than women in Bodily Pain, Social Function-
ing and Vitality, respectively (p = .029), (ES = .64SD); (p
= .016), (ES = .68SD); and (p = .004), (ES = .85SD) (t-
tests, two-tailed). Unemployed men and women, had sig-
nificantly lower health-related quality of life, compared to
employed adults. Low health-related quality of life was
found in Bodily Pain (p = .006), (ES = .81SD); General
Health (p = .002), (ES = .88SD); Mental Health (p = .021),
(ES = .68SD); Physical Functioning (p = .001), (ES =
1.01SD); Role limitations (Physical) (p = .000), (ES =
1.16SD); and Social Functioning (p = .004), (ES = .91SD).
The disease-related strains were infections in more than
four organs, infections more than eight times yearly, more
than two other diseases and/or more than two specific
occurrences of stress in the last 2–3 months. Hepatitis C
infection did not have a negative influence on health-
related quality of life.
Compared to a control group with a normal distribution
(n = 2323) [17], our PAD patients (n = 55) showed signif-
icantly lower functional ability scores in all areas of
health-related quality of life (SF-36). The finding reached
statistical significance (.001) in four areas: General
Health, Role limitations (Physical), Social Functioning
and Vitality. Compared to a sample of psoriasis patients
(n = 283) [4], these PAD patients showed different scores
in two areas (SF-36): Bodily Pain, where adults with PAD
scored higher (p < .01), and General Health, where adults
with PAD scored lower (p < .001).
Of the eight coping strategies measured by the JCS, an
optimistic coping strategy was most frequently used
(mean item rating 2.28, range 0.44–3.00, on a 4-point
scale of 0–3). A palliative coping strategy was rarely used
(1.18, 0.20–2.29). The total score for all coping strategies
used showed a mean item rating of 1.64 (1.13–2.32). This
reflects the extent of use of all coping strategies measured
[20]. Being unemployed was associated with high coping
scores among adults with PAD (p = .013), (ES = .78SD) (t-
tests, two-tailed). Full-time employment was associated
with lower coping scores compared to part-time employ-
ment, housework or unemployment (p = .021), (ES =
.67SD) (Table 1).
The PAD patients had moderate hope values on the NHS
with a mean score of 84.9 (range 52–102, of a possible
total score of 116). Having more than two additional dis-
eases in addition to PAD was associated with a lower hope
value among responders (p = .015), (ES = 1.02SD) (t-tests,
two-tailed). The results are presented in table 1. There was
positive correlation between being hopeful about the
future and quality of life (QLI) in the present, r = .454 (p
< .001) (Pearson correlation). Regression analysis with
quality of life (QLI) as the dependent variable and hope
(NHS) as one of the independent variables, showed R2 =
.206 (p < .001), which suggests that hope explains 20.6%
of the total variance in the quality of life.
Compared to a sample of newly diagnosed cancer patients
(n = 131) [7], our PAD patients (n = 55) had a signifi-
cantly lower total hope value (p < .05) visualized in two
dimensions of NHS: Relates to others (p < .01), and
Future is possible (p < .05).
The interviews
During thematic analysis of the ten interviews, certain cat-
egories appeared to be of particular importance. These cat-
egories were used as the main categories in the theoretical
analysis: quality of life, closeness and competence as resil-
ience, locus of control, and hope. The five responders with
high QLI scores showed more homogeneous results than
the five responders with low QLI scores for the interview
themes resources and pressures in past, coping ability,
quality of life, and hope for future. The latter group was
split into two subgroups based on criteria related to expe-
rience of closeness and competence, and locus of control.
Locus of control was determined by evaluating the
responders' answers about their own experience of inter-
nal control over external occurrences. In spite of a low QLI
score, three of the responders seemed to have strong resil-
ience combined with an internal locus of control.
Based on the theoretical analysis, the subjects with a low
QLI score were divided into two groups (Group 1 and
Group 2). The subjects with a high QLI score were defined
as Group 3. Persons in Group 1 (n = 2) had low scores in
all four subscales of QLI (Health/Functioning, Socio-eco-
nomic, Psychological/Spiritual, Family). They had prob-
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lematic psychological bonds to their mothers, and less
experience of closeness or/and competence (Fig 1). They
experienced difficulties in coping (self-reported), they had
low hope values and either an internal or an external locus
of control. In addition, persons in Group 1 had needed
various forms of social support. However, they expressed
reluctance to receive such support. Persons in Group 2 (n
= 3) had low scores in two subscales of QLI: Health/Func-
tioning and Socio-economic. They had especially close
relationship to their mothers, but a positive experience of
closeness and competence. They were coping successfully
(self-reported), had a moderate hope values and an inter-
nal locus of control. The persons in Group 2 also needed
additional social support, but received such help accord-
ing to their own wishes. Persons in Group 3 (n = 5) had
high scores in all four subscales of QLI. They had experi-
enced closeness and competence, and they were coping
successfully. They had moderate to strong hope values, an
internal locus of control, and reported no need for addi-
tional support.
5. Discussion
The purpose of the present study was to study how adults
with PAD manage their condition and to identify factors
that are conducive to coping, good quality of life, and
hopefulness. Low scores in quality of life were linked to
unemployment and disease-related strains among adults
with PAD. Closeness and competence were preconditions
for coping, good quality of life and hope.
The survey showed that parents and other supporting
adults were the most important caregivers (Resources) in
adolescence. This is in accordance with findings in previ-
ous coping studies [32]. Not surprisingly, the interviews
confirmed the family as the best caregivers during child-
hood. In cases where the parents did not fulfill their func-
tion as caregivers, other people such as neighbors and
health personnel functioned as caregivers. In addition,
social support was not only associated with positive expe-
riences among the responders with low QLI score. Those
with a low QLI score reported a complicated relationship
to their mothers. They wanted to be accepted as adults,
but did not experience that they were.
Experiences related to immunodeficiency (Pressures) were
of major importance, for example: episodes of illness,
absence from school, psychosocial consequences of the
disease, self-respect and respect from other people. These
results came from the survey. The interviews confirmed
that occurrences related to the immunodeficiency were
the most chronic problems. This is in accordance with
Ogden's conclusions [33]. Ogden classified painful school
experiences as a long-term element of risk. Many studies
have emphasized the importance of the impact of previ-
ous pressures on later development [32,34-36]. In accord-
ance with their findings, the results of the present study
point to previous resources and pressures as crucial factors
for future coping ability and maturation.
A high degree of immunodeficiency-related strain as well
as unemployment had a negative impact on Health and
Functioning on the QLI in this sample (n = 55) (Quality of
life). In order to achieve a high total QLI score, a low score
in one dimension has to be compensated by higher scores
in the other dimensions. To be satisfied with one's own
achievement as an experience of coping is seen as crucial
to achieving a high quality of life [37]. Consequently,
unemployment requires that one is able to compensate
for lack of employment with another meaningful activity.
This may be interest in interpreting the finding in this
study that unemployed men reported lower quality of life
than men with a steady job.
Persons with Selective IgA-deficiency achieved a higher
global QLI score than other PAD patients. Patients with
symptomatic selective IgA deficiency are usually healthier
than other PAD patients [2]. Surprisingly, the QLI differ-
ences were not found in the health/function domain, but
in the socioeconomic, family and psychological/spiritual
domains.
We observed a difference in QLI between those who
treated themselves (ScIg) compared to those who were
treated by others (IVIg), but the difference was not statis-
tically significant. However, the PAD patients who treated
themselves (ScIg) had a significantly higher score in Social
Functioning (SF-36) compared to the others. SF-36 meas-
ured health-related quality of life. Our study focused on glo-
bal quality of life, not specific in relation to treatment, and
the results did not elucidate all aspects of these different
treatment methods. Gardulf [3] found a significantly
increased health-related function, and improved self-
rated health among patients with PAD after initiation of
ScIg infusions. However, our study was not designed to
detect differences before and after introduction of a spe-
cific treatment method.
Nine of the 55 responders had experienced Hepatitis C
virus infection due to contaminated IVIg [38]. Surpris-
ingly, HCV infection had no influence on the QLI scores
or scores of SF-36 in this study.
The interviewees with a low QLI score were in poor health
and reported some limitations in daily life functioning.
Still, these patients showed obvious differences within the
group related to other quality of life conditions, as some
of them (Group 2) seemed to fully adjust their experience
of quality of life. Well-being and satisfactory social sup-
port were reported. This was not anticipated because of
low QLI scores from the questionnaire. Wilson and
Health and Quality of Life Outcomes 2005, 3:31 http://www.hqlo.com/content/3/1/31
Page 11 of 13
(page number not for citation purposes)
Cleary's research studies [39] suggest that there is no direct
correlation between serious limitation in health and loss
of quality of life. On the other hand, positive self-esteem,
ability to be active and to use one's abilities are elements
of crucial significance [37,40,41] in achieving a high qual-
ity of life score. In our interview study, there was a lack of
such characteristics in Group 1 who had low scores in all
domains of the QLI. Insufficient involvement,
dependence on others, low self-esteem, and lack of happi-
ness and well-being were characteristic interview
responses in this group.
There were some differences between the findings in the
survey and the interviews: The global QLI scores and SF-
scores did not give a good description of social network.
Interviews indicated that a good network was important
for resilience. The interviews may have described more
comprehensively the responders' experience of different
types of support. Mutual relationships were identified as
important by interview, but had not been included
among the specific items in the survey. Psychological
characteristics, external living conditions and relation-
ships have been evaluated by others [37] as essential fac-
tors for quality of life. The responders with a low QLI
score in Group 2 (the interview study) confirmed that a
good social network had contributed to increasing their
quality of life.
Compared to a Norwegian sample of newly diagnosed
cancer patients [7], our 55 PAD patients had a lower glo-
bal QLI score, along dimensions: Health and functioning
and socio-economic. By nature of their disease, the PAD
patients have had a life-long course, in contrast to the can-
cer patients. Perhaps the chronicity of PAD explains some
of the divergence.
Compared to the cancer cohort [17], our PAD patients
scored lower on functional ability in all areas of health-
related quality of life (SF-36). Other quality-of-life studies
confirm significant negative implications of physical
health limitations [42,43]. Compared to a sample of pso-
riasis patients [16], our PAD patients scored differently in
two areas (SF-36): Bodily Pain, where adults with PAD
had a higher score, and General Health, where adults with
PAD had a lower score. Bodily pain is not characteristic for
PAD patients and can be a possible explanation for the
high score in SF-36. Adults with psoriasis have better gen-
eral health, compared with adults with PAD.
An optimistic coping strategy was most frequently used in
dealing with the illness (survey). This is a consistent find-
ing in other studies of groups with other chronic diseases
[16,44-46]. Employment is linked to competence and
may predispose for successful coping (Fig 1) [11]. Accord-
ing to Sommerschild [11], coping depends on compe-
tence in various areas, e.g. perceived self-efficacy,
usefulness, and problem-solving skills. Unemployment
requires that one is able to compensate in other spheres in
order to achieve a feeling of competence [32]. Compe-
tence and closeness are areas which may be amenable to
psychosocial interventions aimed at increasing quality of
life in adults with PAD. Prospective interventions can be
designed for patients with low quality of life scores or may
include all PAD patients.
The PAD patients had moderate hope scores on the NHS.
Having more than two other diagnoses in addition to
PAD was associated with a lower hope score. Less hopeful-
ness correlated positively with a high degree of disease-
related strain. We found a definite positive correlation
between being hopeful about the future and quality of life
(QLI) in the present. Hope seemed to be responsible for
1/5 of the total variance in the quality of life. Increasing
hope may have an impact on enhancing quality of life.
Compared to the cohort of newly diagnosed cancer
patients [7], our PAD patients had a significantly less glo-
bal hope score in two dimensions of NHS: "Relates to oth-
ers", and "Future is possible". Studies confirm that
persons with a cancer diagnosis, thought to be in a hope-
less situation, often have a positive and hopeful vision of
the future [47]. The PAD patients include people with a
congenital chronic disease for which there is no curative
treatment. All of the newly diagnosed cancer patients had
been diagnosed within the previous year. They were aware
that cancer is a terminal illness, but they may have
retained hope for curative treatment.
Another study, which focused on sources of hope among
people with chronic diseases, emphasized hope as a main
coping strategy [48]. Evangelista [49] found that hope
strongly correlated with quality of life in a cohort of
female heart transplant recipients. The Group 2 and
Group 3 patients in our interviews had plans and dreams,
and were optimistic about the future, and their plans were
related to other people. But in Group 1, thoughts about
the future were characterized by fatalism, less faith in the
future and lack of involvement with others.
The low response rate (60%) may be considered a limita-
tion of the external validity of the survey. Including sub-
jects with other immunodeficiency disorders would have
increased sample size at the cost of homogeneity. Homo-
geneity was chosen to enhance validity. Simple statistical
analyses were employed. We were able to use the t-test
after controlling for statistical assumptions (independent
samples, normal distribution, and homogeneity of vari-
ance). The findings reported as significant reached, with
one exception, levels of significance of .01 and .001. Effect
size varied between moderately large to a large [29]. In
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spite of some concerns regarding statistical power, we
consider that our results have relatively good statistical
validity [50].
Five scales were used; four of them standardized and well
tested by others, and in Norwegian populations. One
scale was specially designed for this study. Seen in a
lifespan perspective, related to previous pressures/strains
and availability of resources, we showed that the results of
this scale also were important for the evaluation of the
results from the other scales. In spite of some variation
between the subscales, the five scales showed good relia-
bility generally (Cronbach's alpha) in keeping with the
main constructs of the study. The four standardized scales
were internally consistent and test-retest reliability was
satisfactory. Despite a thorough testing of the RPP Scale,
the construct validity of this scale may be more uncertain.
Nevertheless, in spite of some limitations, the total con-
struct validity appears robust.
If the group is too special, it may not be correct to gener-
alize the results to other kinds of persons or other dis-
eases. However, this sample was characterized by a wide
age span (23–76 years), different subgroups of PAD, vari-
ous types of treatment, age at diagnosis and number of
disease-related strains. Analysis of the non-responders
showed that the responders in this survey (n = 55) were
representative for the entire cohort (n = 91), and they con-
stitute 75% of all patients registered with PAD in Norway
[1]. Therefore, this survey was has relatively good external
validity relative to this patient group.
The results of the interviews were evaluated in according
to Kvale's methodology [30] for qualitative research inter-
viewing, and the reliability and validity were found to be
reasonably good. An evaluation during the analysis proc-
ess of the interviews concluded that the size of the sample
was sufficient to detect different patterns in these two
groups of extreme cases. And similar patterns have been
found in previous studies on coping [9,10,51]. Such a
confirmation is expected to strengthen the results, and to
some extent compensate for the limited sample size.
However, the low number necessitates a tentative and
explorative use of the study findings.
Since the sample of the ten interview subjects was in
accordance with the strategic sample concerning the most
central variables impacting on quality of life, the generaliz-
ability of the interview study could be evaluated as rela-
tively good.
The interviews were included to elucidate nuances in the
knowledge from the survey results. Triangulation of differ-
ent methods is considered an appropriate strategy for
strengthening the validity of research findings [52,53].
The interview study supplemented the survey, supported
the constructs in the survey and, as a result, strengthened
the validity of the findings. In this project, the results from
the survey were thoroughly examined during the inter-
views. However, the interview study also raised some new
hypotheses, which were not registered in the survey. The
interviews have added new aspects, and functioned as a
supplement to the survey, increasing the relevance of the
project and its results. Combining the findings from both
the survey and the interviews strengthens the validity of
the project's end result.
There may be ethical concerns when inviting patients to
complete questionnaires about coping, quality of life and
hope. In this study, the information letter gave an oppor-
tunity to prepare for potentially sensitive questionnaire
items. Moreover, the interviews made ethical demands on
the interviewer. In an interview, the interviewer is a part of
the method, and has a responsibility to manage separat-
ing roles, having focus on the interview and taking care of
the interviewees in a professional way. In the present
study, to get the interviewees' confidence, the interviewer
had to define the content of the interview precisely, and
explain the interviewers' role. The interviewer referred the
interviewees to other health personnel when needed.
6. Conclusion
Low scores in quality of life were linked to unemployment
and disease-related strain among adults with PAD. Cop-
ing was closely linked to the patients' sense of closeness
and competence. The results are in accordance with previ-
ous studies of other groups with chronic diseases. Close-
ness and competence are areas where psychosocial
interventions may contribute to better quality of life in
adults with PAD. The findings are relevant also for other
groups of patients. Medical interventions should reduce
the patient's strain, and support his or her ability to be
employed.
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Summary:   
We report a twelve years old boy with developmental delay, ataxia, choreoathetosis, muscular 
hypotonia, thyroid dysfunction and severe pulmonary problems characterised by recurrent 
episodes of respiratory distress and pneumonia. He had a heterozygous interstitial 
microdeletion of proximal chromosome 14q resulting in haploinsufficiency of multiple genes 
including TITF1 (NKX2.1) and PAX9. The karyotype was 46,XY, del(14)(q13.1q21.1). He 
was also homozygous for the mannose-binding lectin (MBL) haplotype B, a variant in codon 
54 in the MBL2 gene on chromosome 10q causing absence of functional serum MBL. The 14q 
deletion was confined to the index patient, while the MBL deficiency and corresponding 
MBL2 genotypes were also found in his mother and his younger sibling. 
 
 2 
List of abbreviations: 
 
TITF1 Thyroid transcription factor 1 
PAX9 Paired box gene 9 
GERD gastro-oesophageal reflux  
SP-A Surfactant protein A 
SP-D Surfactant protein D 
MBL Mannose-binding lectin 
 3 
Introduction: 
Deletions of the proximal chromosome 14q region have been reported in patients with various 
neurological and dysmorfic features [1]: midline defects of the central nervous system, 
feeding problems, growth retardation, muscular hypotonia, developmental delay, mild to 
severe mental retardation and craniofacial findings. Respiratory distress and thyroid 
dysfunction are also common findings [1-4] as well as gastroesophageal reflux. Within the 
14q13-q21 region some important genes with documented clinical implications are located, 
such as the TITF1 (NKX2.1) gene, which encodes for thyroid transcription factor 1. This gene 
is important for the development and function of thyroid, forebrain, basal ganglia and lung [5-
9]. Hypothyroidism, neurological abnormalities and respiratory distress are described in 
humans with heterozygous deletions or mutations in the TITF1 gene [8] [10-13]. TITF1 
induces promotor activity of surfactant protein A [14;15], surfactant protein C [16;17] and 
surfactant protein B genes [18;19]. Surfactant proteins are important not only for enhanced 
lung compliance and low alveolar surface tension, but play an important part of the innate 
immunity of the lungs (SP-A and SP-D)[20]. Paired box gene 9 (PAX9) locus is located close 
to TITF1. PAX9 is important for craniofacial skeletogenesis and oral cavity patterning. 
Haploinsufficiency of PAX9 in humans is associated with autosomal dominant hypodontia 
[21]. Here we report a patient with interstitial 14q microdeletion and severe, recurrent 
pulmonary infections probably related to a concomitant MBL deficiency. Even in reports of 
larger 14q deletions, clinical and laboratory signs of immunodeficiency have not been 
described in the patients. 
 4 
CASE REPORT 
Clinical Course 
Second child of healthy, unrelated parents.  He was born at term with cleft lip-palate and pes 
adductus. In addition, short nose, long philtrum, flat broad nasal root and micrognathia were 
observed (Figure 1). He had normal birth weight 3790g, length 52 cm and large head 
circumference 39cm (97.5 th centile). He was first hospitalised 5 weeks old with RSV infection 
necessitating respiratory support for one week. Due to persisting feeding difficulties with 
acute respiratory problems despite operative correction of his cleft lip-palate, he received a 
gastrostomy at 16 months of age and a fundoplicatio ad modum Nissen eight months later. He 
eats some meals per os, but has mainly been fed through the percutaneous endoscopic 
gastrostomy. At present, twelve years old he still has recurrent pulmonary infections, on 
average one per month. The last five years he has been followed by the Cystic Fibrosis 
medical team, intensively treated with active chest physiotherapy including use of cough 
assist machine, inhalations four times a day with N-Acetylcysteine/Salbutamol, periodically 
Fluticason aerosol, and BIPAP (Bilevel Positive Airway Pressure) breath assist machine every 
night. The two last years he has during the autumn/winter seasons been treated with 
Tobramycin inhalations; four week on/four weeks off, resulting in less intercurrent infections. 
Sputum/expectorate samples are collected every 3rd-4th week for routine microbiological 
investigation. Bacteriae including Staphylococcus aureus, Haemophilus influenzae, group B 
streptococcus, Streptococcus pneumoniae, Pseudomonas aerginosa and Stentrophomonas 
maltophilia have regularly been found in his expectorates. He also has had episodes of 
diarrhoea requiring hospitalisation. He has since early childhood had bilateral chronic otitis, 
frequent skin infections around the gastrostomy, repeated chalazions of the eyelids and 
suffered chickenpox twice. After the MMR vaccination he developed a skin abscess. 
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His neuropsychological development has been delayed. At two years of age he started to walk 
with an ataxia that has developed into more choreoatetoid movements during the years. He 
has signs of muscular hypotonia with joint laxity, tendon reflexes are normal. He has 
macroglossia, involuntary tongue movements and dysartria.  The last years he has been 
followed by the dentist because of crowded teeth and persisting primary teeth. 
 
By neuropsychological testing at the age of 6 years 9 months he functioned intellectually 2½ 
years behind his age both according to Wechsler Preschool and Primary Scale of Intelligence - 
Revised (WPPSI-R) and information from his teacher and his parents. Scores of 
Developmental Test of Visual-Motor Integration (VMI) and Grooved Pegboard tests 
corresponded to 4 years when he was 6¾. Nine years old he started to have absence seizures. 
MR imaging of his brain was normal. EEG showed focal spike-wave complexes in the left 
parieto-temporo-occipital regions and also in the right temporal region. Benign epilepsy of 
childhood with Rolandic spikes was diagnosed and since then he has been treated with 450 
mg daily doses of natrium valproate retard tablets. The treatment has reduced the frequency of 
the absence seizures. By neuropsychological testing at the age of 10 years of age he functioned 
3-4 years behind his age according to Wechsler Intelligence Scale for Children (WISC-III), 
5DYHQ¶VSURJUHVVLYHPDWULFHVDQGLQIRUmation from his teacher. At 10 years of age he had 
difficulties performing the Visual-Motor Integration (VMI) and Grooved Pegboard tests 
involving fine movements, and these scores were lower than scores from the pure intelligence 
tests. He cooperated well during the tests, but had signs of attention deficit and hyperactivity; 
$'+'7KHORFRPRWRUEHKDYLRULQFOXGHGERWKYROXQWDU\³UHVWOHVVQHVV´DQGLQYROXQWDU\
movements such as tics. He is a social and humoristic person, without signs of autism.  
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He had elevated TSH levels for many years (10 mU/L, reference 0,4-3,5) while T4 levels (13-
17pmol/L) were within normal range and thyroid autoantibodies had never been detected. 
Thyroxin substitution was started when he was seven years old, but no clinical including 
neurological improvement was achieved. Other hormones such as FSH, LH, prolactin, IGF-1, 
growth hormone and cortisol were normal. He had normal serum levels of alpha fetoprotein. 
And urinary excretion of purines and pyrimidines analysed by high-performance liquid 
chromatography was normal. Ultrasound showed a normal thyroid and thymus was present.  
When he was seven years old his height was 5 cm below the 2.5th centile, weight was at 10th 
centile and normal head circumference at 50th centile (Figure 2). Twelve years old his height 
is at 2.5th centile, weight is at 25th centile. 
 
 
Relatives 
His father and his older brother were healthy, while his mother and his younger brother had a 
history of frequent respiratory infections, but fewer and less severe than seen in the index 
patient. The mother had frequent lower respiratory tract infections, and the younger brother 
had episodes of wheezing. They were included in the genetic and immunolgical study to 
further elucidate the specific 14q deletion phenotypes. 
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Methods 
 
Immunoglobulins, specific antibodies and lymphocytes 
Methods and reference values for quantitation of total IgG, IgA, IgM, IgD, IgE and IgG 
subclasses are fairly described in [22] as are detection of diphtheria antibodies and tetanus 
antitoxin[23-25]. Antibodies to Streptococcus pneumoniae were tested against the 23-valent 
polysaccharide vaccine in an ELISA [26;27] as were antibodies to the capsular polysaccharide 
of Haemophilus influenzae type b [28]. Enzyme immunoassay (EIA) techniques were used for 
anti-varicella-zoster virus (VZV) IgG, anti-herpes simplex virus (HSV) IgG, anti-measles 
IgG, anti-Epstein-Barr virus (EBV) nuclear antigen (EBNA) and anti-EBV virus capsid 
antigen (VCA) IgG, and the microparticle enzyme immunoassay (MEIA) technique for anti-
rubella virus IgG and anti-cytomegalovirus (CMV) IgG. Flowcytometric immunophenotyping 
of peripheral blood leukocytes was performed according to [22].        
 
Vaccine responses  
Diphtheria and tetanus vaccines (0,5 mL containing 15Lf Diphtheria toxin and 3.8 Lf Tetanus 
toxin) and the conjugated pneumococcal vaccine, Prevenar  (Wyeth-Lederle), were used. 
Antibodies were measured prior to and > 6 weeks after the vaccination (Table 1).  
 
Mannose-binding lectin (MBL) 
Serum concentrations of MBL were quantified using ELISA (Antibodyshop/Statens Serum 
Institut, Copenhagen, Denmark) with detection limit at 5 nanogram/mL. Low MBL levels 
were defined as  <400 ng/mL and extremely low if <100 ng/mL. To further characterise the 
role of MBL, a functional ELISA measuring the lectin pathway activation capacity of 
exogenously added purified complement C4b-binding capacity was performed as described by 
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Petersen et al [29;30]. Detection of gene mutations and promoter polymorphisms in the MBL 
gene was performed by polymerase chain reaction according to [31]. The following 
polymorphisms were studied: three point mutations in the promoter region (position -550 
(H/L variants), -221 (X/Y variants), -70 (nt C or T)), one point mutation in the 5' untranslated 
(UT) region at position +4 (P/Q variants) and three point mutations located at codons 52, 54 
and 57 in exon 1, at nucleotide positions 223, 230 and 239. 
 
Surfactant protein D (SP-D) 
SP-D was measured by ELISA as described in [32]. Briefly, microtitre wells were coated with 
F(ab´)2 prepared from rabbit anti-SP-D antibody, incubated with dilutions of test serum, later 
incubated with monoclonal antibody anti-human SP-D, and then peroxidase was added. 
Serum samples from the family were tested simultaneously in 1:5 and 1:10 dilutions and the 
mean value calculated. Reference values for SP-D are 370-1300ng/mL according to [33]. 
Three biallelic polymorphisms at the SP-D codons for the amino acids in position 11, 160, 
270 in the mature SP-D were genotyped using an in house PCR-sequence specific priming 
method. 
 
Genetic investigations 
FISH 
Cosmids covering TITF1 and one covering PAX9 [3]were biotinylated by nick translation. 
Labelling and fluorescent in situ hybridisation (FISH) were performed as described [34]. 
 
Array-CGH  
Microarray-based comparative genomic hybridisation (array-CGH) was performed on a 
Human Genome CGH Microarray 44K (Agilent Technologies, USA) with a resolution of 
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approximately 0.36 Kb. Array-CGH analysis was done according to the supplier´s instructions 
(for details, see www.agilent.com). Briefly, after digestion with Alu I and Rsa I, patient DNA 
and normal reference DNA (1 ȝg each) were labeled with Cy3-dCTP and Cy5-dCTP, 
respectively. Commercial reference DNA was used consisting of a pool from either ten 
normal female donors or ten normal male donors (Promega GmbH, Germany). The DNA´s 
were together with 50 µg human Cot-1 DNA (Invitrogen) hybridized onto the array. The 
arrays were scanned in an Agilent G2565B scanner (Agilent Technologies), and images were 
DQDO\VHGXVLQJWKH³$JLOHQW)HDWXUHH[WUDFWLRQVRIWZDUHY´$JLOHQW7HFKQRORJLHV
Array-&*+UHVXOWVZHUHYLVXDOLVHGLQWKH³$JLOHQW&*+$QDO\WLFV6RIWZDUH´Agilent 
Technologies). Imbalances were identified and located using the ADM-2 algoritm in the 
software with a moving average on 1 Mb, while mapping of the breakpoints of the imbalances 
were manually determined from the individual oligo ratio intensities. The genomic location of 
the oligos is based on the Agilent hg build 18 which is based on the NCBI build 36.2. 
 
 
Results: 
 
Genetics 
The cytogenetic investigations had revealed a microdeletion 14q. Fluorescence in situ 
hybridisation (FISH) analysis with a cosmid containing the NKX2.1 gene yielded a signal on 
only one chromosome 14 homologue and confirmed the presence of a deletion encompassing 
the TITF1 (NKX2.1) locus (Figure 3). In addition, FISH for the PAX9 gene confirmed the 
presence of a deletion of this gene as well (Figure 3). Array-CGH analysis with 44.000 oligos 
(Agilent Technologies) located the deletion breakpoints to 14q13.1 and 14q21.1. The 
breakpoints were mapped to be located at (33,74 Mb ± 33,94 Mb) and (40,83 Mb ± 41,12 Mb) 
distal from 14qter, giving a minimum size of the deletion of 6,9 Mb and a maximum size of 
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7,4 Mb. The deletion spands a region of 36 predicted Ensembl genes: C14orf147, EAPP,  
SNX6, CFL2, BAZ1A, SRP54, C14orf24,  PPP2R3C, KIAA0391, PSMA6, NFKBIA, INSM2, 
GARNL1, BRMS1L, MBIP, XR_017793.1, Q8IWV4, TITF1, YN001_HUMAN, NKX2-8, 
Q96HD_HUMAN, PAX9, SLC25A21, MPOL1, C14orf25, FOXA1, TTC6, SSTR1, CLEC14A, 
SEC23A, SIP1, TRAPPC6B, PNN, MA2, CTAGE5, FBXO33, plus 3 pseudogenes and 9 novel 
genes without known function. Within the deleted area only 5 genes are yet known to be 
associated with human disease: NFKBIA, CFL2, MPOLI, PAX9 and TITF1. Within the 
deleted region is also another interesting gene FOXA1, a transcription activator for liver genes 
such as AFP and albumin. Based on the array-CGH result a more exact karyotype were 
defined: 46,XY, del(14)(q13.1q21.1) de novo. His parents and his siblings had normal 
karyotypes and no deletions were found. 
 
Immunology 
Our patient had low IgG2 (0.38 g/L) and IgE (<3 kU/L), while total IgG, IgA, IgM and IgD 
were normal. Total numbers of lymphocyte subpopulations and proliferative response to 
mitogens were within reference values, with T cells within the lower normal range. He had 
antibodies to measles, mumps, HSV, chickenpox and Hib, but not to diphtheria, tetanus, CMV 
and EBV and low levels of pneumococcal polysaccharide antibodies (Table 1). We performed 
a Diphtheria/Tetanus vaccination, and six weeks later he showed normal antibody levels 
(Table 1). He also responded to the conjugated pneumococcal vaccine with anti-
pneumococcal antibodies. His siblings and his parents had normal immunoglobulin levels and 
protective antibodies to the bacterial antigens tested (Table 1).   
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Collectins: 
Collectin results are presented in Table 2. The patient and also his mother and his younger 
brother had extremely low serum MBL levels (<30ng/mL). Complement C4b-binding 
capacity was measured in the patient and the mother, and both had values < 5%. The patient 
and the youngest brother were homozygous for the MBL mutant variant B, variation in codon 
54, associated with absence of MBL [35]. The mother was compound heterozygous with two 
different MBL variant alleles B and C, which in combination also cause MBL deficiency. The 
oldest brother and the father were heterozygous for the MBL variant allele B. However, in 
front of their normal (wild-type) MBL2 gene a high producing promotor type was found 
(designated HYP) [31]. None of the family members had reduced serum levels of SP-D. The 
index patient, the mother and the youngest brother had no mutation in the SP-D gene. The 
father and the oldest brother were heterozygous for Thr11Met in the SP-D gene, not 
associated with reduced SP-D levels [36].  
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Discussion: 
 
The boy has various neurological problems, thyroid dysfunction and severe pulmonary 
problems. His neurological symptoms correspond very well to those described for TITF1 
(NKX2.1) haploinsufficiency [11;12]. The microdeletion of 14q also involves other genes 
located close to TITF1. However, Krude et al and Doyle et al found that mutations strictly 
within the TITF1 gene also resulted in the complex phenotype with affections of brain, 
thyroid and lung, suggesting that the phenotype of our patient could entirely be due to TITF1 
haploinsufficiency [11;12].  However, compared to others with TITF1 haploinsufficiency 
[2;8;11;12] our patient had a higher frequency of severe respiratory infections. In addition, he 
had diarrhoea and failure to thrive, which are often seen in patients with MBL deficiency [37]. 
The low IgG2 levels may also have contributed to his recurrent respiratory infections. A link 
between IgG2 deficiency, low MBL levels and low levels of spontaneous pneumococcal 
antibodies may exist [38], homozygosity for certain MBL variant alleles is previous shown to 
correlate with an increased frequency of invasive pneumococcal disease [39;40]. 
 
Other children reported with haploinsufficiency of proximal 14q, as well as the patient 
reported by Schuffenhauer with de novo deletion 14(q11.2q13)[4], exhibited cleft lip and 
palate, dysphagia and reduced oesophageal peristalsis [1]. These abnormalities and gastro-
oesophageal reflux with DVSLUDWLRQPD\KDYHFRQWULEXWHGWRRXUSDWLHQW¶VOXQJLQIHFWLRQV
Stockton et al found that haploinsufficiency of the PAX9 gene only, exclusively was 
associated with hypodontia and not with dysmorfic features, developmental delay, hypotonia 
or cleft lip/palate [21]. The deleted 14q chromosomal area contains almost 30 genes and other 
genes than TITF1 and PAX9 PD\EHUHVSRQVLEOHIRURXUER\¶VIHHGLQJGLIILFXOWLHVDQG
respiratory problems. The different pattern of malformations observed in the patients with 
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deletion of proximal 14q, may be due to different chromosomal breakpoints with varying 
number of genes involved [41].   
  
%DVHGRQWKHFKDUDFWHULVWLFVRIWKHER\¶VUHFXUUHQWLQIHFWLRQV7FHOODEQRUPDOLWLHV
were not expected, and he had normal T cell counts. Progressive T cell deficiencies are 
described in PNP (purine nucleoside phosphorylase) deficiency, which is inherited autosomal 
recessive and NP gene located to 14q13.1 close to the deleted area. Our patient had normal 
urinary excretion of purines and pyrimidines, which excludes PNP deficiency. A 
heterogeneity of neurologic abnormalities including ataxia and mental retardation similar to 
our patient have been observed in PNP deficient patients [42;43]. Located to 14q13 within the 
deleted area is another immunodeficiency gene where heterozygosity may lead to 
immunodeficiency. Courtois et al. (2003) described a patient with an autosomal dominant 
form of anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) associated with a 
heterozygous mutation in the NKBIA(IKBA) gene (OMIM 164008)[44;45]. The specific 
mutation was shown to be a gain-of-function mutation enhancing the inhibitory capacity of I-
kappa-B-alpha by preventing its phosphorylation and degradation, and resulting in impaired 
NF-kappa-B activation. Deletions more likely results in loss-of-IXQFWLRQRU³KDOI-the-
IXQFWLRQ´ 
 
We found that serum MBL levels corresponded well to the MBL haplotype and 
clinical phenotype of the relatives as well (Table 2). A strong correlation between MBL 
haplotype and serum MBL levels has also been described by others [31;46]. Previous MBL 
genotyping of 100 Norwegian blood-donor controls showed that 3 % of them were 
homozygous defective for MBL [47]. Both the mother and the youngest brother had low MBL 
and no TITF1 deletion. Based on our results from this little family we propose that expression 
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of serum MBL and SP-D levels are not influenced by TITF1 haploinsufficiency, even if the 
collectin genes MBL2, SP-A (SFTP1, SFTP2) and SP-D (SFTP4) are clustered within the 
10q21-q23 region (OMIM*154545, *178630, *178642, *178635). Our suggestions are 
supported by Y. He and collaborators who reported that, despite finding regions of homology 
to the thyroid transcription factor 1-binding site, SP-D promoter activity did not require 
TITF1[48].  
 
The mild elevation of TSH with normal thyroid hormone secretion points to a 
functional thyroid defect. A functional thyroid defect can be explained by the reduced 
activation of TITF1 targets, such as the thyroglobulin promoter in the thyroid follicular cells 
[49]. Other TITF1 targets are TSH receptor and thyroid peroxidase gene [50;51]. Thyroid 
dysgenesis have been found in other patients with TITF1haploinsufficiency [12], but 
ultrasound of the thyroid gland in our patient showed a present thyroid of normal size and 
shape.  
 
Conclusions: 
 
In conclusion, we suggest that the MBL deficiency and probably also the IgG2 deficiency 
explain why he had more severe and recurrent pulmonary problems than previously reported 
for TITF1 haploinsufficiency. His mother and younger brother had MBL deficiency and a 
history of frequent respiratory infections, although fewer and less severe than in the index 
patient. His 14q deletion involved PAX9 and probably also other genes that may have caused 
his cleft lip-palate, clubfeet (as case 777 in [52]) and feeding difficulties with 
gastrooesophageal reflux. Further studies of patients with single mutations in genes within 
this region may further elucidate genotype-phenotype correlations of proximal 14q deletions, 
 15
although polymorphisms in other genes located outside this chromosomal region may 
influence the clinical phenotype.  
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Figure 3  
 
COS TITF1 
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Figure 4  
 
del14q 
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Figure Legends 
 
Figure 1 Photos  
Photos of the patient 9 months old, including one photo of the cleft lip-palate 
 
Figure 2 Photos 
Photos of the patient 7 years old 
 
Figure 3 FISH TITF1 
Fluorescence in situ hybridisation (FISH) analysis with a cosmid containing the TITF1 gene 
yielded a signal on only one chromosome 14 homologue and demonstrates the presence of a 
deletion encompassing this locus.  
 
Figure 4 FISH PAX 9 
Fluorescence in situ hybridisation (FISH) analysis for the PAX9 gene yielded a signal on only 
one chromosome 14 homologue, demonstrating the presence of a deletion of the PAX9 locus 
 
 
 
 
